Ocumetics Technology Corp. (TSXV:OTC, OTCQB:OTCFF, FRA:2QBO) focuses on a groundbreaking vision enhancement product - the Ocumetics Accommodating Lens. Leading the forefront of research and product development, Ocumetic's intraocular lens (IOL) is engineered to seamlessly shift the eye's focus from close to far distances without any noticeable lag. This process is called accommodation.
The eye's natural lens loses its flexibility to bend light rays accurately due to aging and injuries. This leads to the deterioration of eyesight and potential conditions like cataracts with or without astigmatism. Ocumetics has designed a very unique IOL that is surgically implanted to restore a patient’s vision. This lens is designed to harmoniously align with the eye's natural mechanisms, enhancing vision by appropriately bending light rays. Notably, it's designed to last a lifetime, presenting a significant potential advancement over other cataract technologies.
Ocumetics aims to solve the problem of eyesight degradation. The proposed solution is a surgically implanted lens that takes over the function of properly bending rays of light by working with the eye’s natural mechanisms, resulting in enhanced vision. Following a series of product enhancements, development of surgical procedure protocols, and animal testing for biocompatibility, the Ocumetics Accommodating Lens will soon begin human trials as the company works toward bringing the product to market.
This Ocumetics Technology profile is part of a paid investor education campaign.*
(TheNewswire)
 | |||||||||
 |  | ||||||||
Calgary, Alberta May 24, 2024 - TheNewswire . Â Ocumetics Technology Corp. (" Ocumetics " or the " Corporation ") ( TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) announces that it has completed the first tranche of the private placement of debentures previously announced by the Corporation on May 15, 2024.
News Provided by TheNewsWire via QuoteMedia
(TheNewswire)
| |||||||||
| | ||||||||
Calgary, Alberta TheNewswire - February 29, 2024 - Ocumetics Technology Corp. ("Ocumetics") (TSXV:OTC) (OTC:OTCFF) (FRA:2QBO), is pleased to invite investors and other interested parties to attend an upcoming interview with Market Radius Research.
News Provided by TheNewsWire via QuoteMedia
(TheNewswire)
| |||||||||
| | ||||||||
Calgary, Alberta TheNewswire - December 21, 2023 - Â Ocumetics Technology Corp. (" Ocumetics " or the " Corporation ") (TSXV:OTC) (OTC:OTCFF) (FRA:2QBO) is pleased to announce that the TSX Venture Exchange has granted a 15-day extension to close the Corporation's non-brokered private placement announced on November 15, 2023. Â The new closing deadline for the private placement is January 15, 2024.
News Provided by TheNewsWire via QuoteMedia
(TheNewswire)
| |||||||||
| | ||||||||
Ocumetics Technology Corp. (" Ocumetics ") ( TSXV:OTC) (OTC:OTCFF) (FRA:2QBO) a pioneer in the field of ophthalmic innovation, announces a webinar to discuss the successful completion of its biocompatibility animal study and its upcoming first-in-human study, anticipated to commence in Q1 2024 in the Dominican Republic
Dean Burns, CEO of Ocumetics and 27-year Alcon veteran, will lead the presentation.
Click Image To View Full Size
Join the webinar to:
Learn more about the significance of the biocompatibility animal study;
Learn more about the upcoming first-in-human study; and
Ask questions regarding the Ocumetics Accommodating Lens and the company's plans.
Details are as follows:
Date: Â Â Â Â December 20, 2023
Time: Â Â Â Â 18:00 EST
RSVP: https://ocumetics.com/webinar-december-20-2023/
About Ocumetics
Ocumetics Technology Corp. ( TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), headquartered in Calgary, Alberta, Canada, is an innovator in the field of ophthalmic technology, dedicated to developing and commercializing advanced vision correction solutions that enhance the quality of life for individuals worldwide.
Ocumetics is in the preclinical study stage of a game-changing technology for the ophthalmic industry. Â In its pursuit of a next generation interocular lens solution, Ocumetics has developed the Ocumetics Accommodating Lens, an expandable intraocular lens that fits within the natural lens compartment of the eye potentially to eliminate the need for corrective lenses. Â It is designed to allow the eye's natural muscle activity to seamlessly shift focus from distance to intermediate to near.
FOR FURTHER INFORMATION, PLEASE CONTACT:
Dean Burns
President and CEO
(817) 874-7564
Dayton Marks
Director
(778) 347-2500
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Copyright (c) 2023 TheNewswire - All rights reserved.
News Provided by TheNewsWire via QuoteMedia
Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced Karen S. Lynch has been elected to its board of directors, effective February 19, 2025. The appointment brings the total number of Thermo Fisher board members to 12.
Ms. Lynch is a seasoned health care executive with over three decades of experience in the industry. As the former president and chief executive officer of CVS Health Corporation (NYSE: CVS), a leading health solutions company, she was responsible for leading more than 300,000 employees. Under Ms. Lynch's leadership, CVS Health touched the lives of more than 120 million consumers through its health care benefits and pharmacy benefits management businesses, and presence in over 9,000 community health destinations across the U.S. Prior to her service as president and CEO of CVS Health, Ms. Lynch served as an Executive Vice President of CVS Health and President of Aetna, and prior to that, Ms. Lynch held a number of executive positions at Aetna Inc., a health insurance company, Magellan Health Services, a health care management company, and at Cigna Corporation, a global health insurance company. Ms. Lynch began her career as a Certified Public Accountant at the auditing firm Ernst & Young LLP, and has previously served as a board member of CVS Health and U.S. Bancorp.
"We are extremely pleased to have Karen join the board," said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher Scientific. "Her knowledge and insight will be an incredible asset as we continue to scale our company and deliver for our stakeholders."
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20250219315440/en/
Media Contact Information:
Sandy Pound
Phone: 781-622-1223
E-mail: sandy.pound@thermofisher.com
Investor Contact Information:
Rafael Tejada
Phone: 781-622-1356
E-mail: rafael.tejada@thermofisher.com
News Provided by Business Wire via QuoteMedia
Delivering durable revenue growth with strong earnings power; strength in Pulsed Field Ablation, Pacing, Structural Heart, Diabetes, and Neuromodulation
Medtronic plc (NYSE: MDT) today announced financial results for its third quarter (Q3) of fiscal year 2025 (FY25), which ended January 24, 2025 .
Key Highlights
Financial Results
Medtronic reported Q3 worldwide revenue of $8.292 billion , an increase of 2.5% as reported and 4.1% on an organic basis. Organic revenue growth comparison excludes:
As reported, Q3 GAAP net income and diluted earnings per share (EPS) were $1.294 billion and $1.01 , respectively, representing a decrease of 2% and an increase of 2%, respectively. As detailed in the financial schedules included at the end of this release, Q3 non-GAAP net income and non-GAAP diluted EPS were $1.787 billion and $1.39 , respectively, representing increases of 3% and 7%, respectively.
"We delivered strong earnings this quarter, with significant improvements in both our gross margin and operating margin on the back of our ninth quarter in a row of mid-single digit organic revenue growth," said Geoff Martha , Medtronic chairman and chief executive officer. "We are starting to see the results from our long term investments in groundbreaking innovation, such as pulsed field ablation, to drive growth in some of the most attractive markets in MedTech."
Cardiovascular Portfolio
The Cardiovascular Portfolio includes the Cardiac Rhythm & Heart Failure (CRHF), Structural Heart & Aortic (SHA), and Coronary & Peripheral Vascular (CPV) divisions. Revenue of $3.037 billion increased 3.7% as reported and 5.0% organic, with mid-single digit increases in CRHF and SH&A, and a low-single digit increase in CPV, all on an organic basis.
Neuroscience Portfolio
The Neuroscience Portfolio includes the Cranial & Spinal Technologies (CST), Specialty Therapies, and Neuromodulation divisions. Revenue of $2.458 billion increased 4.4% as reported and 5.2% organic, with a low-double digit increase in Neuromodulation, mid-single digit increase in CST, and low-single digit increase in Specialty Therapies, all on an organic basis.
Medical Surgical Portfolio
The Medical Surgical Portfolio includes the Surgical & Endoscopy (SE) and the Acute Care & Monitoring (ACM) divisions. Revenue of $2.072 billion decreased 1.9% as reported and decreased 0.4% organic, with flat organic result in SE and low-single digit organic decline in ACM.
Diabetes
Revenue of $694 million increased 8.4% as reported and 10.4% organic.
Guidance
Medtronic today reiterated its revenue growth and EPS guidance for FY25.
The company continues to expect FY25 organic revenue growth in the range of 4.75% to 5%. The organic revenue growth guidance excludes the impact of foreign currency and revenue reported as Other. Including Other revenue and the impact of foreign currency exchange, if recent foreign currency exchange rates hold, FY25 revenue growth would be in the range of 3.4% to 3.8%.
The company continues to expect FY25 diluted non-GAAP EPS in the range of $5.44 to $5.50 . This includes an estimated -5% impact from foreign currency exchange based on recent rates. The company's guidance represents FY25 diluted non-GAAP EPS growth in the range of 4.6% to 5.8%.
"EPS came in above the high end of our guidance range. We were pleased with the operational performance of the business this quarter, turning mid-single digit organic growth into leveraged earnings, highlighted by healthy gross margin improvement," said Gary Corona , Medtronic interim chief financial officer. "Looking ahead, our restored earnings power continues. We will accelerate both top and bottom line growth in Q4, resulting in high-single digit adjusted EPS growth in the back half of our fiscal year."
Video Webcast Information
Medtronic will host a video webcast today, February 18 , at 8:00 a.m. EST ( 7:00 a.m. CST ) to provide information about its businesses for the public, investors, analysts, and news media. This webcast can be accessed by clicking on the Events icon at investorrelations.medtronic.com , and this earnings release will be archived at news.medtronic.com . Within 24 hours of the webcast, a replay of the webcast and transcript of the company's prepared remarks will be available by clicking on the Events icon at investorrelations.medtronic.com .
Medtronic plans to report its FY25 fourth quarter results on Wednesday, May 21, 2025 . For fiscal year 2026, Medtronic plans to report its first, second, third, and fourth quarter results on Tuesday, August 19, 2025 , November 18, 2025 , February 17, 2026 , and Wednesday, May 20, 2026 , respectively. Confirmation and additional details will be provided closer to the specific event.
Financial Schedules and Earnings Presentation
The third quarter financial schedules and non-GAAP reconciliations can be viewed by clicking on the Investor Events link at investorrelations.medtronic.com . To view a printable PDF of the financial schedules and non-GAAP reconciliations, click here . To view the third quarter earnings presentation, click here .
MEDTRONIC PLC WORLD WIDE REVENUE (1) (Unaudited) | ||||||||||||||||||||||||||||
THIRD QUARTER | YEAR-TO-DATE | |||||||||||||||||||||||||||
REPORTED | ORGANIC | REPORTED | ORGANIC | |||||||||||||||||||||||||
(in millions) | FY25 | FY24 | Growth | Currency | Adjusted | Adjusted | Growth | FY25 | FY24 | Growth | Currency | Adjusted | Adjusted | Growth | ||||||||||||||
Cardiovascular | $Â Â Â Â 3,037 | $Â Â Â Â 2,929 | 3.7Â % | $Â Â Â Â Â Â Â (38) | $Â Â Â Â 3,075 | $Â Â Â Â 2,929 | 5.0Â % | $Â Â Â Â 9,145 | $Â Â Â Â 8,702 | 5.1Â % | $Â Â Â Â Â Â Â (62) | $Â Â Â Â 9,207 | $Â Â Â Â 8,702 | 5.8Â % | ||||||||||||||
Cardiac Rhythm & Heart Failure | 1,545 | 1,470 | 5.1 | (18) | 1,563 | 1,470 | 6.3 | 4,659 | 4,408 | 5.7 | (26) | 4,684 | 4,408 | 6.3 | ||||||||||||||
Structural Heart & Aortic | 874 | 843 | 3.7 | (13) | 887 | 843 | 5.2 | 2,610 | 2,475 | 5.4 | (21) | 2,631 | 2,475 | 6.3 | ||||||||||||||
Coronary & Peripheral Vascular | 618 | 616 | 0.3 | (8) | 626 | 616 | 1.6 | 1,876 | 1,818 | 3.2 | (15) | 1,891 | 1,818 | 4.0 | ||||||||||||||
Neuroscience | 2,458 | 2,355 | 4.4 | (21) | 2,478 | 2,355 | 5.2 | 7,226 | 6,861 | 5.3 | (29) | 7,255 | 6,861 | 5.7 | ||||||||||||||
Cranial & Spinal Technologies | 1,250 | 1,204 | 3.8 | (9) | 1,259 | 1,204 | 4.6 | 3,632 | 3,465 | 4.8 | (15) | 3,646 | 3,465 | 5.2 | ||||||||||||||
Specialty Therapies | 732 | 726 | 0.8 | (8) | 740 | 726 | 1.9 | 2,181 | 2,126 | 2.6 | (10) | 2,191 | 2,126 | 3.1 | ||||||||||||||
Neuromodulation | 476 | 425 | 12.0 | (4) | 480 | 425 | 12.9 | 1,413 | 1,270 | 11.2 | (5) | 1,417 | 1,270 | 11.6 | ||||||||||||||
Medical Surgical | 2,072 | 2,112 | (1.9) | (32) | 2,104 | 2,112 | (0.4) | 6,196 | 6,219 | (0.4) | (50) | 6,246 | 6,219 | 0.4 | ||||||||||||||
Surgical & Endoscopy | 1,596 | 1,616 | (1.2) | (26) | 1,622 | 1,616 | 0.4 | 4,790 | 4,803 | (0.3) | (40) | 4,829 | 4,803 | 0.5 | ||||||||||||||
Acute Care & Monitoring | 476 | 495 | (3.9) | (5) | 481 | 495 | (2.8) | 1,406 | 1,416 | (0.7) | (10) | 1,417 | 1,416 | — | ||||||||||||||
Diabetes | 694 | 640 | 8.4 | (12) | 706 | 640 | 10.4 | 2,027 | 1,829 | 10.8 | (8) | 2,035 | 1,829 | 11.3 | ||||||||||||||
Total Reportable Segments | 8,260 | 8,035 | 2.8 | (103) | 8,363 | 8,035 | 4.1 | 24,593 | 23,610 | 4.2 | (149) | 24,742 | 23,610 | 4.8 | ||||||||||||||
Other (2) | 32 | 53 | (41.1) | (1) | — | — | — | 17 | 164 | (89.9) | (3) | — | — | — | ||||||||||||||
TOTAL | $Â Â Â Â 8,292 | $Â Â Â Â 8,089 | 2.5Â % | $Â Â Â Â Â (104) | $Â Â Â Â 8,363 | $Â Â Â Â 8,035 | 4.1Â % | $Â Â Â 24,610 | $Â Â Â 23,775 | 3.5Â % | $Â Â Â Â Â (152) | $Â Â Â 24,742 | $Â Â Â 23,610 | 4.8Â % | ||||||||||||||
(1) | The data in this schedule has been intentionally rounded to the nearest million and, therefore, may not sum. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. |
(2) | Includes historical operations and ongoing transition agreements from businesses the Company has exited or divested, and specifically for the three months ended July 26, 2024, impacting year-to-date figures, $90 million of incremental Italian payback accruals resulting from the two July 22, 2024 rulings by the Constitutional Court of Italy relating to certain prior years since 2015. |
(3) | The currency impact to revenue measures the change in revenue between current and prior year periods using constant exchange rates. |
(4) | The three months ended January 24, 2025 excludes $71 million of revenue adjustments related to $32 million of inorganic revenue for the transition activity noted in (2) and $103 million of unfavorable currency impact on the remaining segments. The three months ended January 26, 2024 excludes $53 million of inorganic revenue related to the transition activity noted in (2). |
(5) | The nine months ended January 24, 2025 excludes $132 million of revenue adjustments related to $90 million of incremental Italian payback accruals further described in note (2), $106 million of inorganic revenue related to the transition activity noted in (2), and $149 million of unfavorable currency impact on the remaining segments. The nine months ended January 26, 2024 excludes $164 million of inorganic revenue related to the transition activity noted in (2). |
MEDTRONIC PLC U.S. REVENUE (1)(2) (Unaudited) | ||||||||||||||||||||||||
THIRD QUARTER | YEAR-TO-DATE | |||||||||||||||||||||||
REPORTED | ORGANIC | REPORTED | ORGANIC | |||||||||||||||||||||
(in millions) | FY25 | FY24 | Growth | Adjusted | Adjusted | Growth | FY25 | FY24 | Growth | Adjusted | Adjusted | Growth | ||||||||||||
Cardiovascular | $Â Â Â Â 1,405 | $Â Â Â Â 1,373 | 2.4Â % | $Â Â Â Â 1,405 | $Â Â Â Â 1,373 | 2.4Â % | $Â Â Â Â 4,242 | $Â Â Â Â 4,149 | 2.2Â % | $Â Â Â Â 4,242 | $Â Â Â Â 4,149 | 2.2Â % | ||||||||||||
Cardiac Rhythm & Heart Failure | 775 | 745 | 4.1 | 775 | 745 | 4.1 | 2,309 | 2,247 | 2.8 | 2,309 | 2,247 | 2.8 | ||||||||||||
Structural Heart & Aortic | 372 | 363 | 2.6 | 372 | 363 | 2.6 | 1,129 | 1,087 | 3.9 | 1,129 | 1,087 | 3.9 | ||||||||||||
Coronary & Peripheral Vascular | 258 | 265 | (2.8) | 258 | 265 | (2.8) | 804 | 816 | (1.4) | 804 | 816 | (1.4) | ||||||||||||
Neuroscience | 1,689 | 1,556 | 8.5 | 1,689 | 1,556 | 8.5 | 4,931 | 4,614 | 6.9 | 4,931 | 4,614 | 6.9 | ||||||||||||
Cranial & Spinal Technologies | 943 | 875 | 7.8 | 943 | 875 | 7.8 | 2,724 | 2,560 | 6.4 | 2,724 | 2,560 | 6.4 | ||||||||||||
Specialty Therapies | 419 | 407 | 3.0 | 419 | 407 | 3.0 | 1,235 | 1,202 | 2.7 | 1,235 | 1,202 | 2.7 | ||||||||||||
Neuromodulation | 327 | 275 | 19.0 | 327 | 275 | 19.0 | 972 | 852 | 14.1 | 972 | 852 | 14.1 | ||||||||||||
Medical Surgical | 893 | 947 | (5.8) | 893 | 947 | (5.8) | 2,718 | 2,763 | (1.6) | 2,718 | 2,763 | (1.6) | ||||||||||||
Surgical & Endoscopy | 623 | 663 | (6.1) | 623 | 663 | (6.1) | 1,928 | 1,971 | (2.2) | 1,928 | 1,971 | (2.2) | ||||||||||||
Acute Care & Monitoring | 269 | 284 | (5.1) | 269 | 284 | (5.1) | 790 | 792 | (0.2) | 790 | 792 | (0.2) | ||||||||||||
Diabetes | 236 | 224 | 5.6 | 236 | 224 | 5.6 | 683 | 629 | 8.7 | 683 | 629 | 8.7 | ||||||||||||
Total Reportable Segments | 4,223 | 4,100 | 3.0 | 4,223 | 4,100 | 3.0 | 12,573 | 12,154 | 3.4 | 12,573 | 12,154 | 3.4 | ||||||||||||
Other (3) | 15 | 20 | (26.4) | — | — | — | 51 | 65 | (21.3) | — | — | — | ||||||||||||
TOTAL | $Â Â Â Â 4,237 | $Â Â Â Â 4,120 | 2.8Â % | $Â Â Â Â 4,223 | $Â Â Â Â 4,100 | 3.0Â % | $Â Â 12,624 | $Â Â 12,219 | 3.3Â % | $Â Â 12,573 | $Â Â 12,154 | 3.4Â % | ||||||||||||
(1) | U.S. includes the United States and U.S. territories. |
(2) | The data in this schedule has been intentionally rounded to the nearest million and, therefore, may not sum. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. |
(3) | Includes historical operations and ongoing transition agreements from businesses the Company has exited or divested. |
MEDTRONIC PLC INTERNATIONAL REVENUE (1) (Unaudited) | ||||||||||||||||||||||||||||
THIRD QUARTER | YEAR-TO-DATE | |||||||||||||||||||||||||||
REPORTED | ORGANIC | REPORTED | ORGANIC | |||||||||||||||||||||||||
(in millions) | FY25 | FY24 | Growth | Currency | Adjusted | Adjusted | Growth | FY25 | FY24 | Growth | Currency | Adjusted | Adjusted | Growth | ||||||||||||||
Cardiovascular | $Â Â Â Â 1,632 | $Â Â Â Â 1,556 | 4.9Â % | $Â Â Â Â Â Â Â (38) | $Â Â Â Â 1,670 | $Â Â Â Â 1,556 | 7.3Â % | $Â Â Â Â 4,904 | $Â Â Â Â 4,552 | 7.7Â % | $Â Â Â Â Â Â Â (62) | $Â Â Â Â 4,966 | $Â Â Â Â 4,552 | 9.1Â % | ||||||||||||||
Cardiac Rhythm & Heart Failure | 770 | 726 | 6.1 | (18) | 788 | 726 | 8.6 | 2,350 | 2,161 | 8.7 | (26) | 2,376 | 2,161 | 9.9 | ||||||||||||||
Structural Heart & Aortic | 502 | 480 | 4.6 | (13) | 515 | 480 | 7.2 | 1,482 | 1,389 | 6.7 | (21) | 1,503 | 1,389 | 8.2 | ||||||||||||||
Coronary & Peripheral Vascular | 360 | 350 | 2.6 | (8) | 368 | 350 | 4.9 | 1,072 | 1,002 | 7.0 | (15) | 1,087 | 1,002 | 8.5 | ||||||||||||||
Neuroscience | 769 | 799 | (3.7) | (21) | 790 | 799 | (1.1) | 2,295 | 2,248 | 2.1 | (29) | 2,324 | 2,248 | 3.4 | ||||||||||||||
Cranial & Spinal Technologies | 307 | 329 | (6.7) | (9) | 316 | 329 | (3.9) | 907 | 905 | 0.3 | (15) | 922 | 905 | 1.9 | ||||||||||||||
Specialty Therapies | 313 | 319 | (2.0) | (8) | 321 | 319 | 0.4 | 947 | 924 | 2.4 | (10) | 957 | 924 | 3.5 | ||||||||||||||
Neuromodulation | 149 | 150 | (0.7) | (4) | 153 | 150 | 1.8 | 441 | 419 | 5.4 | (5) | 446 | 419 | 6.5 | ||||||||||||||
Medical Surgical | 1,180 | 1,164 | 1.3 | (32) | 1,211 | 1,164 | 4.0 | 3,478 | 3,456 | 0.6 | (50) | 3,528 | 3,456 | 2.1 | ||||||||||||||
Surgical & Endoscopy | 973 | 953 | 2.1 | (26) | 999 | 953 | 4.9 | 2,862 | 2,832 | 1.1 | (40) | 2,902 | 2,832 | 2.5 | ||||||||||||||
Acute Care & Monitoring | 206 | 211 | (2.3) | (5) | 212 | 211 | 0.2 | 616 | 624 | (1.4) | (10) | 626 | 624 | 0.3 | ||||||||||||||
Diabetes | 457 | 416 | 9.9 | (12) | 470 | 416 | 12.9 | 1,344 | 1,200 | 12.0 | (8) | 1,351 | 1,200 | 12.6 | ||||||||||||||
Total Reportable Segments | 4,038 | 3,935 | 2.6 | (103) | 4,141 | 3,935 | 5.2 | 12,020 | 11,456 | 4.9 | (149) | 12,169 | 11,456 | 6.2 | ||||||||||||||
Other (2) | 17 | 34 | (49.8) | (1) | — | — | — | (35) | 99 | (134.8) | (3) | — | — | — | ||||||||||||||
TOTAL | $Â Â Â Â 4,055 | $Â Â Â Â 3,968 | 2.2Â % | $Â Â Â Â Â (104) | $Â Â Â Â 4,141 | $Â Â Â Â 3,935 | 5.2Â % | $Â Â 11,986 | $Â Â 11,555 | 3.7Â % | $Â Â Â Â Â (152) | $Â Â 12,169 | $Â Â 11,456 | 6.2Â % | ||||||||||||||
(1) | The data in this schedule has been intentionally rounded to the nearest million and, therefore, may not sum. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. |
(2) | Includes historical operations and ongoing transition agreements from businesses the Company has exited or divested, and specifically for the three months ended July 26, 2024, impacting year-to-date figures, $90 million of incremental Italian payback accruals resulting from the two July 22, 2024 rulings by the Constitutional Court of Italy relating to certain prior years since 2015. |
(3) | The currency impact to revenue measures the change in revenue between current and prior year periods using constant exchange rates. |
(4) | The three months ended January 24, 2025 excludes $86 million of revenue adjustments related to $17 million of inorganic revenue for the transition activity noted in (2), and $103 million of unfavorable currency impact on the remaining segments. The three months ended January 26, 2024 excludes $34 million of inorganic revenue related to the transition activity noted in (2). |
(5) | The nine months ended January 24, 2025 excludes $183 million of revenue adjustments related to $90 million of incremental Italian payback accruals further described in note (2), $55 million of inorganic revenue related to the transition activity noted in (2), and $149 million of unfavorable currency impact on the remaining segments. The nine months ended January 26, 2024 excludes $99 million of inorganic revenue related to the transition activity noted in (2). |
MEDTRONIC PLC CONSOLIDATED STATEMENTS OF INCOME (Unaudited) | |||||||
Three months ended | Nine months ended | ||||||
(in millions, except per share data) | January 24, | January 26, | January 24, | January 26, | |||
Net sales | $Â Â Â Â Â Â Â Â Â Â Â 8,292 | $Â Â Â Â Â Â Â Â Â Â Â 8,089 | $Â Â Â Â Â Â Â Â Â 24,610 | $Â Â Â Â Â Â Â Â Â 23,775 | |||
Costs and expenses: | |||||||
Cost of products sold, excluding amortization of intangible assets | 2,779 | 2,782 | 8,485 | 8,172 | |||
Research and development expense | 675 | 695 | 2,048 | 2,060 | |||
Selling, general, and administrative expense | 2,717 | 2,673 | 8,129 | 7,971 | |||
Amortization of intangible assets | 416 | 419 | 1,243 | 1,274 | |||
Restructuring charges, net | 43 | 20 | 120 | 114 | |||
Certain litigation charges, net | 22 | — | 104 | 105 | |||
Other operating (income) expense, net | (5) | 17 | (38) | (13) | |||
Operating profit | 1,646 | 1,483 | 4,519 | 4,091 | |||
Other non-operating income, net | (72) | (177) | (403) | (407) | |||
Interest expense, net | 179 | 188 | 555 | 517 | |||
Income before income taxes | 1,540 | 1,472 | 4,367 | 3,982 | |||
Income tax provision | 237 | 135 | 737 | 936 | |||
Net income | 1,303 | 1,337 | 3,630 | 3,045 | |||
Net income attributable to noncontrolling interests | (9) | (15) | (24) | (23) | |||
Net income attributable to Medtronic | $Â Â Â Â Â Â Â Â Â Â Â 1,294 | $Â Â Â Â Â Â Â Â Â Â Â 1,322 | $Â Â Â Â Â Â Â Â Â Â Â 3,606 | $Â Â Â Â Â Â Â Â Â Â Â 3,022 | |||
Basic earnings per share | $Â Â Â Â Â Â Â 1.01 | $Â Â Â Â Â Â Â 0.99 | $Â Â Â Â Â Â Â 2.80 | $Â Â Â Â Â Â Â 2.27 | |||
Diluted earnings per share | $Â Â Â Â Â Â Â 1.01 | $Â Â Â Â Â Â Â 0.99 | $Â Â Â Â Â Â Â 2.79 | $Â Â Â Â Â Â Â 2.27 | |||
Basic weighted average shares outstanding | 1,282.4 | 1,329.7 | 1,286.7 | 1,330.1 | |||
Diluted weighted average shares outstanding | 1,286.2 | 1,331.7 | 1,290.6 | 1,332.4 | |||
The data in the schedule above has been intentionally rounded to the nearest million. |
MEDTRONIC PLC GAAP TO NON-GAAP RECONCILIATIONS (1) (Unaudited) | |||||||||||||||||
Three months ended January 24, 2025 | |||||||||||||||||
(in millions, except per share data) | Net | Cost of | Gross | Operating | Operating | Income | Net Income | Diluted | Effective | ||||||||
GAAP | $Â 8,292 | $Â Â 2,779 | 66.5Â % | $Â Â Â Â 1,646 | 19.9Â % | $Â Â Â 1,540 | $Â Â Â Â Â Â 1,294 | $Â Â Â Â 1.01 | 15.4Â % | ||||||||
Non-GAAP Adjustments: | |||||||||||||||||
Amortization of intangible assets | — | — | — | 416 | 5.0 | 416 | 339 | 0.26 | 18.5 | ||||||||
Restructuring and associated costs (2) | — | (4) | — | 46 | 0.6 | 46 | 37 | 0.03 | 19.6 | ||||||||
Acquisition and divestiture-related items (3) | — | (1) | — | 28 | 0.3 | 28 | 23 | 0.02 | 17.9 | ||||||||
Certain litigation charges, net | — | — | — | 22 | 0.3 | 22 | 18 | 0.01 | 22.7 | ||||||||
(Gain)/loss on minority investments (4) | — | — | — | — | — | 68 | 52 | 0.04 | 22.1 | ||||||||
Medical device regulations (5) | — | (8) | 0.1 | 11 | 0.1 | 11 | 9 | 0.01 | 18.2 | ||||||||
Certain tax adjustments, net | — | — | — | — | — | — | 15 | 0.01 | — | ||||||||
Non-GAAP | $Â 8,292 | $Â Â 2,766 | 66.6Â % | $Â Â Â Â 2,169 | 26.2Â % | $Â Â Â 2,130 | $Â Â Â Â Â Â 1,787 | $Â Â Â Â 1.39 | 15.7Â % | ||||||||
Currency impact | 104 | 61 | (0.3) | (4) | (0.4) | (0.01) | |||||||||||
Currency Adjusted | $Â 8,396 | $Â Â 2,827 | 66.3Â % | $Â Â Â Â 2,165 | 25.8Â % | $Â Â Â Â 1.38 | |||||||||||
Three months ended January 26, 2024 | |||||||||||||||||
(in millions, except per share data) | Net | Cost of | Gross | Operating | Operating | Income | Net Income | Diluted | Effective | ||||||||
GAAP | $Â 8,089 | $Â Â 2,782 | 65.6Â % | $Â Â Â Â 1,483 | 18.3Â % | $Â Â Â 1,472 | $Â Â Â Â Â Â 1,322 | $Â Â Â Â 0.99 | 9.2Â % | ||||||||
Non-GAAP Adjustments: | |||||||||||||||||
Amortization of intangible assets | — | — | — | 419 | 5.2 | 419 | 354 | 0.27 | 15.5 | ||||||||
Restructuring and associated costs (2) | — | (12) | 0.1 | 55 | 0.7 | 55 | 46 | 0.03 | 16.4 | ||||||||
Acquisition and divestiture-related items (3) | — | (12) | 0.1 | 58 | 0.7 | 58 | 52 | 0.04 | 10.3 | ||||||||
(Gain)/loss on minority investments (4) | — | — | — | — | — | 24 | 24 | 0.02 | — | ||||||||
Medical device regulations (5) | — | (18) | 0.2 | 26 | 0.3 | 26 | 21 | 0.02 | 19.2 | ||||||||
Certain tax adjustments, net (6) | — | — | — | — | — | — | (92) | (0.07) | — | ||||||||
Non-GAAP | $Â 8,089 | $Â Â 2,740 | 66.1Â % | $Â Â Â Â 2,042 | 25.2Â % | $Â Â Â 2,055 | $Â Â Â Â Â Â 1,728 | $Â Â Â Â 1.30 | 15.2Â % | ||||||||
See description of non-GAAP financial measures contained in the press release dated February 18, 2025. | |
(1) | The data in this schedule has been intentionally rounded to the nearest million or $0.01 for EPS figures, and, therefore, may not sum. |
(2) | Associated costs primarily include salaries and wages for employees supporting the restructuring activities, consulting expenses, and asset write-offs. |
(3) | The charges primarily include business combination costs, changes in fair value of contingent consideration, and exit of business-related charges. |
(4) | We exclude unrealized and realized gains and losses on our minority investments as we do not believe that these components of income or expense have a direct correlation to our ongoing or future business operations. |
(5) | The charges represent incremental costs of complying with the new European Union (E.U.) medical device regulations for previously registered products and primarily include charges for contractors supporting the project and other direct third-party expenses. We consider these costs to be duplicative of previously incurred costs and/or one-time costs, which are limited to a specific time period. |
(6) | The net tax benefit primarily relates to a change in a Swiss Cantonal tax rate associated with previously established deferred tax assets from intercompany intellectual property transactions and the step up in tax basis for Swiss Cantonal purposes. |
MEDTRONIC PLC GAAP TO NON-GAAP RECONCILIATIONS (1) (Unaudited) | |||||||||||||||||
Nine months ended January 24, 2025 | |||||||||||||||||
(in millions, except per share data) | Net | Cost of | Gross | Operating | Operating | Income | Net Income | Diluted | Effective | ||||||||
GAAP | $ 24,610 | $Â Â 8,485 | 65.5Â % | $Â Â Â Â 4,519 | 18.4Â % | $Â Â Â 4,367 | $Â Â Â Â Â Â Â Â 3,606 | $Â Â Â Â 2.79 | 16.9Â % | ||||||||
Non-GAAP Adjustments: | |||||||||||||||||
Amortization of intangible assets | — | — | — | 1,243 | 4.9 | 1,243 | 1,017 | 0.79 | 18.3 | ||||||||
Restructuring and associated costs (2) | — | (24) | 0.1 | 154 | 0.6 | 154 | 124 | 0.10 | 19.5 | ||||||||
Acquisition and divestiture-related items (3) | — | (17) | — | 15 | 0.1 | 15 | 3 | — | 73.3 | ||||||||
Certain litigation charges, net | — | — | — | 104 | 0.4 | 104 | 86 | 0.07 | 17.3 | ||||||||
(Gain)/loss on minority investments (4) | — | — | — | — | — | 41 | 14 | 0.01 | 61.0 | ||||||||
Medical device regulations (5) | — | (27) | 0.1 | 38 | 0.2 | 38 | 30 | 0.02 | 21.1 | ||||||||
Other (6) | 90 | — | 0.2 | 90 | 0.4 | 90 | 70 | 0.05 | 22.2 | ||||||||
Certain tax adjustments, net (7) | — | — | — | — | — | — | 49 | 0.04 | — | ||||||||
Non-GAAP | $ 24,700 | $Â Â 8,417 | 65.9Â % | $Â Â Â Â 6,162 | 24.9Â % | $Â Â Â 6,051 | $Â Â Â Â Â Â Â Â 4,999 | $Â Â Â Â 3.87 | 17.0Â % | ||||||||
Currency impact | 150 | (72) | 0.5 | 241 | 0.9 | 0.15 | |||||||||||
Currency Adjusted | $ 24,850 | $Â Â 8,345 | 66.4Â % | $Â Â Â Â 6,403 | 25.8Â % | $Â Â Â Â 4.02 | |||||||||||
Nine months ended January 26, 2024 | |||||||||||||||||
(in millions, except per share data) | Net | Cost of | Gross | Operating | Operating | Income | Net Income | Diluted | Effective | ||||||||
GAAP | $ 23,775 | $Â Â 8,172 | 65.6Â % | $Â Â Â Â 4,091 | 17.2Â % | $Â Â Â 3,982 | $Â Â Â Â Â Â Â Â 3,022 | $Â Â Â Â 2.27 | 23.5Â % | ||||||||
Non-GAAP Adjustments: | |||||||||||||||||
Amortization of intangible assets | — | — | — | 1,274 | 5.4 | 1,274 | 1,078 | 0.81 | 15.4 | ||||||||
Restructuring and associated costs (2) | — | (43) | 0.2 | 237 | 1.0 | 237 | 198 | 0.15 | 16.5 | ||||||||
Acquisition and divestiture-related items (3) | — | (24) | 0.1 | 165 | 0.7 | 165 | 149 | 0.11 | 9.7 | ||||||||
Certain litigation charges, net | — | — | — | 105 | 0.4 | 105 | 81 | 0.06 | 22.9 | ||||||||
(Gain)/loss on minority investments (4) | — | — | — | — | — | 113 | 109 | 0.08 | 4.4 | ||||||||
Medical device regulations (5) | — | (60) | 0.3 | 88 | 0.4 | 88 | 70 | 0.05 | 20.5 | ||||||||
Certain tax adjustments, net (8) | — | — | — | — | — | — | 282 | 0.21 | — | ||||||||
Non-GAAP | $ 23,775 | $Â Â 8,046 | 66.2Â % | $Â Â Â Â 5,961 | 25.1Â % | $Â Â Â 5,965 | $Â Â Â Â Â Â Â Â 4,988 | $Â Â Â Â 3.74 | 16.0Â % | ||||||||
See description of non-GAAP financial measures contained in the press release dated February 18, 2025. | |
(1) | The data in this schedule has been intentionally rounded to the nearest million or $0.01 for EPS figures, and, therefore, may not sum. |
(2) | Associated costs primarily include salaries and wages for employees supporting the restructuring activities, consulting expenses, and asset write-offs. |
(3) | The charges primarily include business combination costs, changes in fair value of contingent consideration, and exit of business-related charges. The nine months ended January 24, 2025, also include gains related to certain business or asset sales. |
(4) | We exclude unrealized and realized gains and losses on our minority investments as we do not believe that these components of income or expense have a direct correlation to our ongoing or future business operations. |
(5) | The charges represent incremental costs of complying with the new European Union (E.U.) medical device regulations for previously registered products and primarily include charges for contractors supporting the project and other direct third-party expenses. We consider these costs to be duplicative of previously incurred costs and/or one-time costs, which are limited to a specific time period. |
(6) | Reflects the recognition of incremental Italian payback accruals resulting from the two July 22, 2024 rulings by the Constitutional Court of Italy relating to certain prior years since 2015. |
(7) | Primarily relates to amortization of previously established deferred tax assets from intercompany intellectual property transactions. |
(8) | The net charge primarily relates to an income tax reserve adjustment associated with the June 2023, Israeli Central-Lod District Court decision and the establishment of a valuation allowance against certain net operating losses which were partially offset by a benefit from the change in a Swiss Cantonal tax rate associated with previously established deferred tax assets from intercompany intellectual property transactions and the step up in tax basis for Swiss Cantonal purposes. |
MEDTRONIC PLC GAAP TO NON-GAAP RECONCILIATIONS (1) (Unaudited) | |||||||||||||||
Three months ended January 24, 2025 | |||||||||||||||
(in millions) | Net Sales | SG&A | SG&A | R&D | R&D | Other | Other | Other Non- | |||||||
GAAP | $Â Â Â Â Â 8,292 | $Â Â Â Â 2,717 | 32.8Â % | $Â Â Â Â Â Â 675 | 8.1Â % | $Â Â Â Â Â Â Â Â Â Â (5) | (0.1)Â % | $Â Â Â Â Â Â Â Â Â Â (72) | |||||||
Non-GAAP Adjustments: | |||||||||||||||
Acquisition and divestiture-related items (2) | — | (13) | (0.2) | — | — | (13) | (0.2) | — | |||||||
Medical device regulations (3) | — | — | — | (3) | — | — | — | — | |||||||
(Gain)/loss on minority investments (4) | — | — | — | — | — | — | — | (68) | |||||||
Non-GAAP | $Â Â Â Â Â 8,292 | $Â Â Â Â 2,704 | 32.6Â % | $Â Â Â Â Â Â 672 | 8.1Â % | $Â Â Â Â Â Â Â Â (18) | (0.2)Â % | $Â Â Â Â Â Â Â Â Â (140) | |||||||
Nine months ended January 24, 2025 | |||||||||||||||
(in millions) | Net Sales | SG&A | SG&A | R&D | R&D | Other | Other | Other Non- | |||||||
GAAP | $Â Â Â 24,610 | $Â Â Â Â 8,129 | 33.0Â % | $Â Â Â 2,048 | 8.3Â % | $Â Â Â Â Â Â Â Â (38) | (0.2)Â % | $Â Â Â Â Â Â Â Â Â (403) | |||||||
Non-GAAP Adjustments: | |||||||||||||||
Restructuring and associated costs (5) | — | (10) | (0.1) | — | — | — | — | — | |||||||
Acquisition and divestiture-related items (2) | — | (40) | (0.3) | — | — | 42 | 0.2 | — | |||||||
Medical device regulations (3) | — | — | — | (10) | — | — | — | — | |||||||
Other (6) | 90 | — | — | — | — | — | — | — | |||||||
(Gain)/loss on minority investments (4) | — | — | — | — | — | — | — | (41) | |||||||
Non-GAAP | $   24,700 | $    8,078 | 32.7 % | $   2,038 | 8.3 % | $            4 | — % | $         (443) | |||||||
See description of non-GAAP financial measures contained in the press release dated February 18, 2025. | |
(1) | The data in this schedule has been intentionally rounded to the nearest million, and, therefore, may not sum. |
(2) | The charges primarily include business combination costs, changes in fair value of contingent consideration, exit of business-related charges, and gains related to certain business or asset sales. The nine months ended January 24, 2025, also include gains related to certain business or asset sales. |
(3) | The charges represent incremental costs of complying with the new European Union medical device regulations for previously registered products and primarily include charges for contractors supporting the project and other direct third-party expenses. We consider these costs to be duplicative of previously incurred costs and/or one-time costs, which are limited to a specific time period. |
(4) | We exclude unrealized and realized gains and losses on our minority investments as we do not believe that these components of income or expense have a direct correlation to our ongoing or future business operations. |
(5) | Associated costs primarily include salaries and wages for employees supporting the restructuring activities, consulting expenses, and asset write-offs. |
(6) | Reflects the recognition of incremental Italian payback accruals resulting from the two July 22, 2024 rulings by the Constitutional Court of Italy relating to certain prior years since 2015. |
MEDTRONIC PLC GAAP TO NON-GAAP RECONCILIATIONS (1) (Unaudited) | |||
Nine months ended | |||
(in millions) | January 24, 2025 | January 26, 2024 | |
Net cash provided by operating activities | $Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 4,516 | $Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 4,010 | |
Additions to property, plant, and equipment | (1,400) | (1,161) | |
Free Cash Flow (2) | $Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 3,116 | $Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 2,849 | |
See description of non-GAAP financial measures contained in the press release dated February 18, 2025. | |
(1) | The data in this schedule has been intentionally rounded to the nearest million, and, therefore, may not sum. |
(2) | Free cash flow represents operating cash flows less property, plant, and equipment additions. |
MEDTRONIC PLC CONSOLIDATED BALANCE SHEETS (Unaudited) | ||||
(in millions) | January 24, 2025 | April 26, 2024 | ||
ASSETS | ||||
Current assets: | ||||
Cash and cash equivalents | $Â Â Â Â Â Â Â Â Â Â Â Â Â Â 1,240 | $Â Â Â Â Â Â Â Â Â Â Â Â Â Â 1,284 | ||
Investments | 6,682 | 6,721 | ||
Accounts receivable, less allowances and credit losses of $204 and $173, respectively | 6,115 | 6,128 | ||
Inventories | 5,610 | 5,217 | ||
Other current assets | 2,865 | 2,584 | ||
Total current assets | 22,513 | 21,935 | ||
Property, plant, and equipment, net | 6,593 | 6,131 | ||
Goodwill | 40,819 | 40,986 | ||
Other intangible assets, net | 12,184 | 13,225 | ||
Tax assets | 3,614 | 3,657 | ||
Other assets | 4,250 | 4,047 | ||
Total assets | $Â Â Â Â Â Â Â Â Â Â Â Â 89,973 | $Â Â Â Â Â Â Â Â Â Â Â Â 89,981 | ||
LIABILITIES AND EQUITY | ||||
Current liabilities: | ||||
Current debt obligations | $Â Â Â Â Â Â Â Â Â Â Â Â Â Â 2,622 | $Â Â Â Â Â Â Â Â Â Â Â Â Â Â 1,092 | ||
Accounts payable | 2,286 | 2,410 | ||
Accrued compensation | 2,281 | 2,375 | ||
Accrued income taxes | 1,125 | 1,330 | ||
Other accrued expenses | 3,526 | 3,582 | ||
Total current liabilities | 11,840 | 10,789 | ||
Long-term debt | 23,985 | 23,932 | ||
Accrued compensation and retirement benefits | 1,063 | 1,101 | ||
Accrued income taxes | 1,485 | 1,859 | ||
Deferred tax liabilities | 452 | 515 | ||
Other liabilities | 1,533 | 1,365 | ||
Total liabilities | 40,358 | 39,561 | ||
Commitments and contingencies | ||||
Shareholders' equity: | ||||
Ordinary shares— par value $0.0001, 2.6 billion shares authorized, 1,283,266,154 and 1,311,337,531 shares issued and outstanding, respectively | — | — | ||
Additional paid-in capital | 20,910 | 23,129 | ||
Retained earnings | 31,317 | 30,403 | ||
Accumulated other comprehensive loss | (2,839) | (3,318) | ||
Total shareholders' equity | 49,387 | 50,214 | ||
Noncontrolling interests | 228 | 206 | ||
Total equity | 49,615 | 50,420 | ||
Total liabilities and equity | $Â Â Â Â Â Â Â Â Â Â Â Â 89,973 | $Â Â Â Â Â Â Â Â Â Â Â Â 89,981 | ||
The data in this schedule has been intentionally rounded to the nearest million, and, therefore, may not sum. |
MEDTRONIC PLC CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) | |||
Nine months ended | |||
(in millions) | January 24, 2025 | January 26, 2024 | |
Operating Activities: | |||
Net income | $Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 3,630 | $Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 3,045 | |
Adjustments to reconcile net income to net cash provided by operating activities: | |||
Depreciation and amortization | 2,021 | 1,993 | |
Provision for credit losses | 96 | 62 | |
Deferred income taxes | (81) | (250) | |
Stock-based compensation | 340 | 303 | |
Other, net | 14 | 265 | |
Change in operating assets and liabilities, net of acquisitions and divestitures: | |||
Accounts receivable, net | (184) | (140) | |
Inventories | (478) | (530) | |
Accounts payable and accrued liabilities | (157) | (253) | |
Other operating assets and liabilities | (685) | (485) | |
Net cash provided by operating activities | 4,516 | 4,010 | |
Investing Activities: | |||
Acquisitions, net of cash acquired | (98) | (74) | |
Additions to property, plant, and equipment | (1,400) | (1,161) | |
Purchases of investments | (6,093) | (5,422) | |
Sales and maturities of investments | 6,255 | 5,142 | |
Other investing activities, net | (111) | (155) | |
Net cash used in investing activities | (1,447) | (1,670) | |
Financing Activities: | |||
Change in current debt obligations, net | (1,070) | 1,010 | |
Issuance of long-term debt | 3,209 | — | |
Dividends to shareholders | (2,692) | (2,753) | |
Issuance of ordinary shares | 400 | 206 | |
Repurchase of ordinary shares | (2,961) | (510) | |
Other financing activities, net | 96 | (44) | |
Net cash used in financing activities | (3,018) | (2,091) | |
Effect of exchange rate changes on cash and cash equivalents | (95) | (170) | |
Net change in cash and cash equivalents | (44) | 80 | |
Cash and cash equivalents at beginning of period | 1,284 | 1,543 | |
Cash and cash equivalents at end of period | $Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 1,240 | $Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 1,623 | |
Supplemental Cash Flow Information | |||
Cash paid for: | |||
Income taxes | $Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 1,515 | $Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 1,403 | |
Interest | 567 | 568 | |
The data in this schedule has been intentionally rounded to the nearest million, and, therefore, may not sum. |
About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland , is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE: MDT), visit www.Medtronic.com and follow on LinkedIn .
FORWARD LOOKING STATEMENTS
 This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties, including risks related to competitive factors, difficulties and delays inherent in the development, manufacturing, marketing and sale of medical products, government regulation, geopolitical conflicts, changing global trade policies, general economic conditions, and other risks and uncertainties described in the company's periodic reports on file with the U.S. Securities and Exchange Commission including the most recent Annual Report on Form 10-K of the company. In some cases, you can identify these statements by forward-looking words or expressions, such as "anticipate," "believe," "could," "estimate," "expect," "forecast," "intend," "looking ahead," "may," "plan," "possible," "potential," "project," "should," "going to," "will," and similar words or expressions, the negative or plural of such words or expressions and other comparable terminology. Actual results may differ materially from anticipated results. Medtronic does not undertake to update its forward-looking statements or any of the information contained in this press release, including to reflect future events or circumstances.
NON-GAAP FINANCIAL MEASURES
 This press release contains financial measures, including adjusted net income, adjusted diluted EPS, and organic revenue, which are considered "non-GAAP" financial measures under applicable SEC rules and regulations. References to quarterly or annual figures increasing, decreasing or remaining flat are in comparison to fiscal year 2024, and references to sequential changes are in comparison to the prior fiscal quarter.
Medtronic management believes that non-GAAP financial measures provide information useful to investors in understanding the company's underlying operational performance and trends and to facilitate comparisons with the performance of other companies in the med tech industry. Non-GAAP net income and diluted EPS exclude the effect of certain charges or gains that contribute to or reduce earnings but that result from transactions or events that management believes may or may not recur with similar materiality or impact to operations in future periods (Non-GAAP Adjustments). Medtronic generally uses non-GAAP financial measures to facilitate management's review of the operational performance of the company and as a basis for strategic planning. Non-GAAP financial measures should be considered supplemental to and not a substitute for financial information prepared in accordance with U.S. generally accepted accounting principles (GAAP), and investors are cautioned that Medtronic may calculate non-GAAP financial measures in a way that is different from other companies. Management strongly encourages investors to review the company's consolidated financial statements and publicly filed reports in their entirety. Reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures are included in the financial schedules accompanying this press release.
Medtronic calculates forward-looking non-GAAP financial measures based on internal forecasts that omit certain amounts that would be included in GAAP financial measures. For instance, forward-looking organic revenue growth guidance excludes the impact of foreign currency fluctuations, as well as significant acquisitions or divestitures. Forward-looking diluted non-GAAP EPS guidance also excludes other potential charges or gains that would be recorded as Non-GAAP Adjustments to earnings during the fiscal year. Medtronic does not attempt to provide reconciliations of forward-looking non-GAAP EPS guidance to projected GAAP EPS guidance because the combined impact and timing of recognition of these potential charges or gains is inherently uncertain and difficult to predict and is unavailable without unreasonable efforts. In addition, the company believes such reconciliations would imply a degree of precision and certainty that could be confusing to investors. Such items could have a substantial impact on GAAP measures of financial performance.
-end-
Contacts: | |
Erika Winkels | Ryan Weispfenning |
Public Relations | Investor Relations |
+1-763-526-8478 | +1-763-505-4626 |
View original content to download multimedia: https://www.prnewswire.com/news-releases/medtronic-reports-third-quarter-fiscal-2025-financial-results-302378617.html
SOURCE Medtronic plc
News Provided by PR Newswire via QuoteMedia
Delivering durable revenue growth with strong earnings power; strength in Pulsed Field Ablation, Pacing, Structural Heart, Diabetes, and Neuromodulation
Medtronic plc (NYSE: MDT) today announced financial results for its third quarter (Q3) of fiscal year 2025 (FY25), which ended January 24, 2025 .
Key Highlights
Financial Results
Medtronic reported Q3 worldwide revenue of $8.292 billion , an increase of 2.5% as reported and 4.1% on an organic basis. Organic revenue growth comparison excludes:
As reported, Q3 GAAP net income and diluted earnings per share (EPS) were $1.294 billion and $1.01 , respectively, representing a decrease of 2% and an increase of 2%, respectively. As detailed in the financial schedules included at the end of this release, Q3 non-GAAP net income and non-GAAP diluted EPS were $1.787 billion and $1.39 , respectively, representing increases of 3% and 7%, respectively.
"We delivered strong earnings this quarter, with significant improvements in both our gross margin and operating margin on the back of our ninth quarter in a row of mid-single digit organic revenue growth," said Geoff Martha , Medtronic chairman and chief executive officer. "We are starting to see the results from our long term investments in groundbreaking innovation, such as pulsed field ablation, to drive growth in some of the most attractive markets in MedTech."
Cardiovascular Portfolio
The Cardiovascular Portfolio includes the Cardiac Rhythm & Heart Failure (CRHF), Structural Heart & Aortic (SHA), and Coronary & Peripheral Vascular (CPV) divisions. Revenue of $3.037 billion increased 3.7% as reported and 5.0% organic, with mid-single digit increases in CRHF and SH&A, and a low-single digit increase in CPV, all on an organic basis.
Neuroscience Portfolio
The Neuroscience Portfolio includes the Cranial & Spinal Technologies (CST), Specialty Therapies, and Neuromodulation divisions. Revenue of $2.458 billion increased 4.4% as reported and 5.2% organic, with a low-double digit increase in Neuromodulation, mid-single digit increase in CST, and low-single digit increase in Specialty Therapies, all on an organic basis.
Medical Surgical Portfolio
The Medical Surgical Portfolio includes the Surgical & Endoscopy (SE) and the Acute Care & Monitoring (ACM) divisions. Revenue of $2.072 billion decreased 1.9% as reported and decreased 0.4% organic, with flat organic result in SE and low-single digit organic decline in ACM.
Diabetes
Revenue of $694 million increased 8.4% as reported and 10.4% organic.
Guidance
Medtronic today reiterated its revenue growth and EPS guidance for FY25.
The company continues to expect FY25 organic revenue growth in the range of 4.75% to 5%. The organic revenue growth guidance excludes the impact of foreign currency and revenue reported as Other. Including Other revenue and the impact of foreign currency exchange, if recent foreign currency exchange rates hold, FY25 revenue growth would be in the range of 3.4% to 3.8%.
The company continues to expect FY25 diluted non-GAAP EPS in the range of $5.44 to $5.50 . This includes an estimated -5% impact from foreign currency exchange based on recent rates. The company's guidance represents FY25 diluted non-GAAP EPS growth in the range of 4.6% to 5.8%.
"EPS came in above the high end of our guidance range. We were pleased with the operational performance of the business this quarter, turning mid-single digit organic growth into leveraged earnings, highlighted by healthy gross margin improvement," said Gary Corona , Medtronic interim chief financial officer. "Looking ahead, our restored earnings power continues. We will accelerate both top and bottom line growth in Q4, resulting in high-single digit adjusted EPS growth in the back half of our fiscal year."
Video Webcast Information
Medtronic will host a video webcast today, February 18 , at 8:00 a.m. EST ( 7:00 a.m. CST ) to provide information about its businesses for the public, investors, analysts, and news media. This webcast can be accessed by clicking on the Events icon at investorrelations.medtronic.com , and this earnings release will be archived at news.medtronic.com . Within 24 hours of the webcast, a replay of the webcast and transcript of the company's prepared remarks will be available by clicking on the Events icon at investorrelations.medtronic.com .
Medtronic plans to report its FY25 fourth quarter results on Wednesday, May 21, 2025 . For fiscal year 2026, Medtronic plans to report its first, second, third, and fourth quarter results on Tuesday, August 19, 2025 , November 18, 2025 , February 17, 2026 , and Wednesday, May 20, 2026 , respectively. Confirmation and additional details will be provided closer to the specific event.
Financial Schedules and Earnings Presentation
The third quarter financial schedules and non-GAAP reconciliations can be viewed by clicking on the Investor Events link at investorrelations.medtronic.com . To view a printable PDF of the financial schedules and non-GAAP reconciliations, click here . To view the third quarter earnings presentation, click here .
MEDTRONIC PLC WORLD WIDE REVENUE (1) (Unaudited) | ||||||||||||||||||||||||||||
THIRD QUARTER | YEAR-TO-DATE | |||||||||||||||||||||||||||
REPORTED | ORGANIC | REPORTED | ORGANIC | |||||||||||||||||||||||||
(in millions) | FY25 | FY24 | Growth | Currency | Adjusted | Adjusted | Growth | FY25 | FY24 | Growth | Currency | Adjusted | Adjusted | Growth | ||||||||||||||
Cardiovascular | $Â Â Â Â 3,037 | $Â Â Â Â 2,929 | 3.7Â % | $Â Â Â Â Â Â Â (38) | $Â Â Â Â 3,075 | $Â Â Â Â 2,929 | 5.0Â % | $Â Â Â Â 9,145 | $Â Â Â Â 8,702 | 5.1Â % | $Â Â Â Â Â Â Â (62) | $Â Â Â Â 9,207 | $Â Â Â Â 8,702 | 5.8Â % | ||||||||||||||
Cardiac Rhythm & Heart Failure | 1,545 | 1,470 | 5.1 | (18) | 1,563 | 1,470 | 6.3 | 4,659 | 4,408 | 5.7 | (26) | 4,684 | 4,408 | 6.3 | ||||||||||||||
Structural Heart & Aortic | 874 | 843 | 3.7 | (13) | 887 | 843 | 5.2 | 2,610 | 2,475 | 5.4 | (21) | 2,631 | 2,475 | 6.3 | ||||||||||||||
Coronary & Peripheral Vascular | 618 | 616 | 0.3 | (8) | 626 | 616 | 1.6 | 1,876 | 1,818 | 3.2 | (15) | 1,891 | 1,818 | 4.0 | ||||||||||||||
Neuroscience | 2,458 | 2,355 | 4.4 | (21) | 2,478 | 2,355 | 5.2 | 7,226 | 6,861 | 5.3 | (29) | 7,255 | 6,861 | 5.7 | ||||||||||||||
Cranial & Spinal Technologies | 1,250 | 1,204 | 3.8 | (9) | 1,259 | 1,204 | 4.6 | 3,632 | 3,465 | 4.8 | (15) | 3,646 | 3,465 | 5.2 | ||||||||||||||
Specialty Therapies | 732 | 726 | 0.8 | (8) | 740 | 726 | 1.9 | 2,181 | 2,126 | 2.6 | (10) | 2,191 | 2,126 | 3.1 | ||||||||||||||
Neuromodulation | 476 | 425 | 12.0 | (4) | 480 | 425 | 12.9 | 1,413 | 1,270 | 11.2 | (5) | 1,417 | 1,270 | 11.6 | ||||||||||||||
Medical Surgical | 2,072 | 2,112 | (1.9) | (32) | 2,104 | 2,112 | (0.4) | 6,196 | 6,219 | (0.4) | (50) | 6,246 | 6,219 | 0.4 | ||||||||||||||
Surgical & Endoscopy | 1,596 | 1,616 | (1.2) | (26) | 1,622 | 1,616 | 0.4 | 4,790 | 4,803 | (0.3) | (40) | 4,829 | 4,803 | 0.5 | ||||||||||||||
Acute Care & Monitoring | 476 | 495 | (3.9) | (5) | 481 | 495 | (2.8) | 1,406 | 1,416 | (0.7) | (10) | 1,417 | 1,416 | — | ||||||||||||||
Diabetes | 694 | 640 | 8.4 | (12) | 706 | 640 | 10.4 | 2,027 | 1,829 | 10.8 | (8) | 2,035 | 1,829 | 11.3 | ||||||||||||||
Total Reportable Segments | 8,260 | 8,035 | 2.8 | (103) | 8,363 | 8,035 | 4.1 | 24,593 | 23,610 | 4.2 | (149) | 24,742 | 23,610 | 4.8 | ||||||||||||||
Other (2) | 32 | 53 | (41.1) | (1) | — | — | — | 17 | 164 | (89.9) | (3) | — | — | — | ||||||||||||||
TOTAL | $Â Â Â Â 8,292 | $Â Â Â Â 8,089 | 2.5Â % | $Â Â Â Â Â (104) | $Â Â Â Â 8,363 | $Â Â Â Â 8,035 | 4.1Â % | $Â Â Â 24,610 | $Â Â Â 23,775 | 3.5Â % | $Â Â Â Â Â (152) | $Â Â Â 24,742 | $Â Â Â 23,610 | 4.8Â % | ||||||||||||||
(1) | The data in this schedule has been intentionally rounded to the nearest million and, therefore, may not sum. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. |
(2) | Includes historical operations and ongoing transition agreements from businesses the Company has exited or divested, and specifically for the three months ended July 26, 2024, impacting year-to-date figures, $90 million of incremental Italian payback accruals resulting from the two July 22, 2024 rulings by the Constitutional Court of Italy relating to certain prior years since 2015. |
(3) | The currency impact to revenue measures the change in revenue between current and prior year periods using constant exchange rates. |
(4) | The three months ended January 24, 2025 excludes $71 million of revenue adjustments related to $32 million of inorganic revenue for the transition activity noted in (2) and $103 million of unfavorable currency impact on the remaining segments. The three months ended January 26, 2024 excludes $53 million of inorganic revenue related to the transition activity noted in (2). |
(5) | The nine months ended January 24, 2025 excludes $132 million of revenue adjustments related to $90 million of incremental Italian payback accruals further described in note (2), $106 million of inorganic revenue related to the transition activity noted in (2), and $149 million of unfavorable currency impact on the remaining segments. The nine months ended January 26, 2024 excludes $164 million of inorganic revenue related to the transition activity noted in (2). |
MEDTRONIC PLC U.S. REVENUE (1)(2) (Unaudited) | ||||||||||||||||||||||||
THIRD QUARTER | YEAR-TO-DATE | |||||||||||||||||||||||
REPORTED | ORGANIC | REPORTED | ORGANIC | |||||||||||||||||||||
(in millions) | FY25 | FY24 | Growth | Adjusted | Adjusted | Growth | FY25 | FY24 | Growth | Adjusted | Adjusted | Growth | ||||||||||||
Cardiovascular | $Â Â Â Â 1,405 | $Â Â Â Â 1,373 | 2.4Â % | $Â Â Â Â 1,405 | $Â Â Â Â 1,373 | 2.4Â % | $Â Â Â Â 4,242 | $Â Â Â Â 4,149 | 2.2Â % | $Â Â Â Â 4,242 | $Â Â Â Â 4,149 | 2.2Â % | ||||||||||||
Cardiac Rhythm & Heart Failure | 775 | 745 | 4.1 | 775 | 745 | 4.1 | 2,309 | 2,247 | 2.8 | 2,309 | 2,247 | 2.8 | ||||||||||||
Structural Heart & Aortic | 372 | 363 | 2.6 | 372 | 363 | 2.6 | 1,129 | 1,087 | 3.9 | 1,129 | 1,087 | 3.9 | ||||||||||||
Coronary & Peripheral Vascular | 258 | 265 | (2.8) | 258 | 265 | (2.8) | 804 | 816 | (1.4) | 804 | 816 | (1.4) | ||||||||||||
Neuroscience | 1,689 | 1,556 | 8.5 | 1,689 | 1,556 | 8.5 | 4,931 | 4,614 | 6.9 | 4,931 | 4,614 | 6.9 | ||||||||||||
Cranial & Spinal Technologies | 943 | 875 | 7.8 | 943 | 875 | 7.8 | 2,724 | 2,560 | 6.4 | 2,724 | 2,560 | 6.4 | ||||||||||||
Specialty Therapies | 419 | 407 | 3.0 | 419 | 407 | 3.0 | 1,235 | 1,202 | 2.7 | 1,235 | 1,202 | 2.7 | ||||||||||||
Neuromodulation | 327 | 275 | 19.0 | 327 | 275 | 19.0 | 972 | 852 | 14.1 | 972 | 852 | 14.1 | ||||||||||||
Medical Surgical | 893 | 947 | (5.8) | 893 | 947 | (5.8) | 2,718 | 2,763 | (1.6) | 2,718 | 2,763 | (1.6) | ||||||||||||
Surgical & Endoscopy | 623 | 663 | (6.1) | 623 | 663 | (6.1) | 1,928 | 1,971 | (2.2) | 1,928 | 1,971 | (2.2) | ||||||||||||
Acute Care & Monitoring | 269 | 284 | (5.1) | 269 | 284 | (5.1) | 790 | 792 | (0.2) | 790 | 792 | (0.2) | ||||||||||||
Diabetes | 236 | 224 | 5.6 | 236 | 224 | 5.6 | 683 | 629 | 8.7 | 683 | 629 | 8.7 | ||||||||||||
Total Reportable Segments | 4,223 | 4,100 | 3.0 | 4,223 | 4,100 | 3.0 | 12,573 | 12,154 | 3.4 | 12,573 | 12,154 | 3.4 | ||||||||||||
Other (3) | 15 | 20 | (26.4) | — | — | — | 51 | 65 | (21.3) | — | — | — | ||||||||||||
TOTAL | $Â Â Â Â 4,237 | $Â Â Â Â 4,120 | 2.8Â % | $Â Â Â Â 4,223 | $Â Â Â Â 4,100 | 3.0Â % | $Â Â 12,624 | $Â Â 12,219 | 3.3Â % | $Â Â 12,573 | $Â Â 12,154 | 3.4Â % | ||||||||||||
(1) | U.S. includes the United States and U.S. territories. |
(2) | The data in this schedule has been intentionally rounded to the nearest million and, therefore, may not sum. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. |
(3) | Includes historical operations and ongoing transition agreements from businesses the Company has exited or divested. |
MEDTRONIC PLC INTERNATIONAL REVENUE (1) (Unaudited) | ||||||||||||||||||||||||||||
THIRD QUARTER | YEAR-TO-DATE | |||||||||||||||||||||||||||
REPORTED | ORGANIC | REPORTED | ORGANIC | |||||||||||||||||||||||||
(in millions) | FY25 | FY24 | Growth | Currency | Adjusted | Adjusted | Growth | FY25 | FY24 | Growth | Currency | Adjusted | Adjusted | Growth | ||||||||||||||
Cardiovascular | $Â Â Â Â 1,632 | $Â Â Â Â 1,556 | 4.9Â % | $Â Â Â Â Â Â Â (38) | $Â Â Â Â 1,670 | $Â Â Â Â 1,556 | 7.3Â % | $Â Â Â Â 4,904 | $Â Â Â Â 4,552 | 7.7Â % | $Â Â Â Â Â Â Â (62) | $Â Â Â Â 4,966 | $Â Â Â Â 4,552 | 9.1Â % | ||||||||||||||
Cardiac Rhythm & Heart Failure | 770 | 726 | 6.1 | (18) | 788 | 726 | 8.6 | 2,350 | 2,161 | 8.7 | (26) | 2,376 | 2,161 | 9.9 | ||||||||||||||
Structural Heart & Aortic | 502 | 480 | 4.6 | (13) | 515 | 480 | 7.2 | 1,482 | 1,389 | 6.7 | (21) | 1,503 | 1,389 | 8.2 | ||||||||||||||
Coronary & Peripheral Vascular | 360 | 350 | 2.6 | (8) | 368 | 350 | 4.9 | 1,072 | 1,002 | 7.0 | (15) | 1,087 | 1,002 | 8.5 | ||||||||||||||
Neuroscience | 769 | 799 | (3.7) | (21) | 790 | 799 | (1.1) | 2,295 | 2,248 | 2.1 | (29) | 2,324 | 2,248 | 3.4 | ||||||||||||||
Cranial & Spinal Technologies | 307 | 329 | (6.7) | (9) | 316 | 329 | (3.9) | 907 | 905 | 0.3 | (15) | 922 | 905 | 1.9 | ||||||||||||||
Specialty Therapies | 313 | 319 | (2.0) | (8) | 321 | 319 | 0.4 | 947 | 924 | 2.4 | (10) | 957 | 924 | 3.5 | ||||||||||||||
Neuromodulation | 149 | 150 | (0.7) | (4) | 153 | 150 | 1.8 | 441 | 419 | 5.4 | (5) | 446 | 419 | 6.5 | ||||||||||||||
Medical Surgical | 1,180 | 1,164 | 1.3 | (32) | 1,211 | 1,164 | 4.0 | 3,478 | 3,456 | 0.6 | (50) | 3,528 | 3,456 | 2.1 | ||||||||||||||
Surgical & Endoscopy | 973 | 953 | 2.1 | (26) | 999 | 953 | 4.9 | 2,862 | 2,832 | 1.1 | (40) | 2,902 | 2,832 | 2.5 | ||||||||||||||
Acute Care & Monitoring | 206 | 211 | (2.3) | (5) | 212 | 211 | 0.2 | 616 | 624 | (1.4) | (10) | 626 | 624 | 0.3 | ||||||||||||||
Diabetes | 457 | 416 | 9.9 | (12) | 470 | 416 | 12.9 | 1,344 | 1,200 | 12.0 | (8) | 1,351 | 1,200 | 12.6 | ||||||||||||||
Total Reportable Segments | 4,038 | 3,935 | 2.6 | (103) | 4,141 | 3,935 | 5.2 | 12,020 | 11,456 | 4.9 | (149) | 12,169 | 11,456 | 6.2 | ||||||||||||||
Other (2) | 17 | 34 | (49.8) | (1) | — | — | — | (35) | 99 | (134.8) | (3) | — | — | — | ||||||||||||||
TOTAL | $Â Â Â Â 4,055 | $Â Â Â Â 3,968 | 2.2Â % | $Â Â Â Â Â (104) | $Â Â Â Â 4,141 | $Â Â Â Â 3,935 | 5.2Â % | $Â Â 11,986 | $Â Â 11,555 | 3.7Â % | $Â Â Â Â Â (152) | $Â Â 12,169 | $Â Â 11,456 | 6.2Â % | ||||||||||||||
(1) | The data in this schedule has been intentionally rounded to the nearest million and, therefore, may not sum. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. |
(2) | Includes historical operations and ongoing transition agreements from businesses the Company has exited or divested, and specifically for the three months ended July 26, 2024, impacting year-to-date figures, $90 million of incremental Italian payback accruals resulting from the two July 22, 2024 rulings by the Constitutional Court of Italy relating to certain prior years since 2015. |
(3) | The currency impact to revenue measures the change in revenue between current and prior year periods using constant exchange rates. |
(4) | The three months ended January 24, 2025 excludes $86 million of revenue adjustments related to $17 million of inorganic revenue for the transition activity noted in (2), and $103 million of unfavorable currency impact on the remaining segments. The three months ended January 26, 2024 excludes $34 million of inorganic revenue related to the transition activity noted in (2). |
(5) | The nine months ended January 24, 2025 excludes $183 million of revenue adjustments related to $90 million of incremental Italian payback accruals further described in note (2), $55 million of inorganic revenue related to the transition activity noted in (2), and $149 million of unfavorable currency impact on the remaining segments. The nine months ended January 26, 2024 excludes $99 million of inorganic revenue related to the transition activity noted in (2). |
MEDTRONIC PLC CONSOLIDATED STATEMENTS OF INCOME (Unaudited) | |||||||
Three months ended | Nine months ended | ||||||
(in millions, except per share data) | January 24, | January 26, | January 24, | January 26, | |||
Net sales | $Â Â Â Â Â Â Â Â Â Â Â 8,292 | $Â Â Â Â Â Â Â Â Â Â Â 8,089 | $Â Â Â Â Â Â Â Â Â 24,610 | $Â Â Â Â Â Â Â Â Â 23,775 | |||
Costs and expenses: | |||||||
Cost of products sold, excluding amortization of intangible assets | 2,779 | 2,782 | 8,485 | 8,172 | |||
Research and development expense | 675 | 695 | 2,048 | 2,060 | |||
Selling, general, and administrative expense | 2,717 | 2,673 | 8,129 | 7,971 | |||
Amortization of intangible assets | 416 | 419 | 1,243 | 1,274 | |||
Restructuring charges, net | 43 | 20 | 120 | 114 | |||
Certain litigation charges, net | 22 | — | 104 | 105 | |||
Other operating (income) expense, net | (5) | 17 | (38) | (13) | |||
Operating profit | 1,646 | 1,483 | 4,519 | 4,091 | |||
Other non-operating income, net | (72) | (177) | (403) | (407) | |||
Interest expense, net | 179 | 188 | 555 | 517 | |||
Income before income taxes | 1,540 | 1,472 | 4,367 | 3,982 | |||
Income tax provision | 237 | 135 | 737 | 936 | |||
Net income | 1,303 | 1,337 | 3,630 | 3,045 | |||
Net income attributable to noncontrolling interests | (9) | (15) | (24) | (23) | |||
Net income attributable to Medtronic | $Â Â Â Â Â Â Â Â Â Â Â 1,294 | $Â Â Â Â Â Â Â Â Â Â Â 1,322 | $Â Â Â Â Â Â Â Â Â Â Â 3,606 | $Â Â Â Â Â Â Â Â Â Â Â 3,022 | |||
Basic earnings per share | $Â Â Â Â Â Â Â 1.01 | $Â Â Â Â Â Â Â 0.99 | $Â Â Â Â Â Â Â 2.80 | $Â Â Â Â Â Â Â 2.27 | |||
Diluted earnings per share | $Â Â Â Â Â Â Â 1.01 | $Â Â Â Â Â Â Â 0.99 | $Â Â Â Â Â Â Â 2.79 | $Â Â Â Â Â Â Â 2.27 | |||
Basic weighted average shares outstanding | 1,282.4 | 1,329.7 | 1,286.7 | 1,330.1 | |||
Diluted weighted average shares outstanding | 1,286.2 | 1,331.7 | 1,290.6 | 1,332.4 | |||
The data in the schedule above has been intentionally rounded to the nearest million. |
MEDTRONIC PLC GAAP TO NON-GAAP RECONCILIATIONS (1) (Unaudited) | |||||||||||||||||
Three months ended January 24, 2025 | |||||||||||||||||
(in millions, except per share data) | Net | Cost of | Gross | Operating | Operating | Income | Net Income | Diluted | Effective | ||||||||
GAAP | $Â 8,292 | $Â Â 2,779 | 66.5Â % | $Â Â Â Â 1,646 | 19.9Â % | $Â Â Â 1,540 | $Â Â Â Â Â Â 1,294 | $Â Â Â Â 1.01 | 15.4Â % | ||||||||
Non-GAAP Adjustments: | |||||||||||||||||
Amortization of intangible assets | — | — | — | 416 | 5.0 | 416 | 339 | 0.26 | 18.5 | ||||||||
Restructuring and associated costs (2) | — | (4) | — | 46 | 0.6 | 46 | 37 | 0.03 | 19.6 | ||||||||
Acquisition and divestiture-related items (3) | — | (1) | — | 28 | 0.3 | 28 | 23 | 0.02 | 17.9 | ||||||||
Certain litigation charges, net | — | — | — | 22 | 0.3 | 22 | 18 | 0.01 | 22.7 | ||||||||
(Gain)/loss on minority investments (4) | — | — | — | — | — | 68 | 52 | 0.04 | 22.1 | ||||||||
Medical device regulations (5) | — | (8) | 0.1 | 11 | 0.1 | 11 | 9 | 0.01 | 18.2 | ||||||||
Certain tax adjustments, net | — | — | — | — | — | — | 15 | 0.01 | — | ||||||||
Non-GAAP | $Â 8,292 | $Â Â 2,766 | 66.6Â % | $Â Â Â Â 2,169 | 26.2Â % | $Â Â Â 2,130 | $Â Â Â Â Â Â 1,787 | $Â Â Â Â 1.39 | 15.7Â % | ||||||||
Currency impact | 104 | 61 | (0.3) | (4) | (0.4) | (0.01) | |||||||||||
Currency Adjusted | $Â 8,396 | $Â Â 2,827 | 66.3Â % | $Â Â Â Â 2,165 | 25.8Â % | $Â Â Â Â 1.38 | |||||||||||
Three months ended January 26, 2024 | |||||||||||||||||
(in millions, except per share data) | Net | Cost of | Gross | Operating | Operating | Income | Net Income | Diluted | Effective | ||||||||
GAAP | $Â 8,089 | $Â Â 2,782 | 65.6Â % | $Â Â Â Â 1,483 | 18.3Â % | $Â Â Â 1,472 | $Â Â Â Â Â Â 1,322 | $Â Â Â Â 0.99 | 9.2Â % | ||||||||
Non-GAAP Adjustments: | |||||||||||||||||
Amortization of intangible assets | — | — | — | 419 | 5.2 | 419 | 354 | 0.27 | 15.5 | ||||||||
Restructuring and associated costs (2) | — | (12) | 0.1 | 55 | 0.7 | 55 | 46 | 0.03 | 16.4 | ||||||||
Acquisition and divestiture-related items (3) | — | (12) | 0.1 | 58 | 0.7 | 58 | 52 | 0.04 | 10.3 | ||||||||
(Gain)/loss on minority investments (4) | — | — | — | — | — | 24 | 24 | 0.02 | — | ||||||||
Medical device regulations (5) | — | (18) | 0.2 | 26 | 0.3 | 26 | 21 | 0.02 | 19.2 | ||||||||
Certain tax adjustments, net (6) | — | — | — | — | — | — | (92) | (0.07) | — | ||||||||
Non-GAAP | $Â 8,089 | $Â Â 2,740 | 66.1Â % | $Â Â Â Â 2,042 | 25.2Â % | $Â Â Â 2,055 | $Â Â Â Â Â Â 1,728 | $Â Â Â Â 1.30 | 15.2Â % | ||||||||
See description of non-GAAP financial measures contained in the press release dated February 18, 2025. | |
(1) | The data in this schedule has been intentionally rounded to the nearest million or $0.01 for EPS figures, and, therefore, may not sum. |
(2) | Associated costs primarily include salaries and wages for employees supporting the restructuring activities, consulting expenses, and asset write-offs. |
(3) | The charges primarily include business combination costs, changes in fair value of contingent consideration, and exit of business-related charges. |
(4) | We exclude unrealized and realized gains and losses on our minority investments as we do not believe that these components of income or expense have a direct correlation to our ongoing or future business operations. |
(5) | The charges represent incremental costs of complying with the new European Union (E.U.) medical device regulations for previously registered products and primarily include charges for contractors supporting the project and other direct third-party expenses. We consider these costs to be duplicative of previously incurred costs and/or one-time costs, which are limited to a specific time period. |
(6) | The net tax benefit primarily relates to a change in a Swiss Cantonal tax rate associated with previously established deferred tax assets from intercompany intellectual property transactions and the step up in tax basis for Swiss Cantonal purposes. |
MEDTRONIC PLC GAAP TO NON-GAAP RECONCILIATIONS (1) (Unaudited) | |||||||||||||||||
Nine months ended January 24, 2025 | |||||||||||||||||
(in millions, except per share data) | Net | Cost of | Gross | Operating | Operating | Income | Net Income | Diluted | Effective | ||||||||
GAAP | $ 24,610 | $Â Â 8,485 | 65.5Â % | $Â Â Â Â 4,519 | 18.4Â % | $Â Â Â 4,367 | $Â Â Â Â Â Â Â Â 3,606 | $Â Â Â Â 2.79 | 16.9Â % | ||||||||
Non-GAAP Adjustments: | |||||||||||||||||
Amortization of intangible assets | — | — | — | 1,243 | 4.9 | 1,243 | 1,017 | 0.79 | 18.3 | ||||||||
Restructuring and associated costs (2) | — | (24) | 0.1 | 154 | 0.6 | 154 | 124 | 0.10 | 19.5 | ||||||||
Acquisition and divestiture-related items (3) | — | (17) | — | 15 | 0.1 | 15 | 3 | — | 73.3 | ||||||||
Certain litigation charges, net | — | — | — | 104 | 0.4 | 104 | 86 | 0.07 | 17.3 | ||||||||
(Gain)/loss on minority investments (4) | — | — | — | — | — | 41 | 14 | 0.01 | 61.0 | ||||||||
Medical device regulations (5) | — | (27) | 0.1 | 38 | 0.2 | 38 | 30 | 0.02 | 21.1 | ||||||||
Other (6) | 90 | — | 0.2 | 90 | 0.4 | 90 | 70 | 0.05 | 22.2 | ||||||||
Certain tax adjustments, net (7) | — | — | — | — | — | — | 49 | 0.04 | — | ||||||||
Non-GAAP | $ 24,700 | $Â Â 8,417 | 65.9Â % | $Â Â Â Â 6,162 | 24.9Â % | $Â Â Â 6,051 | $Â Â Â Â Â Â Â Â 4,999 | $Â Â Â Â 3.87 | 17.0Â % | ||||||||
Currency impact | 150 | (72) | 0.5 | 241 | 0.9 | 0.15 | |||||||||||
Currency Adjusted | $ 24,850 | $Â Â 8,345 | 66.4Â % | $Â Â Â Â 6,403 | 25.8Â % | $Â Â Â Â 4.02 | |||||||||||
Nine months ended January 26, 2024 | |||||||||||||||||
(in millions, except per share data) | Net | Cost of | Gross | Operating | Operating | Income | Net Income | Diluted | Effective | ||||||||
GAAP | $ 23,775 | $Â Â 8,172 | 65.6Â % | $Â Â Â Â 4,091 | 17.2Â % | $Â Â Â 3,982 | $Â Â Â Â Â Â Â Â 3,022 | $Â Â Â Â 2.27 | 23.5Â % | ||||||||
Non-GAAP Adjustments: | |||||||||||||||||
Amortization of intangible assets | — | — | — | 1,274 | 5.4 | 1,274 | 1,078 | 0.81 | 15.4 | ||||||||
Restructuring and associated costs (2) | — | (43) | 0.2 | 237 | 1.0 | 237 | 198 | 0.15 | 16.5 | ||||||||
Acquisition and divestiture-related items (3) | — | (24) | 0.1 | 165 | 0.7 | 165 | 149 | 0.11 | 9.7 | ||||||||
Certain litigation charges, net | — | — | — | 105 | 0.4 | 105 | 81 | 0.06 | 22.9 | ||||||||
(Gain)/loss on minority investments (4) | — | — | — | — | — | 113 | 109 | 0.08 | 4.4 | ||||||||
Medical device regulations (5) | — | (60) | 0.3 | 88 | 0.4 | 88 | 70 | 0.05 | 20.5 | ||||||||
Certain tax adjustments, net (8) | — | — | — | — | — | — | 282 | 0.21 | — | ||||||||
Non-GAAP | $ 23,775 | $Â Â 8,046 | 66.2Â % | $Â Â Â Â 5,961 | 25.1Â % | $Â Â Â 5,965 | $Â Â Â Â Â Â Â Â 4,988 | $Â Â Â Â 3.74 | 16.0Â % | ||||||||
See description of non-GAAP financial measures contained in the press release dated February 18, 2025. | |
(1) | The data in this schedule has been intentionally rounded to the nearest million or $0.01 for EPS figures, and, therefore, may not sum. |
(2) | Associated costs primarily include salaries and wages for employees supporting the restructuring activities, consulting expenses, and asset write-offs. |
(3) | The charges primarily include business combination costs, changes in fair value of contingent consideration, and exit of business-related charges. The nine months ended January 24, 2025, also include gains related to certain business or asset sales. |
(4) | We exclude unrealized and realized gains and losses on our minority investments as we do not believe that these components of income or expense have a direct correlation to our ongoing or future business operations. |
(5) | The charges represent incremental costs of complying with the new European Union (E.U.) medical device regulations for previously registered products and primarily include charges for contractors supporting the project and other direct third-party expenses. We consider these costs to be duplicative of previously incurred costs and/or one-time costs, which are limited to a specific time period. |
(6) | Reflects the recognition of incremental Italian payback accruals resulting from the two July 22, 2024 rulings by the Constitutional Court of Italy relating to certain prior years since 2015. |
(7) | Primarily relates to amortization of previously established deferred tax assets from intercompany intellectual property transactions. |
(8) | The net charge primarily relates to an income tax reserve adjustment associated with the June 2023, Israeli Central-Lod District Court decision and the establishment of a valuation allowance against certain net operating losses which were partially offset by a benefit from the change in a Swiss Cantonal tax rate associated with previously established deferred tax assets from intercompany intellectual property transactions and the step up in tax basis for Swiss Cantonal purposes. |
MEDTRONIC PLC GAAP TO NON-GAAP RECONCILIATIONS (1) (Unaudited) | |||||||||||||||
Three months ended January 24, 2025 | |||||||||||||||
(in millions) | Net Sales | SG&A | SG&A | R&D | R&D | Other | Other | Other Non- | |||||||
GAAP | $Â Â Â Â Â 8,292 | $Â Â Â Â 2,717 | 32.8Â % | $Â Â Â Â Â Â 675 | 8.1Â % | $Â Â Â Â Â Â Â Â Â Â (5) | (0.1)Â % | $Â Â Â Â Â Â Â Â Â Â (72) | |||||||
Non-GAAP Adjustments: | |||||||||||||||
Acquisition and divestiture-related items (2) | — | (13) | (0.2) | — | — | (13) | (0.2) | — | |||||||
Medical device regulations (3) | — | — | — | (3) | — | — | — | — | |||||||
(Gain)/loss on minority investments (4) | — | — | — | — | — | — | — | (68) | |||||||
Non-GAAP | $Â Â Â Â Â 8,292 | $Â Â Â Â 2,704 | 32.6Â % | $Â Â Â Â Â Â 672 | 8.1Â % | $Â Â Â Â Â Â Â Â (18) | (0.2)Â % | $Â Â Â Â Â Â Â Â Â (140) | |||||||
Nine months ended January 24, 2025 | |||||||||||||||
(in millions) | Net Sales | SG&A | SG&A | R&D | R&D | Other | Other | Other Non- | |||||||
GAAP | $Â Â Â 24,610 | $Â Â Â Â 8,129 | 33.0Â % | $Â Â Â 2,048 | 8.3Â % | $Â Â Â Â Â Â Â Â (38) | (0.2)Â % | $Â Â Â Â Â Â Â Â Â (403) | |||||||
Non-GAAP Adjustments: | |||||||||||||||
Restructuring and associated costs (5) | — | (10) | (0.1) | — | — | — | — | — | |||||||
Acquisition and divestiture-related items (2) | — | (40) | (0.3) | — | — | 42 | 0.2 | — | |||||||
Medical device regulations (3) | — | — | — | (10) | — | — | — | — | |||||||
Other (6) | 90 | — | — | — | — | — | — | — | |||||||
(Gain)/loss on minority investments (4) | — | — | — | — | — | — | — | (41) | |||||||
Non-GAAP | $   24,700 | $    8,078 | 32.7 % | $   2,038 | 8.3 % | $            4 | — % | $         (443) | |||||||
See description of non-GAAP financial measures contained in the press release dated February 18, 2025. | |
(1) | The data in this schedule has been intentionally rounded to the nearest million, and, therefore, may not sum. |
(2) | The charges primarily include business combination costs, changes in fair value of contingent consideration, exit of business-related charges, and gains related to certain business or asset sales. The nine months ended January 24, 2025, also include gains related to certain business or asset sales. |
(3) | The charges represent incremental costs of complying with the new European Union medical device regulations for previously registered products and primarily include charges for contractors supporting the project and other direct third-party expenses. We consider these costs to be duplicative of previously incurred costs and/or one-time costs, which are limited to a specific time period. |
(4) | We exclude unrealized and realized gains and losses on our minority investments as we do not believe that these components of income or expense have a direct correlation to our ongoing or future business operations. |
(5) | Associated costs primarily include salaries and wages for employees supporting the restructuring activities, consulting expenses, and asset write-offs. |
(6) | Reflects the recognition of incremental Italian payback accruals resulting from the two July 22, 2024 rulings by the Constitutional Court of Italy relating to certain prior years since 2015. |
MEDTRONIC PLC GAAP TO NON-GAAP RECONCILIATIONS (1) (Unaudited) | |||
Nine months ended | |||
(in millions) | January 24, 2025 | January 26, 2024 | |
Net cash provided by operating activities | $Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 4,516 | $Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 4,010 | |
Additions to property, plant, and equipment | (1,400) | (1,161) | |
Free Cash Flow (2) | $Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 3,116 | $Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 2,849 | |
See description of non-GAAP financial measures contained in the press release dated February 18, 2025. | |
(1) | The data in this schedule has been intentionally rounded to the nearest million, and, therefore, may not sum. |
(2) | Free cash flow represents operating cash flows less property, plant, and equipment additions. |
MEDTRONIC PLC CONSOLIDATED BALANCE SHEETS (Unaudited) | ||||
(in millions) | January 24, 2025 | April 26, 2024 | ||
ASSETS | ||||
Current assets: | ||||
Cash and cash equivalents | $Â Â Â Â Â Â Â Â Â Â Â Â Â Â 1,240 | $Â Â Â Â Â Â Â Â Â Â Â Â Â Â 1,284 | ||
Investments | 6,682 | 6,721 | ||
Accounts receivable, less allowances and credit losses of $204 and $173, respectively | 6,115 | 6,128 | ||
Inventories | 5,610 | 5,217 | ||
Other current assets | 2,865 | 2,584 | ||
Total current assets | 22,513 | 21,935 | ||
Property, plant, and equipment, net | 6,593 | 6,131 | ||
Goodwill | 40,819 | 40,986 | ||
Other intangible assets, net | 12,184 | 13,225 | ||
Tax assets | 3,614 | 3,657 | ||
Other assets | 4,250 | 4,047 | ||
Total assets | $Â Â Â Â Â Â Â Â Â Â Â Â 89,973 | $Â Â Â Â Â Â Â Â Â Â Â Â 89,981 | ||
LIABILITIES AND EQUITY | ||||
Current liabilities: | ||||
Current debt obligations | $Â Â Â Â Â Â Â Â Â Â Â Â Â Â 2,622 | $Â Â Â Â Â Â Â Â Â Â Â Â Â Â 1,092 | ||
Accounts payable | 2,286 | 2,410 | ||
Accrued compensation | 2,281 | 2,375 | ||
Accrued income taxes | 1,125 | 1,330 | ||
Other accrued expenses | 3,526 | 3,582 | ||
Total current liabilities | 11,840 | 10,789 | ||
Long-term debt | 23,985 | 23,932 | ||
Accrued compensation and retirement benefits | 1,063 | 1,101 | ||
Accrued income taxes | 1,485 | 1,859 | ||
Deferred tax liabilities | 452 | 515 | ||
Other liabilities | 1,533 | 1,365 | ||
Total liabilities | 40,358 | 39,561 | ||
Commitments and contingencies | ||||
Shareholders' equity: | ||||
Ordinary shares— par value $0.0001, 2.6 billion shares authorized, 1,283,266,154 and 1,311,337,531 shares issued and outstanding, respectively | — | — | ||
Additional paid-in capital | 20,910 | 23,129 | ||
Retained earnings | 31,317 | 30,403 | ||
Accumulated other comprehensive loss | (2,839) | (3,318) | ||
Total shareholders' equity | 49,387 | 50,214 | ||
Noncontrolling interests | 228 | 206 | ||
Total equity | 49,615 | 50,420 | ||
Total liabilities and equity | $Â Â Â Â Â Â Â Â Â Â Â Â 89,973 | $Â Â Â Â Â Â Â Â Â Â Â Â 89,981 | ||
The data in this schedule has been intentionally rounded to the nearest million, and, therefore, may not sum. |
MEDTRONIC PLC CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) | |||
Nine months ended | |||
(in millions) | January 24, 2025 | January 26, 2024 | |
Operating Activities: | |||
Net income | $Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 3,630 | $Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 3,045 | |
Adjustments to reconcile net income to net cash provided by operating activities: | |||
Depreciation and amortization | 2,021 | 1,993 | |
Provision for credit losses | 96 | 62 | |
Deferred income taxes | (81) | (250) | |
Stock-based compensation | 340 | 303 | |
Other, net | 14 | 265 | |
Change in operating assets and liabilities, net of acquisitions and divestitures: | |||
Accounts receivable, net | (184) | (140) | |
Inventories | (478) | (530) | |
Accounts payable and accrued liabilities | (157) | (253) | |
Other operating assets and liabilities | (685) | (485) | |
Net cash provided by operating activities | 4,516 | 4,010 | |
Investing Activities: | |||
Acquisitions, net of cash acquired | (98) | (74) | |
Additions to property, plant, and equipment | (1,400) | (1,161) | |
Purchases of investments | (6,093) | (5,422) | |
Sales and maturities of investments | 6,255 | 5,142 | |
Other investing activities, net | (111) | (155) | |
Net cash used in investing activities | (1,447) | (1,670) | |
Financing Activities: | |||
Change in current debt obligations, net | (1,070) | 1,010 | |
Issuance of long-term debt | 3,209 | — | |
Dividends to shareholders | (2,692) | (2,753) | |
Issuance of ordinary shares | 400 | 206 | |
Repurchase of ordinary shares | (2,961) | (510) | |
Other financing activities, net | 96 | (44) | |
Net cash used in financing activities | (3,018) | (2,091) | |
Effect of exchange rate changes on cash and cash equivalents | (95) | (170) | |
Net change in cash and cash equivalents | (44) | 80 | |
Cash and cash equivalents at beginning of period | 1,284 | 1,543 | |
Cash and cash equivalents at end of period | $Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 1,240 | $Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 1,623 | |
Supplemental Cash Flow Information | |||
Cash paid for: | |||
Income taxes | $Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 1,515 | $Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 1,403 | |
Interest | 567 | 568 | |
The data in this schedule has been intentionally rounded to the nearest million, and, therefore, may not sum. |
About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland , is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE: MDT), visit www.Medtronic.com and follow on LinkedIn .
FORWARD LOOKING STATEMENTS
 This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties, including risks related to competitive factors, difficulties and delays inherent in the development, manufacturing, marketing and sale of medical products, government regulation, geopolitical conflicts, changing global trade policies, general economic conditions, and other risks and uncertainties described in the company's periodic reports on file with the U.S. Securities and Exchange Commission including the most recent Annual Report on Form 10-K of the company. In some cases, you can identify these statements by forward-looking words or expressions, such as "anticipate," "believe," "could," "estimate," "expect," "forecast," "intend," "looking ahead," "may," "plan," "possible," "potential," "project," "should," "going to," "will," and similar words or expressions, the negative or plural of such words or expressions and other comparable terminology. Actual results may differ materially from anticipated results. Medtronic does not undertake to update its forward-looking statements or any of the information contained in this press release, including to reflect future events or circumstances.
NON-GAAP FINANCIAL MEASURES
 This press release contains financial measures, including adjusted net income, adjusted diluted EPS, and organic revenue, which are considered "non-GAAP" financial measures under applicable SEC rules and regulations. References to quarterly or annual figures increasing, decreasing or remaining flat are in comparison to fiscal year 2024, and references to sequential changes are in comparison to the prior fiscal quarter.
Medtronic management believes that non-GAAP financial measures provide information useful to investors in understanding the company's underlying operational performance and trends and to facilitate comparisons with the performance of other companies in the med tech industry. Non-GAAP net income and diluted EPS exclude the effect of certain charges or gains that contribute to or reduce earnings but that result from transactions or events that management believes may or may not recur with similar materiality or impact to operations in future periods (Non-GAAP Adjustments). Medtronic generally uses non-GAAP financial measures to facilitate management's review of the operational performance of the company and as a basis for strategic planning. Non-GAAP financial measures should be considered supplemental to and not a substitute for financial information prepared in accordance with U.S. generally accepted accounting principles (GAAP), and investors are cautioned that Medtronic may calculate non-GAAP financial measures in a way that is different from other companies. Management strongly encourages investors to review the company's consolidated financial statements and publicly filed reports in their entirety. Reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures are included in the financial schedules accompanying this press release.
Medtronic calculates forward-looking non-GAAP financial measures based on internal forecasts that omit certain amounts that would be included in GAAP financial measures. For instance, forward-looking organic revenue growth guidance excludes the impact of foreign currency fluctuations, as well as significant acquisitions or divestitures. Forward-looking diluted non-GAAP EPS guidance also excludes other potential charges or gains that would be recorded as Non-GAAP Adjustments to earnings during the fiscal year. Medtronic does not attempt to provide reconciliations of forward-looking non-GAAP EPS guidance to projected GAAP EPS guidance because the combined impact and timing of recognition of these potential charges or gains is inherently uncertain and difficult to predict and is unavailable without unreasonable efforts. In addition, the company believes such reconciliations would imply a degree of precision and certainty that could be confusing to investors. Such items could have a substantial impact on GAAP measures of financial performance.
-end-
Contacts: | |
Erika Winkels | Ryan Weispfenning |
Public Relations | Investor Relations |
+1-763-526-8478 | +1-763-505-4626 |
View original content to download multimedia: https://www.prnewswire.com/news-releases/medtronic-reports-third-quarter-fiscal-2025-financial-results-302378617.html
SOURCE Medtronic plc
News Provided by PR Newswire via QuoteMedia
Delivering durable revenue growth with strong earnings power; strength in Pulsed Field Ablation, Pacing, Structural Heart, Diabetes, and Neuromodulation
Medtronic plc (NYSE: MDT) today announced financial results for its third quarter (Q3) of fiscal year 2025 (FY25), which ended January 24, 2025 .
Key Highlights
Financial Results
Medtronic reported Q3 worldwide revenue of $8.292 billion , an increase of 2.5% as reported and 4.1% on an organic basis. Organic revenue growth comparison excludes:
As reported, Q3 GAAP net income and diluted earnings per share (EPS) were $1.294 billion and $1.01 , respectively, representing a decrease of 2% and an increase of 2%, respectively. As detailed in the financial schedules included at the end of this release, Q3 non-GAAP net income and non-GAAP diluted EPS were $1.787 billion and $1.39 , respectively, representing increases of 3% and 7%, respectively.
"We delivered strong earnings this quarter, with significant improvements in both our gross margin and operating margin on the back of our ninth quarter in a row of mid-single digit organic revenue growth," said Geoff Martha , Medtronic chairman and chief executive officer. "We are starting to see the results from our long term investments in groundbreaking innovation, such as pulsed field ablation, to drive growth in some of the most attractive markets in MedTech."
Cardiovascular Portfolio
The Cardiovascular Portfolio includes the Cardiac Rhythm & Heart Failure (CRHF), Structural Heart & Aortic (SHA), and Coronary & Peripheral Vascular (CPV) divisions. Revenue of $3.037 billion increased 3.7% as reported and 5.0% organic, with mid-single digit increases in CRHF and SH&A, and a low-single digit increase in CPV, all on an organic basis.
Neuroscience Portfolio
The Neuroscience Portfolio includes the Cranial & Spinal Technologies (CST), Specialty Therapies, and Neuromodulation divisions. Revenue of $2.458 billion increased 4.4% as reported and 5.2% organic, with a low-double digit increase in Neuromodulation, mid-single digit increase in CST, and low-single digit increase in Specialty Therapies, all on an organic basis.
Medical Surgical Portfolio
The Medical Surgical Portfolio includes the Surgical & Endoscopy (SE) and the Acute Care & Monitoring (ACM) divisions. Revenue of $2.072 billion decreased 1.9% as reported and decreased 0.4% organic, with flat organic result in SE and low-single digit organic decline in ACM.
Diabetes
Revenue of $694 million increased 8.4% as reported and 10.4% organic.
Guidance
Medtronic today reiterated its revenue growth and EPS guidance for FY25.
The company continues to expect FY25 organic revenue growth in the range of 4.75% to 5%. The organic revenue growth guidance excludes the impact of foreign currency and revenue reported as Other. Including Other revenue and the impact of foreign currency exchange, if recent foreign currency exchange rates hold, FY25 revenue growth would be in the range of 3.4% to 3.8%.
The company continues to expect FY25 diluted non-GAAP EPS in the range of $5.44 to $5.50 . This includes an estimated -5% impact from foreign currency exchange based on recent rates. The company's guidance represents FY25 diluted non-GAAP EPS growth in the range of 4.6% to 5.8%.
"EPS came in above the high end of our guidance range. We were pleased with the operational performance of the business this quarter, turning mid-single digit organic growth into leveraged earnings, highlighted by healthy gross margin improvement," said Gary Corona , Medtronic interim chief financial officer. "Looking ahead, our restored earnings power continues. We will accelerate both top and bottom line growth in Q4, resulting in high-single digit adjusted EPS growth in the back half of our fiscal year."
Video Webcast Information
Medtronic will host a video webcast today, February 18 , at 8:00 a.m. EST ( 7:00 a.m. CST ) to provide information about its businesses for the public, investors, analysts, and news media. This webcast can be accessed by clicking on the Events icon at investorrelations.medtronic.com , and this earnings release will be archived at news.medtronic.com . Within 24 hours of the webcast, a replay of the webcast and transcript of the company's prepared remarks will be available by clicking on the Events icon at investorrelations.medtronic.com .
Medtronic plans to report its FY25 fourth quarter results on Wednesday, May 21, 2025 . For fiscal year 2026, Medtronic plans to report its first, second, third, and fourth quarter results on Tuesday, August 19, 2025 , November 18, 2025 , February 17, 2026 , and Wednesday, May 20, 2026 , respectively. Confirmation and additional details will be provided closer to the specific event.
Financial Schedules and Earnings Presentation
The third quarter financial schedules and non-GAAP reconciliations can be viewed by clicking on the Investor Events link at investorrelations.medtronic.com . To view a printable PDF of the financial schedules and non-GAAP reconciliations, click here . To view the third quarter earnings presentation, click here .
MEDTRONIC PLC WORLD WIDE REVENUE (1) (Unaudited) | ||||||||||||||||||||||||||||
THIRD QUARTER | YEAR-TO-DATE | |||||||||||||||||||||||||||
REPORTED | ORGANIC | REPORTED | ORGANIC | |||||||||||||||||||||||||
(in millions) | FY25 | FY24 | Growth | Currency | Adjusted | Adjusted | Growth | FY25 | FY24 | Growth | Currency | Adjusted | Adjusted | Growth | ||||||||||||||
Cardiovascular | $Â Â Â Â 3,037 | $Â Â Â Â 2,929 | 3.7Â % | $Â Â Â Â Â Â Â (38) | $Â Â Â Â 3,075 | $Â Â Â Â 2,929 | 5.0Â % | $Â Â Â Â 9,145 | $Â Â Â Â 8,702 | 5.1Â % | $Â Â Â Â Â Â Â (62) | $Â Â Â Â 9,207 | $Â Â Â Â 8,702 | 5.8Â % | ||||||||||||||
Cardiac Rhythm & Heart Failure | 1,545 | 1,470 | 5.1 | (18) | 1,563 | 1,470 | 6.3 | 4,659 | 4,408 | 5.7 | (26) | 4,684 | 4,408 | 6.3 | ||||||||||||||
Structural Heart & Aortic | 874 | 843 | 3.7 | (13) | 887 | 843 | 5.2 | 2,610 | 2,475 | 5.4 | (21) | 2,631 | 2,475 | 6.3 | ||||||||||||||
Coronary & Peripheral Vascular | 618 | 616 | 0.3 | (8) | 626 | 616 | 1.6 | 1,876 | 1,818 | 3.2 | (15) | 1,891 | 1,818 | 4.0 | ||||||||||||||
Neuroscience | 2,458 | 2,355 | 4.4 | (21) | 2,478 | 2,355 | 5.2 | 7,226 | 6,861 | 5.3 | (29) | 7,255 | 6,861 | 5.7 | ||||||||||||||
Cranial & Spinal Technologies | 1,250 | 1,204 | 3.8 | (9) | 1,259 | 1,204 | 4.6 | 3,632 | 3,465 | 4.8 | (15) | 3,646 | 3,465 | 5.2 | ||||||||||||||
Specialty Therapies | 732 | 726 | 0.8 | (8) | 740 | 726 | 1.9 | 2,181 | 2,126 | 2.6 | (10) | 2,191 | 2,126 | 3.1 | ||||||||||||||
Neuromodulation | 476 | 425 | 12.0 | (4) | 480 | 425 | 12.9 | 1,413 | 1,270 | 11.2 | (5) | 1,417 | 1,270 | 11.6 | ||||||||||||||
Medical Surgical | 2,072 | 2,112 | (1.9) | (32) | 2,104 | 2,112 | (0.4) | 6,196 | 6,219 | (0.4) | (50) | 6,246 | 6,219 | 0.4 | ||||||||||||||
Surgical & Endoscopy | 1,596 | 1,616 | (1.2) | (26) | 1,622 | 1,616 | 0.4 | 4,790 | 4,803 | (0.3) | (40) | 4,829 | 4,803 | 0.5 | ||||||||||||||
Acute Care & Monitoring | 476 | 495 | (3.9) | (5) | 481 | 495 | (2.8) | 1,406 | 1,416 | (0.7) | (10) | 1,417 | 1,416 | — | ||||||||||||||
Diabetes | 694 | 640 | 8.4 | (12) | 706 | 640 | 10.4 | 2,027 | 1,829 | 10.8 | (8) | 2,035 | 1,829 | 11.3 | ||||||||||||||
Total Reportable Segments | 8,260 | 8,035 | 2.8 | (103) | 8,363 | 8,035 | 4.1 | 24,593 | 23,610 | 4.2 | (149) | 24,742 | 23,610 | 4.8 | ||||||||||||||
Other (2) | 32 | 53 | (41.1) | (1) | — | — | — | 17 | 164 | (89.9) | (3) | — | — | — | ||||||||||||||
TOTAL | $Â Â Â Â 8,292 | $Â Â Â Â 8,089 | 2.5Â % | $Â Â Â Â Â (104) | $Â Â Â Â 8,363 | $Â Â Â Â 8,035 | 4.1Â % | $Â Â Â 24,610 | $Â Â Â 23,775 | 3.5Â % | $Â Â Â Â Â (152) | $Â Â Â 24,742 | $Â Â Â 23,610 | 4.8Â % | ||||||||||||||
(1) | The data in this schedule has been intentionally rounded to the nearest million and, therefore, may not sum. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. |
(2) | Includes historical operations and ongoing transition agreements from businesses the Company has exited or divested, and specifically for the three months ended July 26, 2024, impacting year-to-date figures, $90 million of incremental Italian payback accruals resulting from the two July 22, 2024 rulings by the Constitutional Court of Italy relating to certain prior years since 2015. |
(3) | The currency impact to revenue measures the change in revenue between current and prior year periods using constant exchange rates. |
(4) | The three months ended January 24, 2025 excludes $71 million of revenue adjustments related to $32 million of inorganic revenue for the transition activity noted in (2) and $103 million of unfavorable currency impact on the remaining segments. The three months ended January 26, 2024 excludes $53 million of inorganic revenue related to the transition activity noted in (2). |
(5) | The nine months ended January 24, 2025 excludes $132 million of revenue adjustments related to $90 million of incremental Italian payback accruals further described in note (2), $106 million of inorganic revenue related to the transition activity noted in (2), and $149 million of unfavorable currency impact on the remaining segments. The nine months ended January 26, 2024 excludes $164 million of inorganic revenue related to the transition activity noted in (2). |
MEDTRONIC PLC U.S. REVENUE (1)(2) (Unaudited) | ||||||||||||||||||||||||
THIRD QUARTER | YEAR-TO-DATE | |||||||||||||||||||||||
REPORTED | ORGANIC | REPORTED | ORGANIC | |||||||||||||||||||||
(in millions) | FY25 | FY24 | Growth | Adjusted | Adjusted | Growth | FY25 | FY24 | Growth | Adjusted | Adjusted | Growth | ||||||||||||
Cardiovascular | $Â Â Â Â 1,405 | $Â Â Â Â 1,373 | 2.4Â % | $Â Â Â Â 1,405 | $Â Â Â Â 1,373 | 2.4Â % | $Â Â Â Â 4,242 | $Â Â Â Â 4,149 | 2.2Â % | $Â Â Â Â 4,242 | $Â Â Â Â 4,149 | 2.2Â % | ||||||||||||
Cardiac Rhythm & Heart Failure | 775 | 745 | 4.1 | 775 | 745 | 4.1 | 2,309 | 2,247 | 2.8 | 2,309 | 2,247 | 2.8 | ||||||||||||
Structural Heart & Aortic | 372 | 363 | 2.6 | 372 | 363 | 2.6 | 1,129 | 1,087 | 3.9 | 1,129 | 1,087 | 3.9 | ||||||||||||
Coronary & Peripheral Vascular | 258 | 265 | (2.8) | 258 | 265 | (2.8) | 804 | 816 | (1.4) | 804 | 816 | (1.4) | ||||||||||||
Neuroscience | 1,689 | 1,556 | 8.5 | 1,689 | 1,556 | 8.5 | 4,931 | 4,614 | 6.9 | 4,931 | 4,614 | 6.9 | ||||||||||||
Cranial & Spinal Technologies | 943 | 875 | 7.8 | 943 | 875 | 7.8 | 2,724 | 2,560 | 6.4 | 2,724 | 2,560 | 6.4 | ||||||||||||
Specialty Therapies | 419 | 407 | 3.0 | 419 | 407 | 3.0 | 1,235 | 1,202 | 2.7 | 1,235 | 1,202 | 2.7 | ||||||||||||
Neuromodulation | 327 | 275 | 19.0 | 327 | 275 | 19.0 | 972 | 852 | 14.1 | 972 | 852 | 14.1 | ||||||||||||
Medical Surgical | 893 | 947 | (5.8) | 893 | 947 | (5.8) | 2,718 | 2,763 | (1.6) | 2,718 | 2,763 | (1.6) | ||||||||||||
Surgical & Endoscopy | 623 | 663 | (6.1) | 623 | 663 | (6.1) | 1,928 | 1,971 | (2.2) | 1,928 | 1,971 | (2.2) | ||||||||||||
Acute Care & Monitoring | 269 | 284 | (5.1) | 269 | 284 | (5.1) | 790 | 792 | (0.2) | 790 | 792 | (0.2) | ||||||||||||
Diabetes | 236 | 224 | 5.6 | 236 | 224 | 5.6 | 683 | 629 | 8.7 | 683 | 629 | 8.7 | ||||||||||||
Total Reportable Segments | 4,223 | 4,100 | 3.0 | 4,223 | 4,100 | 3.0 | 12,573 | 12,154 | 3.4 | 12,573 | 12,154 | 3.4 | ||||||||||||
Other (3) | 15 | 20 | (26.4) | — | — | — | 51 | 65 | (21.3) | — | — | — | ||||||||||||
TOTAL | $Â Â Â Â 4,237 | $Â Â Â Â 4,120 | 2.8Â % | $Â Â Â Â 4,223 | $Â Â Â Â 4,100 | 3.0Â % | $Â Â 12,624 | $Â Â 12,219 | 3.3Â % | $Â Â 12,573 | $Â Â 12,154 | 3.4Â % | ||||||||||||
(1) | U.S. includes the United States and U.S. territories. |
(2) | The data in this schedule has been intentionally rounded to the nearest million and, therefore, may not sum. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. |
(3) | Includes historical operations and ongoing transition agreements from businesses the Company has exited or divested. |
MEDTRONIC PLC INTERNATIONAL REVENUE (1) (Unaudited) | ||||||||||||||||||||||||||||
THIRD QUARTER | YEAR-TO-DATE | |||||||||||||||||||||||||||
REPORTED | ORGANIC | REPORTED | ORGANIC | |||||||||||||||||||||||||
(in millions) | FY25 | FY24 | Growth | Currency | Adjusted | Adjusted | Growth | FY25 | FY24 | Growth | Currency | Adjusted | Adjusted | Growth | ||||||||||||||
Cardiovascular | $Â Â Â Â 1,632 | $Â Â Â Â 1,556 | 4.9Â % | $Â Â Â Â Â Â Â (38) | $Â Â Â Â 1,670 | $Â Â Â Â 1,556 | 7.3Â % | $Â Â Â Â 4,904 | $Â Â Â Â 4,552 | 7.7Â % | $Â Â Â Â Â Â Â (62) | $Â Â Â Â 4,966 | $Â Â Â Â 4,552 | 9.1Â % | ||||||||||||||
Cardiac Rhythm & Heart Failure | 770 | 726 | 6.1 | (18) | 788 | 726 | 8.6 | 2,350 | 2,161 | 8.7 | (26) | 2,376 | 2,161 | 9.9 | ||||||||||||||
Structural Heart & Aortic | 502 | 480 | 4.6 | (13) | 515 | 480 | 7.2 | 1,482 | 1,389 | 6.7 | (21) | 1,503 | 1,389 | 8.2 | ||||||||||||||
Coronary & Peripheral Vascular | 360 | 350 | 2.6 | (8) | 368 | 350 | 4.9 | 1,072 | 1,002 | 7.0 | (15) | 1,087 | 1,002 | 8.5 | ||||||||||||||
Neuroscience | 769 | 799 | (3.7) | (21) | 790 | 799 | (1.1) | 2,295 | 2,248 | 2.1 | (29) | 2,324 | 2,248 | 3.4 | ||||||||||||||
Cranial & Spinal Technologies | 307 | 329 | (6.7) | (9) | 316 | 329 | (3.9) | 907 | 905 | 0.3 | (15) | 922 | 905 | 1.9 | ||||||||||||||
Specialty Therapies | 313 | 319 | (2.0) | (8) | 321 | 319 | 0.4 | 947 | 924 | 2.4 | (10) | 957 | 924 | 3.5 | ||||||||||||||
Neuromodulation | 149 | 150 | (0.7) | (4) | 153 | 150 | 1.8 | 441 | 419 | 5.4 | (5) | 446 | 419 | 6.5 | ||||||||||||||
Medical Surgical | 1,180 | 1,164 | 1.3 | (32) | 1,211 | 1,164 | 4.0 | 3,478 | 3,456 | 0.6 | (50) | 3,528 | 3,456 | 2.1 | ||||||||||||||
Surgical & Endoscopy | 973 | 953 | 2.1 | (26) | 999 | 953 | 4.9 | 2,862 | 2,832 | 1.1 | (40) | 2,902 | 2,832 | 2.5 | ||||||||||||||
Acute Care & Monitoring | 206 | 211 | (2.3) | (5) | 212 | 211 | 0.2 | 616 | 624 | (1.4) | (10) | 626 | 624 | 0.3 | ||||||||||||||
Diabetes | 457 | 416 | 9.9 | (12) | 470 | 416 | 12.9 | 1,344 | 1,200 | 12.0 | (8) | 1,351 | 1,200 | 12.6 | ||||||||||||||
Total Reportable Segments | 4,038 | 3,935 | 2.6 | (103) | 4,141 | 3,935 | 5.2 | 12,020 | 11,456 | 4.9 | (149) | 12,169 | 11,456 | 6.2 | ||||||||||||||
Other (2) | 17 | 34 | (49.8) | (1) | — | — | — | (35) | 99 | (134.8) | (3) | — | — | — | ||||||||||||||
TOTAL | $Â Â Â Â 4,055 | $Â Â Â Â 3,968 | 2.2Â % | $Â Â Â Â Â (104) | $Â Â Â Â 4,141 | $Â Â Â Â 3,935 | 5.2Â % | $Â Â 11,986 | $Â Â 11,555 | 3.7Â % | $Â Â Â Â Â (152) | $Â Â 12,169 | $Â Â 11,456 | 6.2Â % | ||||||||||||||
(1) | The data in this schedule has been intentionally rounded to the nearest million and, therefore, may not sum. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. |
(2) | Includes historical operations and ongoing transition agreements from businesses the Company has exited or divested, and specifically for the three months ended July 26, 2024, impacting year-to-date figures, $90 million of incremental Italian payback accruals resulting from the two July 22, 2024 rulings by the Constitutional Court of Italy relating to certain prior years since 2015. |
(3) | The currency impact to revenue measures the change in revenue between current and prior year periods using constant exchange rates. |
(4) | The three months ended January 24, 2025 excludes $86 million of revenue adjustments related to $17 million of inorganic revenue for the transition activity noted in (2), and $103 million of unfavorable currency impact on the remaining segments. The three months ended January 26, 2024 excludes $34 million of inorganic revenue related to the transition activity noted in (2). |
(5) | The nine months ended January 24, 2025 excludes $183 million of revenue adjustments related to $90 million of incremental Italian payback accruals further described in note (2), $55 million of inorganic revenue related to the transition activity noted in (2), and $149 million of unfavorable currency impact on the remaining segments. The nine months ended January 26, 2024 excludes $99 million of inorganic revenue related to the transition activity noted in (2). |
MEDTRONIC PLC CONSOLIDATED STATEMENTS OF INCOME (Unaudited) | |||||||
Three months ended | Nine months ended | ||||||
(in millions, except per share data) | January 24, | January 26, | January 24, | January 26, | |||
Net sales | $Â Â Â Â Â Â Â Â Â Â Â 8,292 | $Â Â Â Â Â Â Â Â Â Â Â 8,089 | $Â Â Â Â Â Â Â Â Â 24,610 | $Â Â Â Â Â Â Â Â Â 23,775 | |||
Costs and expenses: | |||||||
Cost of products sold, excluding amortization of intangible assets | 2,779 | 2,782 | 8,485 | 8,172 | |||
Research and development expense | 675 | 695 | 2,048 | 2,060 | |||
Selling, general, and administrative expense | 2,717 | 2,673 | 8,129 | 7,971 | |||
Amortization of intangible assets | 416 | 419 | 1,243 | 1,274 | |||
Restructuring charges, net | 43 | 20 | 120 | 114 | |||
Certain litigation charges, net | 22 | — | 104 | 105 | |||
Other operating (income) expense, net | (5) | 17 | (38) | (13) | |||
Operating profit | 1,646 | 1,483 | 4,519 | 4,091 | |||
Other non-operating income, net | (72) | (177) | (403) | (407) | |||
Interest expense, net | 179 | 188 | 555 | 517 | |||
Income before income taxes | 1,540 | 1,472 | 4,367 | 3,982 | |||
Income tax provision | 237 | 135 | 737 | 936 | |||
Net income | 1,303 | 1,337 | 3,630 | 3,045 | |||
Net income attributable to noncontrolling interests | (9) | (15) | (24) | (23) | |||
Net income attributable to Medtronic | $Â Â Â Â Â Â Â Â Â Â Â 1,294 | $Â Â Â Â Â Â Â Â Â Â Â 1,322 | $Â Â Â Â Â Â Â Â Â Â Â 3,606 | $Â Â Â Â Â Â Â Â Â Â Â 3,022 | |||
Basic earnings per share | $Â Â Â Â Â Â Â 1.01 | $Â Â Â Â Â Â Â 0.99 | $Â Â Â Â Â Â Â 2.80 | $Â Â Â Â Â Â Â 2.27 | |||
Diluted earnings per share | $Â Â Â Â Â Â Â 1.01 | $Â Â Â Â Â Â Â 0.99 | $Â Â Â Â Â Â Â 2.79 | $Â Â Â Â Â Â Â 2.27 | |||
Basic weighted average shares outstanding | 1,282.4 | 1,329.7 | 1,286.7 | 1,330.1 | |||
Diluted weighted average shares outstanding | 1,286.2 | 1,331.7 | 1,290.6 | 1,332.4 | |||
The data in the schedule above has been intentionally rounded to the nearest million. |
MEDTRONIC PLC GAAP TO NON-GAAP RECONCILIATIONS (1) (Unaudited) | |||||||||||||||||
Three months ended January 24, 2025 | |||||||||||||||||
(in millions, except per share data) | Net | Cost of | Gross | Operating | Operating | Income | Net Income | Diluted | Effective | ||||||||
GAAP | $Â 8,292 | $Â Â 2,779 | 66.5Â % | $Â Â Â Â 1,646 | 19.9Â % | $Â Â Â 1,540 | $Â Â Â Â Â Â 1,294 | $Â Â Â Â 1.01 | 15.4Â % | ||||||||
Non-GAAP Adjustments: | |||||||||||||||||
Amortization of intangible assets | — | — | — | 416 | 5.0 | 416 | 339 | 0.26 | 18.5 | ||||||||
Restructuring and associated costs (2) | — | (4) | — | 46 | 0.6 | 46 | 37 | 0.03 | 19.6 | ||||||||
Acquisition and divestiture-related items (3) | — | (1) | — | 28 | 0.3 | 28 | 23 | 0.02 | 17.9 | ||||||||
Certain litigation charges, net | — | — | — | 22 | 0.3 | 22 | 18 | 0.01 | 22.7 | ||||||||
(Gain)/loss on minority investments (4) | — | — | — | — | — | 68 | 52 | 0.04 | 22.1 | ||||||||
Medical device regulations (5) | — | (8) | 0.1 | 11 | 0.1 | 11 | 9 | 0.01 | 18.2 | ||||||||
Certain tax adjustments, net | — | — | — | — | — | — | 15 | 0.01 | — | ||||||||
Non-GAAP | $Â 8,292 | $Â Â 2,766 | 66.6Â % | $Â Â Â Â 2,169 | 26.2Â % | $Â Â Â 2,130 | $Â Â Â Â Â Â 1,787 | $Â Â Â Â 1.39 | 15.7Â % | ||||||||
Currency impact | 104 | 61 | (0.3) | (4) | (0.4) | (0.01) | |||||||||||
Currency Adjusted | $Â 8,396 | $Â Â 2,827 | 66.3Â % | $Â Â Â Â 2,165 | 25.8Â % | $Â Â Â Â 1.38 | |||||||||||
Three months ended January 26, 2024 | |||||||||||||||||
(in millions, except per share data) | Net | Cost of | Gross | Operating | Operating | Income | Net Income | Diluted | Effective | ||||||||
GAAP | $Â 8,089 | $Â Â 2,782 | 65.6Â % | $Â Â Â Â 1,483 | 18.3Â % | $Â Â Â 1,472 | $Â Â Â Â Â Â 1,322 | $Â Â Â Â 0.99 | 9.2Â % | ||||||||
Non-GAAP Adjustments: | |||||||||||||||||
Amortization of intangible assets | — | — | — | 419 | 5.2 | 419 | 354 | 0.27 | 15.5 | ||||||||
Restructuring and associated costs (2) | — | (12) | 0.1 | 55 | 0.7 | 55 | 46 | 0.03 | 16.4 | ||||||||
Acquisition and divestiture-related items (3) | — | (12) | 0.1 | 58 | 0.7 | 58 | 52 | 0.04 | 10.3 | ||||||||
(Gain)/loss on minority investments (4) | — | — | — | — | — | 24 | 24 | 0.02 | — | ||||||||
Medical device regulations (5) | — | (18) | 0.2 | 26 | 0.3 | 26 | 21 | 0.02 | 19.2 | ||||||||
Certain tax adjustments, net (6) | — | — | — | — | — | — | (92) | (0.07) | — | ||||||||
Non-GAAP | $Â 8,089 | $Â Â 2,740 | 66.1Â % | $Â Â Â Â 2,042 | 25.2Â % | $Â Â Â 2,055 | $Â Â Â Â Â Â 1,728 | $Â Â Â Â 1.30 | 15.2Â % | ||||||||
See description of non-GAAP financial measures contained in the press release dated February 18, 2025. | |
(1) | The data in this schedule has been intentionally rounded to the nearest million or $0.01 for EPS figures, and, therefore, may not sum. |
(2) | Associated costs primarily include salaries and wages for employees supporting the restructuring activities, consulting expenses, and asset write-offs. |
(3) | The charges primarily include business combination costs, changes in fair value of contingent consideration, and exit of business-related charges. |
(4) | We exclude unrealized and realized gains and losses on our minority investments as we do not believe that these components of income or expense have a direct correlation to our ongoing or future business operations. |
(5) | The charges represent incremental costs of complying with the new European Union (E.U.) medical device regulations for previously registered products and primarily include charges for contractors supporting the project and other direct third-party expenses. We consider these costs to be duplicative of previously incurred costs and/or one-time costs, which are limited to a specific time period. |
(6) | The net tax benefit primarily relates to a change in a Swiss Cantonal tax rate associated with previously established deferred tax assets from intercompany intellectual property transactions and the step up in tax basis for Swiss Cantonal purposes. |
MEDTRONIC PLC GAAP TO NON-GAAP RECONCILIATIONS (1) (Unaudited) | |||||||||||||||||
Nine months ended January 24, 2025 | |||||||||||||||||
(in millions, except per share data) | Net | Cost of | Gross | Operating | Operating | Income | Net Income | Diluted | Effective | ||||||||
GAAP | $ 24,610 | $Â Â 8,485 | 65.5Â % | $Â Â Â Â 4,519 | 18.4Â % | $Â Â Â 4,367 | $Â Â Â Â Â Â Â Â 3,606 | $Â Â Â Â 2.79 | 16.9Â % | ||||||||
Non-GAAP Adjustments: | |||||||||||||||||
Amortization of intangible assets | — | — | — | 1,243 | 4.9 | 1,243 | 1,017 | 0.79 | 18.3 | ||||||||
Restructuring and associated costs (2) | — | (24) | 0.1 | 154 | 0.6 | 154 | 124 | 0.10 | 19.5 | ||||||||
Acquisition and divestiture-related items (3) | — | (17) | — | 15 | 0.1 | 15 | 3 | — | 73.3 | ||||||||
Certain litigation charges, net | — | — | — | 104 | 0.4 | 104 | 86 | 0.07 | 17.3 | ||||||||
(Gain)/loss on minority investments (4) | — | — | — | — | — | 41 | 14 | 0.01 | 61.0 | ||||||||
Medical device regulations (5) | — | (27) | 0.1 | 38 | 0.2 | 38 | 30 | 0.02 | 21.1 | ||||||||
Other (6) | 90 | — | 0.2 | 90 | 0.4 | 90 | 70 | 0.05 | 22.2 | ||||||||
Certain tax adjustments, net (7) | — | — | — | — | — | — | 49 | 0.04 | — | ||||||||
Non-GAAP | $ 24,700 | $Â Â 8,417 | 65.9Â % | $Â Â Â Â 6,162 | 24.9Â % | $Â Â Â 6,051 | $Â Â Â Â Â Â Â Â 4,999 | $Â Â Â Â 3.87 | 17.0Â % | ||||||||
Currency impact | 150 | (72) | 0.5 | 241 | 0.9 | 0.15 | |||||||||||
Currency Adjusted | $ 24,850 | $Â Â 8,345 | 66.4Â % | $Â Â Â Â 6,403 | 25.8Â % | $Â Â Â Â 4.02 | |||||||||||
Nine months ended January 26, 2024 | |||||||||||||||||
(in millions, except per share data) | Net | Cost of | Gross | Operating | Operating | Income | Net Income | Diluted | Effective | ||||||||
GAAP | $ 23,775 | $Â Â 8,172 | 65.6Â % | $Â Â Â Â 4,091 | 17.2Â % | $Â Â Â 3,982 | $Â Â Â Â Â Â Â Â 3,022 | $Â Â Â Â 2.27 | 23.5Â % | ||||||||
Non-GAAP Adjustments: | |||||||||||||||||
Amortization of intangible assets | — | — | — | 1,274 | 5.4 | 1,274 | 1,078 | 0.81 | 15.4 | ||||||||
Restructuring and associated costs (2) | — | (43) | 0.2 | 237 | 1.0 | 237 | 198 | 0.15 | 16.5 | ||||||||
Acquisition and divestiture-related items (3) | — | (24) | 0.1 | 165 | 0.7 | 165 | 149 | 0.11 | 9.7 | ||||||||
Certain litigation charges, net | — | — | — | 105 | 0.4 | 105 | 81 | 0.06 | 22.9 | ||||||||
(Gain)/loss on minority investments (4) | — | — | — | — | — | 113 | 109 | 0.08 | 4.4 | ||||||||
Medical device regulations (5) | — | (60) | 0.3 | 88 | 0.4 | 88 | 70 | 0.05 | 20.5 | ||||||||
Certain tax adjustments, net (8) | — | — | — | — | — | — | 282 | 0.21 | — | ||||||||
Non-GAAP | $ 23,775 | $Â Â 8,046 | 66.2Â % | $Â Â Â Â 5,961 | 25.1Â % | $Â Â Â 5,965 | $Â Â Â Â Â Â Â Â 4,988 | $Â Â Â Â 3.74 | 16.0Â % | ||||||||
See description of non-GAAP financial measures contained in the press release dated February 18, 2025. | |
(1) | The data in this schedule has been intentionally rounded to the nearest million or $0.01 for EPS figures, and, therefore, may not sum. |
(2) | Associated costs primarily include salaries and wages for employees supporting the restructuring activities, consulting expenses, and asset write-offs. |
(3) | The charges primarily include business combination costs, changes in fair value of contingent consideration, and exit of business-related charges. The nine months ended January 24, 2025, also include gains related to certain business or asset sales. |
(4) | We exclude unrealized and realized gains and losses on our minority investments as we do not believe that these components of income or expense have a direct correlation to our ongoing or future business operations. |
(5) | The charges represent incremental costs of complying with the new European Union (E.U.) medical device regulations for previously registered products and primarily include charges for contractors supporting the project and other direct third-party expenses. We consider these costs to be duplicative of previously incurred costs and/or one-time costs, which are limited to a specific time period. |
(6) | Reflects the recognition of incremental Italian payback accruals resulting from the two July 22, 2024 rulings by the Constitutional Court of Italy relating to certain prior years since 2015. |
(7) | Primarily relates to amortization of previously established deferred tax assets from intercompany intellectual property transactions. |
(8) | The net charge primarily relates to an income tax reserve adjustment associated with the June 2023, Israeli Central-Lod District Court decision and the establishment of a valuation allowance against certain net operating losses which were partially offset by a benefit from the change in a Swiss Cantonal tax rate associated with previously established deferred tax assets from intercompany intellectual property transactions and the step up in tax basis for Swiss Cantonal purposes. |
MEDTRONIC PLC GAAP TO NON-GAAP RECONCILIATIONS (1) (Unaudited) | |||||||||||||||
Three months ended January 24, 2025 | |||||||||||||||
(in millions) | Net Sales | SG&A | SG&A | R&D | R&D | Other | Other | Other Non- | |||||||
GAAP | $Â Â Â Â Â 8,292 | $Â Â Â Â 2,717 | 32.8Â % | $Â Â Â Â Â Â 675 | 8.1Â % | $Â Â Â Â Â Â Â Â Â Â (5) | (0.1)Â % | $Â Â Â Â Â Â Â Â Â Â (72) | |||||||
Non-GAAP Adjustments: | |||||||||||||||
Acquisition and divestiture-related items (2) | — | (13) | (0.2) | — | — | (13) | (0.2) | — | |||||||
Medical device regulations (3) | — | — | — | (3) | — | — | — | — | |||||||
(Gain)/loss on minority investments (4) | — | — | — | — | — | — | — | (68) | |||||||
Non-GAAP | $Â Â Â Â Â 8,292 | $Â Â Â Â 2,704 | 32.6Â % | $Â Â Â Â Â Â 672 | 8.1Â % | $Â Â Â Â Â Â Â Â (18) | (0.2)Â % | $Â Â Â Â Â Â Â Â Â (140) | |||||||
Nine months ended January 24, 2025 | |||||||||||||||
(in millions) | Net Sales | SG&A | SG&A | R&D | R&D | Other | Other | Other Non- | |||||||
GAAP | $Â Â Â 24,610 | $Â Â Â Â 8,129 | 33.0Â % | $Â Â Â 2,048 | 8.3Â % | $Â Â Â Â Â Â Â Â (38) | (0.2)Â % | $Â Â Â Â Â Â Â Â Â (403) | |||||||
Non-GAAP Adjustments: | |||||||||||||||
Restructuring and associated costs (5) | — | (10) | (0.1) | — | — | — | — | — | |||||||
Acquisition and divestiture-related items (2) | — | (40) | (0.3) | — | — | 42 | 0.2 | — | |||||||
Medical device regulations (3) | — | — | — | (10) | — | — | — | — | |||||||
Other (6) | 90 | — | — | — | — | — | — | — | |||||||
(Gain)/loss on minority investments (4) | — | — | — | — | — | — | — | (41) | |||||||
Non-GAAP | $   24,700 | $    8,078 | 32.7 % | $   2,038 | 8.3 % | $            4 | — % | $         (443) | |||||||
See description of non-GAAP financial measures contained in the press release dated February 18, 2025. | |
(1) | The data in this schedule has been intentionally rounded to the nearest million, and, therefore, may not sum. |
(2) | The charges primarily include business combination costs, changes in fair value of contingent consideration, exit of business-related charges, and gains related to certain business or asset sales. The nine months ended January 24, 2025, also include gains related to certain business or asset sales. |
(3) | The charges represent incremental costs of complying with the new European Union medical device regulations for previously registered products and primarily include charges for contractors supporting the project and other direct third-party expenses. We consider these costs to be duplicative of previously incurred costs and/or one-time costs, which are limited to a specific time period. |
(4) | We exclude unrealized and realized gains and losses on our minority investments as we do not believe that these components of income or expense have a direct correlation to our ongoing or future business operations. |
(5) | Associated costs primarily include salaries and wages for employees supporting the restructuring activities, consulting expenses, and asset write-offs. |
(6) | Reflects the recognition of incremental Italian payback accruals resulting from the two July 22, 2024 rulings by the Constitutional Court of Italy relating to certain prior years since 2015. |
MEDTRONIC PLC GAAP TO NON-GAAP RECONCILIATIONS (1) (Unaudited) | |||
Nine months ended | |||
(in millions) | January 24, 2025 | January 26, 2024 | |
Net cash provided by operating activities | $Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 4,516 | $Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 4,010 | |
Additions to property, plant, and equipment | (1,400) | (1,161) | |
Free Cash Flow (2) | $Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 3,116 | $Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 2,849 | |
See description of non-GAAP financial measures contained in the press release dated February 18, 2025. | |
(1) | The data in this schedule has been intentionally rounded to the nearest million, and, therefore, may not sum. |
(2) | Free cash flow represents operating cash flows less property, plant, and equipment additions. |
MEDTRONIC PLC CONSOLIDATED BALANCE SHEETS (Unaudited) | ||||
(in millions) | January 24, 2025 | April 26, 2024 | ||
ASSETS | ||||
Current assets: | ||||
Cash and cash equivalents | $Â Â Â Â Â Â Â Â Â Â Â Â Â Â 1,240 | $Â Â Â Â Â Â Â Â Â Â Â Â Â Â 1,284 | ||
Investments | 6,682 | 6,721 | ||
Accounts receivable, less allowances and credit losses of $204 and $173, respectively | 6,115 | 6,128 | ||
Inventories | 5,610 | 5,217 | ||
Other current assets | 2,865 | 2,584 | ||
Total current assets | 22,513 | 21,935 | ||
Property, plant, and equipment, net | 6,593 | 6,131 | ||
Goodwill | 40,819 | 40,986 | ||
Other intangible assets, net | 12,184 | 13,225 | ||
Tax assets | 3,614 | 3,657 | ||
Other assets | 4,250 | 4,047 | ||
Total assets | $Â Â Â Â Â Â Â Â Â Â Â Â 89,973 | $Â Â Â Â Â Â Â Â Â Â Â Â 89,981 | ||
LIABILITIES AND EQUITY | ||||
Current liabilities: | ||||
Current debt obligations | $Â Â Â Â Â Â Â Â Â Â Â Â Â Â 2,622 | $Â Â Â Â Â Â Â Â Â Â Â Â Â Â 1,092 | ||
Accounts payable | 2,286 | 2,410 | ||
Accrued compensation | 2,281 | 2,375 | ||
Accrued income taxes | 1,125 | 1,330 | ||
Other accrued expenses | 3,526 | 3,582 | ||
Total current liabilities | 11,840 | 10,789 | ||
Long-term debt | 23,985 | 23,932 | ||
Accrued compensation and retirement benefits | 1,063 | 1,101 | ||
Accrued income taxes | 1,485 | 1,859 | ||
Deferred tax liabilities | 452 | 515 | ||
Other liabilities | 1,533 | 1,365 | ||
Total liabilities | 40,358 | 39,561 | ||
Commitments and contingencies | ||||
Shareholders' equity: | ||||
Ordinary shares— par value $0.0001, 2.6 billion shares authorized, 1,283,266,154 and 1,311,337,531 shares issued and outstanding, respectively | — | — | ||
Additional paid-in capital | 20,910 | 23,129 | ||
Retained earnings | 31,317 | 30,403 | ||
Accumulated other comprehensive loss | (2,839) | (3,318) | ||
Total shareholders' equity | 49,387 | 50,214 | ||
Noncontrolling interests | 228 | 206 | ||
Total equity | 49,615 | 50,420 | ||
Total liabilities and equity | $Â Â Â Â Â Â Â Â Â Â Â Â 89,973 | $Â Â Â Â Â Â Â Â Â Â Â Â 89,981 | ||
The data in this schedule has been intentionally rounded to the nearest million, and, therefore, may not sum. |
MEDTRONIC PLC CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) | |||
Nine months ended | |||
(in millions) | January 24, 2025 | January 26, 2024 | |
Operating Activities: | |||
Net income | $Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 3,630 | $Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 3,045 | |
Adjustments to reconcile net income to net cash provided by operating activities: | |||
Depreciation and amortization | 2,021 | 1,993 | |
Provision for credit losses | 96 | 62 | |
Deferred income taxes | (81) | (250) | |
Stock-based compensation | 340 | 303 | |
Other, net | 14 | 265 | |
Change in operating assets and liabilities, net of acquisitions and divestitures: | |||
Accounts receivable, net | (184) | (140) | |
Inventories | (478) | (530) | |
Accounts payable and accrued liabilities | (157) | (253) | |
Other operating assets and liabilities | (685) | (485) | |
Net cash provided by operating activities | 4,516 | 4,010 | |
Investing Activities: | |||
Acquisitions, net of cash acquired | (98) | (74) | |
Additions to property, plant, and equipment | (1,400) | (1,161) | |
Purchases of investments | (6,093) | (5,422) | |
Sales and maturities of investments | 6,255 | 5,142 | |
Other investing activities, net | (111) | (155) | |
Net cash used in investing activities | (1,447) | (1,670) | |
Financing Activities: | |||
Change in current debt obligations, net | (1,070) | 1,010 | |
Issuance of long-term debt | 3,209 | — | |
Dividends to shareholders | (2,692) | (2,753) | |
Issuance of ordinary shares | 400 | 206 | |
Repurchase of ordinary shares | (2,961) | (510) | |
Other financing activities, net | 96 | (44) | |
Net cash used in financing activities | (3,018) | (2,091) | |
Effect of exchange rate changes on cash and cash equivalents | (95) | (170) | |
Net change in cash and cash equivalents | (44) | 80 | |
Cash and cash equivalents at beginning of period | 1,284 | 1,543 | |
Cash and cash equivalents at end of period | $Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 1,240 | $Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 1,623 | |
Supplemental Cash Flow Information | |||
Cash paid for: | |||
Income taxes | $Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 1,515 | $Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 1,403 | |
Interest | 567 | 568 | |
The data in this schedule has been intentionally rounded to the nearest million, and, therefore, may not sum. |
About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland , is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE: MDT), visit www.Medtronic.com and follow on LinkedIn .
FORWARD LOOKING STATEMENTS
 This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties, including risks related to competitive factors, difficulties and delays inherent in the development, manufacturing, marketing and sale of medical products, government regulation, geopolitical conflicts, changing global trade policies, general economic conditions, and other risks and uncertainties described in the company's periodic reports on file with the U.S. Securities and Exchange Commission including the most recent Annual Report on Form 10-K of the company. In some cases, you can identify these statements by forward-looking words or expressions, such as "anticipate," "believe," "could," "estimate," "expect," "forecast," "intend," "looking ahead," "may," "plan," "possible," "potential," "project," "should," "going to," "will," and similar words or expressions, the negative or plural of such words or expressions and other comparable terminology. Actual results may differ materially from anticipated results. Medtronic does not undertake to update its forward-looking statements or any of the information contained in this press release, including to reflect future events or circumstances.
NON-GAAP FINANCIAL MEASURES
 This press release contains financial measures, including adjusted net income, adjusted diluted EPS, and organic revenue, which are considered "non-GAAP" financial measures under applicable SEC rules and regulations. References to quarterly or annual figures increasing, decreasing or remaining flat are in comparison to fiscal year 2024, and references to sequential changes are in comparison to the prior fiscal quarter.
Medtronic management believes that non-GAAP financial measures provide information useful to investors in understanding the company's underlying operational performance and trends and to facilitate comparisons with the performance of other companies in the med tech industry. Non-GAAP net income and diluted EPS exclude the effect of certain charges or gains that contribute to or reduce earnings but that result from transactions or events that management believes may or may not recur with similar materiality or impact to operations in future periods (Non-GAAP Adjustments). Medtronic generally uses non-GAAP financial measures to facilitate management's review of the operational performance of the company and as a basis for strategic planning. Non-GAAP financial measures should be considered supplemental to and not a substitute for financial information prepared in accordance with U.S. generally accepted accounting principles (GAAP), and investors are cautioned that Medtronic may calculate non-GAAP financial measures in a way that is different from other companies. Management strongly encourages investors to review the company's consolidated financial statements and publicly filed reports in their entirety. Reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures are included in the financial schedules accompanying this press release.
Medtronic calculates forward-looking non-GAAP financial measures based on internal forecasts that omit certain amounts that would be included in GAAP financial measures. For instance, forward-looking organic revenue growth guidance excludes the impact of foreign currency fluctuations, as well as significant acquisitions or divestitures. Forward-looking diluted non-GAAP EPS guidance also excludes other potential charges or gains that would be recorded as Non-GAAP Adjustments to earnings during the fiscal year. Medtronic does not attempt to provide reconciliations of forward-looking non-GAAP EPS guidance to projected GAAP EPS guidance because the combined impact and timing of recognition of these potential charges or gains is inherently uncertain and difficult to predict and is unavailable without unreasonable efforts. In addition, the company believes such reconciliations would imply a degree of precision and certainty that could be confusing to investors. Such items could have a substantial impact on GAAP measures of financial performance.
-end-
Contacts: | |
Erika Winkels | Ryan Weispfenning |
Public Relations | Investor Relations |
+1-763-526-8478 | +1-763-505-4626 |
View original content to download multimedia: https://www.prnewswire.com/news-releases/medtronic-reports-third-quarter-fiscal-2025-financial-results-302378617.html
SOURCE Medtronic plc
News Provided by PR Newswire via QuoteMedia
Delivering durable revenue growth with strong earnings power; strength in Pulsed Field Ablation, Pacing, Structural Heart, Diabetes, and Neuromodulation
Medtronic plc (NYSE: MDT) today announced financial results for its third quarter (Q3) of fiscal year 2025 (FY25), which ended January 24, 2025 .
Key Highlights
Financial Results
Medtronic reported Q3 worldwide revenue of $8.292 billion , an increase of 2.5% as reported and 4.1% on an organic basis. Organic revenue growth comparison excludes:
As reported, Q3 GAAP net income and diluted earnings per share (EPS) were $1.294 billion and $1.01 , respectively, representing a decrease of 2% and an increase of 2%, respectively. As detailed in the financial schedules included at the end of this release, Q3 non-GAAP net income and non-GAAP diluted EPS were $1.787 billion and $1.39 , respectively, representing increases of 3% and 7%, respectively.
"We delivered strong earnings this quarter, with significant improvements in both our gross margin and operating margin on the back of our ninth quarter in a row of mid-single digit organic revenue growth," said Geoff Martha , Medtronic chairman and chief executive officer. "We are starting to see the results from our long term investments in groundbreaking innovation, such as pulsed field ablation, to drive growth in some of the most attractive markets in MedTech."
Cardiovascular Portfolio
The Cardiovascular Portfolio includes the Cardiac Rhythm & Heart Failure (CRHF), Structural Heart & Aortic (SHA), and Coronary & Peripheral Vascular (CPV) divisions. Revenue of $3.037 billion increased 3.7% as reported and 5.0% organic, with mid-single digit increases in CRHF and SH&A, and a low-single digit increase in CPV, all on an organic basis.
Neuroscience Portfolio
The Neuroscience Portfolio includes the Cranial & Spinal Technologies (CST), Specialty Therapies, and Neuromodulation divisions. Revenue of $2.458 billion increased 4.4% as reported and 5.2% organic, with a low-double digit increase in Neuromodulation, mid-single digit increase in CST, and low-single digit increase in Specialty Therapies, all on an organic basis.
Medical Surgical Portfolio
The Medical Surgical Portfolio includes the Surgical & Endoscopy (SE) and the Acute Care & Monitoring (ACM) divisions. Revenue of $2.072 billion decreased 1.9% as reported and decreased 0.4% organic, with flat organic result in SE and low-single digit organic decline in ACM.
Diabetes
Revenue of $694 million increased 8.4% as reported and 10.4% organic.
Guidance
Medtronic today reiterated its revenue growth and EPS guidance for FY25.
The company continues to expect FY25 organic revenue growth in the range of 4.75% to 5%. The organic revenue growth guidance excludes the impact of foreign currency and revenue reported as Other. Including Other revenue and the impact of foreign currency exchange, if recent foreign currency exchange rates hold, FY25 revenue growth would be in the range of 3.4% to 3.8%.
The company continues to expect FY25 diluted non-GAAP EPS in the range of $5.44 to $5.50 . This includes an estimated -5% impact from foreign currency exchange based on recent rates. The company's guidance represents FY25 diluted non-GAAP EPS growth in the range of 4.6% to 5.8%.
"EPS came in above the high end of our guidance range. We were pleased with the operational performance of the business this quarter, turning mid-single digit organic growth into leveraged earnings, highlighted by healthy gross margin improvement," said Gary Corona , Medtronic interim chief financial officer. "Looking ahead, our restored earnings power continues. We will accelerate both top and bottom line growth in Q4, resulting in high-single digit adjusted EPS growth in the back half of our fiscal year."
Video Webcast Information
Medtronic will host a video webcast today, February 18 , at 8:00 a.m. EST ( 7:00 a.m. CST ) to provide information about its businesses for the public, investors, analysts, and news media. This webcast can be accessed by clicking on the Events icon at investorrelations.medtronic.com , and this earnings release will be archived at news.medtronic.com . Within 24 hours of the webcast, a replay of the webcast and transcript of the company's prepared remarks will be available by clicking on the Events icon at investorrelations.medtronic.com .
Medtronic plans to report its FY25 fourth quarter results on Wednesday, May 21, 2025 . For fiscal year 2026, Medtronic plans to report its first, second, third, and fourth quarter results on Tuesday, August 19, 2025 , November 18, 2025 , February 17, 2026 , and Wednesday, May 20, 2026 , respectively. Confirmation and additional details will be provided closer to the specific event.
Financial Schedules and Earnings Presentation
The third quarter financial schedules and non-GAAP reconciliations can be viewed by clicking on the Investor Events link at investorrelations.medtronic.com . To view a printable PDF of the financial schedules and non-GAAP reconciliations, click here . To view the third quarter earnings presentation, click here .
MEDTRONIC PLC WORLD WIDE REVENUE (1) (Unaudited) | ||||||||||||||||||||||||||||
THIRD QUARTER | YEAR-TO-DATE | |||||||||||||||||||||||||||
REPORTED | ORGANIC | REPORTED | ORGANIC | |||||||||||||||||||||||||
(in millions) | FY25 | FY24 | Growth | Currency | Adjusted | Adjusted | Growth | FY25 | FY24 | Growth | Currency | Adjusted | Adjusted | Growth | ||||||||||||||
Cardiovascular | $Â Â Â Â 3,037 | $Â Â Â Â 2,929 | 3.7Â % | $Â Â Â Â Â Â Â (38) | $Â Â Â Â 3,075 | $Â Â Â Â 2,929 | 5.0Â % | $Â Â Â Â 9,145 | $Â Â Â Â 8,702 | 5.1Â % | $Â Â Â Â Â Â Â (62) | $Â Â Â Â 9,207 | $Â Â Â Â 8,702 | 5.8Â % | ||||||||||||||
Cardiac Rhythm & Heart Failure | 1,545 | 1,470 | 5.1 | (18) | 1,563 | 1,470 | 6.3 | 4,659 | 4,408 | 5.7 | (26) | 4,684 | 4,408 | 6.3 | ||||||||||||||
Structural Heart & Aortic | 874 | 843 | 3.7 | (13) | 887 | 843 | 5.2 | 2,610 | 2,475 | 5.4 | (21) | 2,631 | 2,475 | 6.3 | ||||||||||||||
Coronary & Peripheral Vascular | 618 | 616 | 0.3 | (8) | 626 | 616 | 1.6 | 1,876 | 1,818 | 3.2 | (15) | 1,891 | 1,818 | 4.0 | ||||||||||||||
Neuroscience | 2,458 | 2,355 | 4.4 | (21) | 2,478 | 2,355 | 5.2 | 7,226 | 6,861 | 5.3 | (29) | 7,255 | 6,861 | 5.7 | ||||||||||||||
Cranial & Spinal Technologies | 1,250 | 1,204 | 3.8 | (9) | 1,259 | 1,204 | 4.6 | 3,632 | 3,465 | 4.8 | (15) | 3,646 | 3,465 | 5.2 | ||||||||||||||
Specialty Therapies | 732 | 726 | 0.8 | (8) | 740 | 726 | 1.9 | 2,181 | 2,126 | 2.6 | (10) | 2,191 | 2,126 | 3.1 | ||||||||||||||
Neuromodulation | 476 | 425 | 12.0 | (4) | 480 | 425 | 12.9 | 1,413 | 1,270 | 11.2 | (5) | 1,417 | 1,270 | 11.6 | ||||||||||||||
Medical Surgical | 2,072 | 2,112 | (1.9) | (32) | 2,104 | 2,112 | (0.4) | 6,196 | 6,219 | (0.4) | (50) | 6,246 | 6,219 | 0.4 | ||||||||||||||
Surgical & Endoscopy | 1,596 | 1,616 | (1.2) | (26) | 1,622 | 1,616 | 0.4 | 4,790 | 4,803 | (0.3) | (40) | 4,829 | 4,803 | 0.5 | ||||||||||||||
Acute Care & Monitoring | 476 | 495 | (3.9) | (5) | 481 | 495 | (2.8) | 1,406 | 1,416 | (0.7) | (10) | 1,417 | 1,416 | — | ||||||||||||||
Diabetes | 694 | 640 | 8.4 | (12) | 706 | 640 | 10.4 | 2,027 | 1,829 | 10.8 | (8) | 2,035 | 1,829 | 11.3 | ||||||||||||||
Total Reportable Segments | 8,260 | 8,035 | 2.8 | (103) | 8,363 | 8,035 | 4.1 | 24,593 | 23,610 | 4.2 | (149) | 24,742 | 23,610 | 4.8 | ||||||||||||||
Other (2) | 32 | 53 | (41.1) | (1) | — | — | — | 17 | 164 | (89.9) | (3) | — | — | — | ||||||||||||||
TOTAL | $Â Â Â Â 8,292 | $Â Â Â Â 8,089 | 2.5Â % | $Â Â Â Â Â (104) | $Â Â Â Â 8,363 | $Â Â Â Â 8,035 | 4.1Â % | $Â Â Â 24,610 | $Â Â Â 23,775 | 3.5Â % | $Â Â Â Â Â (152) | $Â Â Â 24,742 | $Â Â Â 23,610 | 4.8Â % | ||||||||||||||
(1) | The data in this schedule has been intentionally rounded to the nearest million and, therefore, may not sum. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. |
(2) | Includes historical operations and ongoing transition agreements from businesses the Company has exited or divested, and specifically for the three months ended July 26, 2024, impacting year-to-date figures, $90 million of incremental Italian payback accruals resulting from the two July 22, 2024 rulings by the Constitutional Court of Italy relating to certain prior years since 2015. |
(3) | The currency impact to revenue measures the change in revenue between current and prior year periods using constant exchange rates. |
(4) | The three months ended January 24, 2025 excludes $71 million of revenue adjustments related to $32 million of inorganic revenue for the transition activity noted in (2) and $103 million of unfavorable currency impact on the remaining segments. The three months ended January 26, 2024 excludes $53 million of inorganic revenue related to the transition activity noted in (2). |
(5) | The nine months ended January 24, 2025 excludes $132 million of revenue adjustments related to $90 million of incremental Italian payback accruals further described in note (2), $106 million of inorganic revenue related to the transition activity noted in (2), and $149 million of unfavorable currency impact on the remaining segments. The nine months ended January 26, 2024 excludes $164 million of inorganic revenue related to the transition activity noted in (2). |
MEDTRONIC PLC U.S. REVENUE (1)(2) (Unaudited) | ||||||||||||||||||||||||
THIRD QUARTER | YEAR-TO-DATE | |||||||||||||||||||||||
REPORTED | ORGANIC | REPORTED | ORGANIC | |||||||||||||||||||||
(in millions) | FY25 | FY24 | Growth | Adjusted | Adjusted | Growth | FY25 | FY24 | Growth | Adjusted | Adjusted | Growth | ||||||||||||
Cardiovascular | $Â Â Â Â 1,405 | $Â Â Â Â 1,373 | 2.4Â % | $Â Â Â Â 1,405 | $Â Â Â Â 1,373 | 2.4Â % | $Â Â Â Â 4,242 | $Â Â Â Â 4,149 | 2.2Â % | $Â Â Â Â 4,242 | $Â Â Â Â 4,149 | 2.2Â % | ||||||||||||
Cardiac Rhythm & Heart Failure | 775 | 745 | 4.1 | 775 | 745 | 4.1 | 2,309 | 2,247 | 2.8 | 2,309 | 2,247 | 2.8 | ||||||||||||
Structural Heart & Aortic | 372 | 363 | 2.6 | 372 | 363 | 2.6 | 1,129 | 1,087 | 3.9 | 1,129 | 1,087 | 3.9 | ||||||||||||
Coronary & Peripheral Vascular | 258 | 265 | (2.8) | 258 | 265 | (2.8) | 804 | 816 | (1.4) | 804 | 816 | (1.4) | ||||||||||||
Neuroscience | 1,689 | 1,556 | 8.5 | 1,689 | 1,556 | 8.5 | 4,931 | 4,614 | 6.9 | 4,931 | 4,614 | 6.9 | ||||||||||||
Cranial & Spinal Technologies | 943 | 875 | 7.8 | 943 | 875 | 7.8 | 2,724 | 2,560 | 6.4 | 2,724 | 2,560 | 6.4 | ||||||||||||
Specialty Therapies | 419 | 407 | 3.0 | 419 | 407 | 3.0 | 1,235 | 1,202 | 2.7 | 1,235 | 1,202 | 2.7 | ||||||||||||
Neuromodulation | 327 | 275 | 19.0 | 327 | 275 | 19.0 | 972 | 852 | 14.1 | 972 | 852 | 14.1 | ||||||||||||
Medical Surgical | 893 | 947 | (5.8) | 893 | 947 | (5.8) | 2,718 | 2,763 | (1.6) | 2,718 | 2,763 | (1.6) | ||||||||||||
Surgical & Endoscopy | 623 | 663 | (6.1) | 623 | 663 | (6.1) | 1,928 | 1,971 | (2.2) | 1,928 | 1,971 | (2.2) | ||||||||||||
Acute Care & Monitoring | 269 | 284 | (5.1) | 269 | 284 | (5.1) | 790 | 792 | (0.2) | 790 | 792 | (0.2) | ||||||||||||
Diabetes | 236 | 224 | 5.6 | 236 | 224 | 5.6 | 683 | 629 | 8.7 | 683 | 629 | 8.7 | ||||||||||||
Total Reportable Segments | 4,223 | 4,100 | 3.0 | 4,223 | 4,100 | 3.0 | 12,573 | 12,154 | 3.4 | 12,573 | 12,154 | 3.4 | ||||||||||||
Other (3) | 15 | 20 | (26.4) | — | — | — | 51 | 65 | (21.3) | — | — | — | ||||||||||||
TOTAL | $Â Â Â Â 4,237 | $Â Â Â Â 4,120 | 2.8Â % | $Â Â Â Â 4,223 | $Â Â Â Â 4,100 | 3.0Â % | $Â Â 12,624 | $Â Â 12,219 | 3.3Â % | $Â Â 12,573 | $Â Â 12,154 | 3.4Â % | ||||||||||||
(1) | U.S. includes the United States and U.S. territories. |
(2) | The data in this schedule has been intentionally rounded to the nearest million and, therefore, may not sum. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. |
(3) | Includes historical operations and ongoing transition agreements from businesses the Company has exited or divested. |
MEDTRONIC PLC INTERNATIONAL REVENUE (1) (Unaudited) | ||||||||||||||||||||||||||||
THIRD QUARTER | YEAR-TO-DATE | |||||||||||||||||||||||||||
REPORTED | ORGANIC | REPORTED | ORGANIC | |||||||||||||||||||||||||
(in millions) | FY25 | FY24 | Growth | Currency | Adjusted | Adjusted | Growth | FY25 | FY24 | Growth | Currency | Adjusted | Adjusted | Growth | ||||||||||||||
Cardiovascular | $Â Â Â Â 1,632 | $Â Â Â Â 1,556 | 4.9Â % | $Â Â Â Â Â Â Â (38) | $Â Â Â Â 1,670 | $Â Â Â Â 1,556 | 7.3Â % | $Â Â Â Â 4,904 | $Â Â Â Â 4,552 | 7.7Â % | $Â Â Â Â Â Â Â (62) | $Â Â Â Â 4,966 | $Â Â Â Â 4,552 | 9.1Â % | ||||||||||||||
Cardiac Rhythm & Heart Failure | 770 | 726 | 6.1 | (18) | 788 | 726 | 8.6 | 2,350 | 2,161 | 8.7 | (26) | 2,376 | 2,161 | 9.9 | ||||||||||||||
Structural Heart & Aortic | 502 | 480 | 4.6 | (13) | 515 | 480 | 7.2 | 1,482 | 1,389 | 6.7 | (21) | 1,503 | 1,389 | 8.2 | ||||||||||||||
Coronary & Peripheral Vascular | 360 | 350 | 2.6 | (8) | 368 | 350 | 4.9 | 1,072 | 1,002 | 7.0 | (15) | 1,087 | 1,002 | 8.5 | ||||||||||||||
Neuroscience | 769 | 799 | (3.7) | (21) | 790 | 799 | (1.1) | 2,295 | 2,248 | 2.1 | (29) | 2,324 | 2,248 | 3.4 | ||||||||||||||
Cranial & Spinal Technologies | 307 | 329 | (6.7) | (9) | 316 | 329 | (3.9) | 907 | 905 | 0.3 | (15) | 922 | 905 | 1.9 | ||||||||||||||
Specialty Therapies | 313 | 319 | (2.0) | (8) | 321 | 319 | 0.4 | 947 | 924 | 2.4 | (10) | 957 | 924 | 3.5 | ||||||||||||||
Neuromodulation | 149 | 150 | (0.7) | (4) | 153 | 150 | 1.8 | 441 | 419 | 5.4 | (5) | 446 | 419 | 6.5 | ||||||||||||||
Medical Surgical | 1,180 | 1,164 | 1.3 | (32) | 1,211 | 1,164 | 4.0 | 3,478 | 3,456 | 0.6 | (50) | 3,528 | 3,456 | 2.1 | ||||||||||||||
Surgical & Endoscopy | 973 | 953 | 2.1 | (26) | 999 | 953 | 4.9 | 2,862 | 2,832 | 1.1 | (40) | 2,902 | 2,832 | 2.5 | ||||||||||||||
Acute Care & Monitoring | 206 | 211 | (2.3) | (5) | 212 | 211 | 0.2 | 616 | 624 | (1.4) | (10) | 626 | 624 | 0.3 | ||||||||||||||
Diabetes | 457 | 416 | 9.9 | (12) | 470 | 416 | 12.9 | 1,344 | 1,200 | 12.0 | (8) | 1,351 | 1,200 | 12.6 | ||||||||||||||
Total Reportable Segments | 4,038 | 3,935 | 2.6 | (103) | 4,141 | 3,935 | 5.2 | 12,020 | 11,456 | 4.9 | (149) | 12,169 | 11,456 | 6.2 | ||||||||||||||
Other (2) | 17 | 34 | (49.8) | (1) | — | — | — | (35) | 99 | (134.8) | (3) | — | — | — | ||||||||||||||
TOTAL | $Â Â Â Â 4,055 | $Â Â Â Â 3,968 | 2.2Â % | $Â Â Â Â Â (104) | $Â Â Â Â 4,141 | $Â Â Â Â 3,935 | 5.2Â % | $Â Â 11,986 | $Â Â 11,555 | 3.7Â % | $Â Â Â Â Â (152) | $Â Â 12,169 | $Â Â 11,456 | 6.2Â % | ||||||||||||||
(1) | The data in this schedule has been intentionally rounded to the nearest million and, therefore, may not sum. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. |
(2) | Includes historical operations and ongoing transition agreements from businesses the Company has exited or divested, and specifically for the three months ended July 26, 2024, impacting year-to-date figures, $90 million of incremental Italian payback accruals resulting from the two July 22, 2024 rulings by the Constitutional Court of Italy relating to certain prior years since 2015. |
(3) | The currency impact to revenue measures the change in revenue between current and prior year periods using constant exchange rates. |
(4) | The three months ended January 24, 2025 excludes $86 million of revenue adjustments related to $17 million of inorganic revenue for the transition activity noted in (2), and $103 million of unfavorable currency impact on the remaining segments. The three months ended January 26, 2024 excludes $34 million of inorganic revenue related to the transition activity noted in (2). |
(5) | The nine months ended January 24, 2025 excludes $183 million of revenue adjustments related to $90 million of incremental Italian payback accruals further described in note (2), $55 million of inorganic revenue related to the transition activity noted in (2), and $149 million of unfavorable currency impact on the remaining segments. The nine months ended January 26, 2024 excludes $99 million of inorganic revenue related to the transition activity noted in (2). |
MEDTRONIC PLC CONSOLIDATED STATEMENTS OF INCOME (Unaudited) | |||||||
Three months ended | Nine months ended | ||||||
(in millions, except per share data) | January 24, | January 26, | January 24, | January 26, | |||
Net sales | $Â Â Â Â Â Â Â Â Â Â Â 8,292 | $Â Â Â Â Â Â Â Â Â Â Â 8,089 | $Â Â Â Â Â Â Â Â Â 24,610 | $Â Â Â Â Â Â Â Â Â 23,775 | |||
Costs and expenses: | |||||||
Cost of products sold, excluding amortization of intangible assets | 2,779 | 2,782 | 8,485 | 8,172 | |||
Research and development expense | 675 | 695 | 2,048 | 2,060 | |||
Selling, general, and administrative expense | 2,717 | 2,673 | 8,129 | 7,971 | |||
Amortization of intangible assets | 416 | 419 | 1,243 | 1,274 | |||
Restructuring charges, net | 43 | 20 | 120 | 114 | |||
Certain litigation charges, net | 22 | — | 104 | 105 | |||
Other operating (income) expense, net | (5) | 17 | (38) | (13) | |||
Operating profit | 1,646 | 1,483 | 4,519 | 4,091 | |||
Other non-operating income, net | (72) | (177) | (403) | (407) | |||
Interest expense, net | 179 | 188 | 555 | 517 | |||
Income before income taxes | 1,540 | 1,472 | 4,367 | 3,982 | |||
Income tax provision | 237 | 135 | 737 | 936 | |||
Net income | 1,303 | 1,337 | 3,630 | 3,045 | |||
Net income attributable to noncontrolling interests | (9) | (15) | (24) | (23) | |||
Net income attributable to Medtronic | $Â Â Â Â Â Â Â Â Â Â Â 1,294 | $Â Â Â Â Â Â Â Â Â Â Â 1,322 | $Â Â Â Â Â Â Â Â Â Â Â 3,606 | $Â Â Â Â Â Â Â Â Â Â Â 3,022 | |||
Basic earnings per share | $Â Â Â Â Â Â Â 1.01 | $Â Â Â Â Â Â Â 0.99 | $Â Â Â Â Â Â Â 2.80 | $Â Â Â Â Â Â Â 2.27 | |||
Diluted earnings per share | $Â Â Â Â Â Â Â 1.01 | $Â Â Â Â Â Â Â 0.99 | $Â Â Â Â Â Â Â 2.79 | $Â Â Â Â Â Â Â 2.27 | |||
Basic weighted average shares outstanding | 1,282.4 | 1,329.7 | 1,286.7 | 1,330.1 | |||
Diluted weighted average shares outstanding | 1,286.2 | 1,331.7 | 1,290.6 | 1,332.4 | |||
The data in the schedule above has been intentionally rounded to the nearest million. |
MEDTRONIC PLC GAAP TO NON-GAAP RECONCILIATIONS (1) (Unaudited) | |||||||||||||||||
Three months ended January 24, 2025 | |||||||||||||||||
(in millions, except per share data) | Net | Cost of | Gross | Operating | Operating | Income | Net Income | Diluted | Effective | ||||||||
GAAP | $Â 8,292 | $Â Â 2,779 | 66.5Â % | $Â Â Â Â 1,646 | 19.9Â % | $Â Â Â 1,540 | $Â Â Â Â Â Â 1,294 | $Â Â Â Â 1.01 | 15.4Â % | ||||||||
Non-GAAP Adjustments: | |||||||||||||||||
Amortization of intangible assets | — | — | — | 416 | 5.0 | 416 | 339 | 0.26 | 18.5 | ||||||||
Restructuring and associated costs (2) | — | (4) | — | 46 | 0.6 | 46 | 37 | 0.03 | 19.6 | ||||||||
Acquisition and divestiture-related items (3) | — | (1) | — | 28 | 0.3 | 28 | 23 | 0.02 | 17.9 | ||||||||
Certain litigation charges, net | — | — | — | 22 | 0.3 | 22 | 18 | 0.01 | 22.7 | ||||||||
(Gain)/loss on minority investments (4) | — | — | — | — | — | 68 | 52 | 0.04 | 22.1 | ||||||||
Medical device regulations (5) | — | (8) | 0.1 | 11 | 0.1 | 11 | 9 | 0.01 | 18.2 | ||||||||
Certain tax adjustments, net | — | — | — | — | — | — | 15 | 0.01 | — | ||||||||
Non-GAAP | $Â 8,292 | $Â Â 2,766 | 66.6Â % | $Â Â Â Â 2,169 | 26.2Â % | $Â Â Â 2,130 | $Â Â Â Â Â Â 1,787 | $Â Â Â Â 1.39 | 15.7Â % | ||||||||
Currency impact | 104 | 61 | (0.3) | (4) | (0.4) | (0.01) | |||||||||||
Currency Adjusted | $Â 8,396 | $Â Â 2,827 | 66.3Â % | $Â Â Â Â 2,165 | 25.8Â % | $Â Â Â Â 1.38 | |||||||||||
Three months ended January 26, 2024 | |||||||||||||||||
(in millions, except per share data) | Net | Cost of | Gross | Operating | Operating | Income | Net Income | Diluted | Effective | ||||||||
GAAP | $Â 8,089 | $Â Â 2,782 | 65.6Â % | $Â Â Â Â 1,483 | 18.3Â % | $Â Â Â 1,472 | $Â Â Â Â Â Â 1,322 | $Â Â Â Â 0.99 | 9.2Â % | ||||||||
Non-GAAP Adjustments: | |||||||||||||||||
Amortization of intangible assets | — | — | — | 419 | 5.2 | 419 | 354 | 0.27 | 15.5 | ||||||||
Restructuring and associated costs (2) | — | (12) | 0.1 | 55 | 0.7 | 55 | 46 | 0.03 | 16.4 | ||||||||
Acquisition and divestiture-related items (3) | — | (12) | 0.1 | 58 | 0.7 | 58 | 52 | 0.04 | 10.3 | ||||||||
(Gain)/loss on minority investments (4) | — | — | — | — | — | 24 | 24 | 0.02 | — | ||||||||
Medical device regulations (5) | — | (18) | 0.2 | 26 | 0.3 | 26 | 21 | 0.02 | 19.2 | ||||||||
Certain tax adjustments, net (6) | — | — | — | — | — | — | (92) | (0.07) | — | ||||||||
Non-GAAP | $Â 8,089 | $Â Â 2,740 | 66.1Â % | $Â Â Â Â 2,042 | 25.2Â % | $Â Â Â 2,055 | $Â Â Â Â Â Â 1,728 | $Â Â Â Â 1.30 | 15.2Â % | ||||||||
See description of non-GAAP financial measures contained in the press release dated February 18, 2025. | |
(1) | The data in this schedule has been intentionally rounded to the nearest million or $0.01 for EPS figures, and, therefore, may not sum. |
(2) | Associated costs primarily include salaries and wages for employees supporting the restructuring activities, consulting expenses, and asset write-offs. |
(3) | The charges primarily include business combination costs, changes in fair value of contingent consideration, and exit of business-related charges. |
(4) | We exclude unrealized and realized gains and losses on our minority investments as we do not believe that these components of income or expense have a direct correlation to our ongoing or future business operations. |
(5) | The charges represent incremental costs of complying with the new European Union (E.U.) medical device regulations for previously registered products and primarily include charges for contractors supporting the project and other direct third-party expenses. We consider these costs to be duplicative of previously incurred costs and/or one-time costs, which are limited to a specific time period. |
(6) | The net tax benefit primarily relates to a change in a Swiss Cantonal tax rate associated with previously established deferred tax assets from intercompany intellectual property transactions and the step up in tax basis for Swiss Cantonal purposes. |
MEDTRONIC PLC GAAP TO NON-GAAP RECONCILIATIONS (1) (Unaudited) | |||||||||||||||||
Nine months ended January 24, 2025 | |||||||||||||||||
(in millions, except per share data) | Net | Cost of | Gross | Operating | Operating | Income | Net Income | Diluted | Effective | ||||||||
GAAP | $ 24,610 | $Â Â 8,485 | 65.5Â % | $Â Â Â Â 4,519 | 18.4Â % | $Â Â Â 4,367 | $Â Â Â Â Â Â Â Â 3,606 | $Â Â Â Â 2.79 | 16.9Â % | ||||||||
Non-GAAP Adjustments: | |||||||||||||||||
Amortization of intangible assets | — | — | — | 1,243 | 4.9 | 1,243 | 1,017 | 0.79 | 18.3 | ||||||||
Restructuring and associated costs (2) | — | (24) | 0.1 | 154 | 0.6 | 154 | 124 | 0.10 | 19.5 | ||||||||
Acquisition and divestiture-related items (3) | — | (17) | — | 15 | 0.1 | 15 | 3 | — | 73.3 | ||||||||
Certain litigation charges, net | — | — | — | 104 | 0.4 | 104 | 86 | 0.07 | 17.3 | ||||||||
(Gain)/loss on minority investments (4) | — | — | — | — | — | 41 | 14 | 0.01 | 61.0 | ||||||||
Medical device regulations (5) | — | (27) | 0.1 | 38 | 0.2 | 38 | 30 | 0.02 | 21.1 | ||||||||
Other (6) | 90 | — | 0.2 | 90 | 0.4 | 90 | 70 | 0.05 | 22.2 | ||||||||
Certain tax adjustments, net (7) | — | — | — | — | — | — | 49 | 0.04 | — | ||||||||
Non-GAAP | $ 24,700 | $Â Â 8,417 | 65.9Â % | $Â Â Â Â 6,162 | 24.9Â % | $Â Â Â 6,051 | $Â Â Â Â Â Â Â Â 4,999 | $Â Â Â Â 3.87 | 17.0Â % | ||||||||
Currency impact | 150 | (72) | 0.5 | 241 | 0.9 | 0.15 | |||||||||||
Currency Adjusted | $ 24,850 | $Â Â 8,345 | 66.4Â % | $Â Â Â Â 6,403 | 25.8Â % | $Â Â Â Â 4.02 | |||||||||||
Nine months ended January 26, 2024 | |||||||||||||||||
(in millions, except per share data) | Net | Cost of | Gross | Operating | Operating | Income | Net Income | Diluted | Effective | ||||||||
GAAP | $ 23,775 | $Â Â 8,172 | 65.6Â % | $Â Â Â Â 4,091 | 17.2Â % | $Â Â Â 3,982 | $Â Â Â Â Â Â Â Â 3,022 | $Â Â Â Â 2.27 | 23.5Â % | ||||||||
Non-GAAP Adjustments: | |||||||||||||||||
Amortization of intangible assets | — | — | — | 1,274 | 5.4 | 1,274 | 1,078 | 0.81 | 15.4 | ||||||||
Restructuring and associated costs (2) | — | (43) | 0.2 | 237 | 1.0 | 237 | 198 | 0.15 | 16.5 | ||||||||
Acquisition and divestiture-related items (3) | — | (24) | 0.1 | 165 | 0.7 | 165 | 149 | 0.11 | 9.7 | ||||||||
Certain litigation charges, net | — | — | — | 105 | 0.4 | 105 | 81 | 0.06 | 22.9 | ||||||||
(Gain)/loss on minority investments (4) | — | — | — | — | — | 113 | 109 | 0.08 | 4.4 | ||||||||
Medical device regulations (5) | — | (60) | 0.3 | 88 | 0.4 | 88 | 70 | 0.05 | 20.5 | ||||||||
Certain tax adjustments, net (8) | — | — | — | — | — | — | 282 | 0.21 | — | ||||||||
Non-GAAP | $ 23,775 | $Â Â 8,046 | 66.2Â % | $Â Â Â Â 5,961 | 25.1Â % | $Â Â Â 5,965 | $Â Â Â Â Â Â Â Â 4,988 | $Â Â Â Â 3.74 | 16.0Â % | ||||||||
See description of non-GAAP financial measures contained in the press release dated February 18, 2025. | |
(1) | The data in this schedule has been intentionally rounded to the nearest million or $0.01 for EPS figures, and, therefore, may not sum. |
(2) | Associated costs primarily include salaries and wages for employees supporting the restructuring activities, consulting expenses, and asset write-offs. |
(3) | The charges primarily include business combination costs, changes in fair value of contingent consideration, and exit of business-related charges. The nine months ended January 24, 2025, also include gains related to certain business or asset sales. |
(4) | We exclude unrealized and realized gains and losses on our minority investments as we do not believe that these components of income or expense have a direct correlation to our ongoing or future business operations. |
(5) | The charges represent incremental costs of complying with the new European Union (E.U.) medical device regulations for previously registered products and primarily include charges for contractors supporting the project and other direct third-party expenses. We consider these costs to be duplicative of previously incurred costs and/or one-time costs, which are limited to a specific time period. |
(6) | Reflects the recognition of incremental Italian payback accruals resulting from the two July 22, 2024 rulings by the Constitutional Court of Italy relating to certain prior years since 2015. |
(7) | Primarily relates to amortization of previously established deferred tax assets from intercompany intellectual property transactions. |
(8) | The net charge primarily relates to an income tax reserve adjustment associated with the June 2023, Israeli Central-Lod District Court decision and the establishment of a valuation allowance against certain net operating losses which were partially offset by a benefit from the change in a Swiss Cantonal tax rate associated with previously established deferred tax assets from intercompany intellectual property transactions and the step up in tax basis for Swiss Cantonal purposes. |
MEDTRONIC PLC GAAP TO NON-GAAP RECONCILIATIONS (1) (Unaudited) | |||||||||||||||
Three months ended January 24, 2025 | |||||||||||||||
(in millions) | Net Sales | SG&A | SG&A | R&D | R&D | Other | Other | Other Non- | |||||||
GAAP | $Â Â Â Â Â 8,292 | $Â Â Â Â 2,717 | 32.8Â % | $Â Â Â Â Â Â 675 | 8.1Â % | $Â Â Â Â Â Â Â Â Â Â (5) | (0.1)Â % | $Â Â Â Â Â Â Â Â Â Â (72) | |||||||
Non-GAAP Adjustments: | |||||||||||||||
Acquisition and divestiture-related items (2) | — | (13) | (0.2) | — | — | (13) | (0.2) | — | |||||||
Medical device regulations (3) | — | — | — | (3) | — | — | — | — | |||||||
(Gain)/loss on minority investments (4) | — | — | — | — | — | — | — | (68) | |||||||
Non-GAAP | $Â Â Â Â Â 8,292 | $Â Â Â Â 2,704 | 32.6Â % | $Â Â Â Â Â Â 672 | 8.1Â % | $Â Â Â Â Â Â Â Â (18) | (0.2)Â % | $Â Â Â Â Â Â Â Â Â (140) | |||||||
Nine months ended January 24, 2025 | |||||||||||||||
(in millions) | Net Sales | SG&A | SG&A | R&D | R&D | Other | Other | Other Non- | |||||||
GAAP | $Â Â Â 24,610 | $Â Â Â Â 8,129 | 33.0Â % | $Â Â Â 2,048 | 8.3Â % | $Â Â Â Â Â Â Â Â (38) | (0.2)Â % | $Â Â Â Â Â Â Â Â Â (403) | |||||||
Non-GAAP Adjustments: | |||||||||||||||
Restructuring and associated costs (5) | — | (10) | (0.1) | — | — | — | — | — | |||||||
Acquisition and divestiture-related items (2) | — | (40) | (0.3) | — | — | 42 | 0.2 | — | |||||||
Medical device regulations (3) | — | — | — | (10) | — | — | — | — | |||||||
Other (6) | 90 | — | — | — | — | — | — | — | |||||||
(Gain)/loss on minority investments (4) | — | — | — | — | — | — | — | (41) | |||||||
Non-GAAP | $   24,700 | $    8,078 | 32.7 % | $   2,038 | 8.3 % | $            4 | — % | $         (443) | |||||||
See description of non-GAAP financial measures contained in the press release dated February 18, 2025. | |
(1) | The data in this schedule has been intentionally rounded to the nearest million, and, therefore, may not sum. |
(2) | The charges primarily include business combination costs, changes in fair value of contingent consideration, exit of business-related charges, and gains related to certain business or asset sales. The nine months ended January 24, 2025, also include gains related to certain business or asset sales. |
(3) | The charges represent incremental costs of complying with the new European Union medical device regulations for previously registered products and primarily include charges for contractors supporting the project and other direct third-party expenses. We consider these costs to be duplicative of previously incurred costs and/or one-time costs, which are limited to a specific time period. |
(4) | We exclude unrealized and realized gains and losses on our minority investments as we do not believe that these components of income or expense have a direct correlation to our ongoing or future business operations. |
(5) | Associated costs primarily include salaries and wages for employees supporting the restructuring activities, consulting expenses, and asset write-offs. |
(6) | Reflects the recognition of incremental Italian payback accruals resulting from the two July 22, 2024 rulings by the Constitutional Court of Italy relating to certain prior years since 2015. |
MEDTRONIC PLC GAAP TO NON-GAAP RECONCILIATIONS (1) (Unaudited) | |||
Nine months ended | |||
(in millions) | January 24, 2025 | January 26, 2024 | |
Net cash provided by operating activities | $Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 4,516 | $Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 4,010 | |
Additions to property, plant, and equipment | (1,400) | (1,161) | |
Free Cash Flow (2) | $Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 3,116 | $Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 2,849 | |
See description of non-GAAP financial measures contained in the press release dated February 18, 2025. | |
(1) | The data in this schedule has been intentionally rounded to the nearest million, and, therefore, may not sum. |
(2) | Free cash flow represents operating cash flows less property, plant, and equipment additions. |
MEDTRONIC PLC CONSOLIDATED BALANCE SHEETS (Unaudited) | ||||
(in millions) | January 24, 2025 | April 26, 2024 | ||
ASSETS | ||||
Current assets: | ||||
Cash and cash equivalents | $Â Â Â Â Â Â Â Â Â Â Â Â Â Â 1,240 | $Â Â Â Â Â Â Â Â Â Â Â Â Â Â 1,284 | ||
Investments | 6,682 | 6,721 | ||
Accounts receivable, less allowances and credit losses of $204 and $173, respectively | 6,115 | 6,128 | ||
Inventories | 5,610 | 5,217 | ||
Other current assets | 2,865 | 2,584 | ||
Total current assets | 22,513 | 21,935 | ||
Property, plant, and equipment, net | 6,593 | 6,131 | ||
Goodwill | 40,819 | 40,986 | ||
Other intangible assets, net | 12,184 | 13,225 | ||
Tax assets | 3,614 | 3,657 | ||
Other assets | 4,250 | 4,047 | ||
Total assets | $Â Â Â Â Â Â Â Â Â Â Â Â 89,973 | $Â Â Â Â Â Â Â Â Â Â Â Â 89,981 | ||
LIABILITIES AND EQUITY | ||||
Current liabilities: | ||||
Current debt obligations | $Â Â Â Â Â Â Â Â Â Â Â Â Â Â 2,622 | $Â Â Â Â Â Â Â Â Â Â Â Â Â Â 1,092 | ||
Accounts payable | 2,286 | 2,410 | ||
Accrued compensation | 2,281 | 2,375 | ||
Accrued income taxes | 1,125 | 1,330 | ||
Other accrued expenses | 3,526 | 3,582 | ||
Total current liabilities | 11,840 | 10,789 | ||
Long-term debt | 23,985 | 23,932 | ||
Accrued compensation and retirement benefits | 1,063 | 1,101 | ||
Accrued income taxes | 1,485 | 1,859 | ||
Deferred tax liabilities | 452 | 515 | ||
Other liabilities | 1,533 | 1,365 | ||
Total liabilities | 40,358 | 39,561 | ||
Commitments and contingencies | ||||
Shareholders' equity: | ||||
Ordinary shares— par value $0.0001, 2.6 billion shares authorized, 1,283,266,154 and 1,311,337,531 shares issued and outstanding, respectively | — | — | ||
Additional paid-in capital | 20,910 | 23,129 | ||
Retained earnings | 31,317 | 30,403 | ||
Accumulated other comprehensive loss | (2,839) | (3,318) | ||
Total shareholders' equity | 49,387 | 50,214 | ||
Noncontrolling interests | 228 | 206 | ||
Total equity | 49,615 | 50,420 | ||
Total liabilities and equity | $Â Â Â Â Â Â Â Â Â Â Â Â 89,973 | $Â Â Â Â Â Â Â Â Â Â Â Â 89,981 | ||
The data in this schedule has been intentionally rounded to the nearest million, and, therefore, may not sum. |
MEDTRONIC PLC CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) | |||
Nine months ended | |||
(in millions) | January 24, 2025 | January 26, 2024 | |
Operating Activities: | |||
Net income | $Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 3,630 | $Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 3,045 | |
Adjustments to reconcile net income to net cash provided by operating activities: | |||
Depreciation and amortization | 2,021 | 1,993 | |
Provision for credit losses | 96 | 62 | |
Deferred income taxes | (81) | (250) | |
Stock-based compensation | 340 | 303 | |
Other, net | 14 | 265 | |
Change in operating assets and liabilities, net of acquisitions and divestitures: | |||
Accounts receivable, net | (184) | (140) | |
Inventories | (478) | (530) | |
Accounts payable and accrued liabilities | (157) | (253) | |
Other operating assets and liabilities | (685) | (485) | |
Net cash provided by operating activities | 4,516 | 4,010 | |
Investing Activities: | |||
Acquisitions, net of cash acquired | (98) | (74) | |
Additions to property, plant, and equipment | (1,400) | (1,161) | |
Purchases of investments | (6,093) | (5,422) | |
Sales and maturities of investments | 6,255 | 5,142 | |
Other investing activities, net | (111) | (155) | |
Net cash used in investing activities | (1,447) | (1,670) | |
Financing Activities: | |||
Change in current debt obligations, net | (1,070) | 1,010 | |
Issuance of long-term debt | 3,209 | — | |
Dividends to shareholders | (2,692) | (2,753) | |
Issuance of ordinary shares | 400 | 206 | |
Repurchase of ordinary shares | (2,961) | (510) | |
Other financing activities, net | 96 | (44) | |
Net cash used in financing activities | (3,018) | (2,091) | |
Effect of exchange rate changes on cash and cash equivalents | (95) | (170) | |
Net change in cash and cash equivalents | (44) | 80 | |
Cash and cash equivalents at beginning of period | 1,284 | 1,543 | |
Cash and cash equivalents at end of period | $Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 1,240 | $Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 1,623 | |
Supplemental Cash Flow Information | |||
Cash paid for: | |||
Income taxes | $Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 1,515 | $Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 1,403 | |
Interest | 567 | 568 | |
The data in this schedule has been intentionally rounded to the nearest million, and, therefore, may not sum. |
About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland , is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE: MDT), visit www.Medtronic.com and follow on LinkedIn .
FORWARD LOOKING STATEMENTS
 This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties, including risks related to competitive factors, difficulties and delays inherent in the development, manufacturing, marketing and sale of medical products, government regulation, geopolitical conflicts, changing global trade policies, general economic conditions, and other risks and uncertainties described in the company's periodic reports on file with the U.S. Securities and Exchange Commission including the most recent Annual Report on Form 10-K of the company. In some cases, you can identify these statements by forward-looking words or expressions, such as "anticipate," "believe," "could," "estimate," "expect," "forecast," "intend," "looking ahead," "may," "plan," "possible," "potential," "project," "should," "going to," "will," and similar words or expressions, the negative or plural of such words or expressions and other comparable terminology. Actual results may differ materially from anticipated results. Medtronic does not undertake to update its forward-looking statements or any of the information contained in this press release, including to reflect future events or circumstances.
NON-GAAP FINANCIAL MEASURES
 This press release contains financial measures, including adjusted net income, adjusted diluted EPS, and organic revenue, which are considered "non-GAAP" financial measures under applicable SEC rules and regulations. References to quarterly or annual figures increasing, decreasing or remaining flat are in comparison to fiscal year 2024, and references to sequential changes are in comparison to the prior fiscal quarter.
Medtronic management believes that non-GAAP financial measures provide information useful to investors in understanding the company's underlying operational performance and trends and to facilitate comparisons with the performance of other companies in the med tech industry. Non-GAAP net income and diluted EPS exclude the effect of certain charges or gains that contribute to or reduce earnings but that result from transactions or events that management believes may or may not recur with similar materiality or impact to operations in future periods (Non-GAAP Adjustments). Medtronic generally uses non-GAAP financial measures to facilitate management's review of the operational performance of the company and as a basis for strategic planning. Non-GAAP financial measures should be considered supplemental to and not a substitute for financial information prepared in accordance with U.S. generally accepted accounting principles (GAAP), and investors are cautioned that Medtronic may calculate non-GAAP financial measures in a way that is different from other companies. Management strongly encourages investors to review the company's consolidated financial statements and publicly filed reports in their entirety. Reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures are included in the financial schedules accompanying this press release.
Medtronic calculates forward-looking non-GAAP financial measures based on internal forecasts that omit certain amounts that would be included in GAAP financial measures. For instance, forward-looking organic revenue growth guidance excludes the impact of foreign currency fluctuations, as well as significant acquisitions or divestitures. Forward-looking diluted non-GAAP EPS guidance also excludes other potential charges or gains that would be recorded as Non-GAAP Adjustments to earnings during the fiscal year. Medtronic does not attempt to provide reconciliations of forward-looking non-GAAP EPS guidance to projected GAAP EPS guidance because the combined impact and timing of recognition of these potential charges or gains is inherently uncertain and difficult to predict and is unavailable without unreasonable efforts. In addition, the company believes such reconciliations would imply a degree of precision and certainty that could be confusing to investors. Such items could have a substantial impact on GAAP measures of financial performance.
-end-
Contacts: | |
Erika Winkels | Ryan Weispfenning |
Public Relations | Investor Relations |
+1-763-526-8478 | +1-763-505-4626 |
View original content to download multimedia: https://www.prnewswire.com/news-releases/medtronic-reports-third-quarter-fiscal-2025-financial-results-302378617.html
SOURCE Medtronic plc
News Provided by PR Newswire via QuoteMedia
Delivering durable revenue growth with strong earnings power; strength in Pulsed Field Ablation, Pacing, Structural Heart, Diabetes, and Neuromodulation
Medtronic plc (NYSE: MDT) today announced financial results for its third quarter (Q3) of fiscal year 2025 (FY25), which ended January 24, 2025 .
Key Highlights
Financial Results
Medtronic reported Q3 worldwide revenue of $8.292 billion , an increase of 2.5% as reported and 4.1% on an organic basis. Organic revenue growth comparison excludes:
As reported, Q3 GAAP net income and diluted earnings per share (EPS) were $1.294 billion and $1.01 , respectively, representing a decrease of 2% and an increase of 2%, respectively. As detailed in the financial schedules included at the end of this release, Q3 non-GAAP net income and non-GAAP diluted EPS were $1.787 billion and $1.39 , respectively, representing increases of 3% and 7%, respectively.
"We delivered strong earnings this quarter, with significant improvements in both our gross margin and operating margin on the back of our ninth quarter in a row of mid-single digit organic revenue growth," said Geoff Martha , Medtronic chairman and chief executive officer. "We are starting to see the results from our long term investments in groundbreaking innovation, such as pulsed field ablation, to drive growth in some of the most attractive markets in MedTech."
Cardiovascular Portfolio
The Cardiovascular Portfolio includes the Cardiac Rhythm & Heart Failure (CRHF), Structural Heart & Aortic (SHA), and Coronary & Peripheral Vascular (CPV) divisions. Revenue of $3.037 billion increased 3.7% as reported and 5.0% organic, with mid-single digit increases in CRHF and SH&A, and a low-single digit increase in CPV, all on an organic basis.
Neuroscience Portfolio
The Neuroscience Portfolio includes the Cranial & Spinal Technologies (CST), Specialty Therapies, and Neuromodulation divisions. Revenue of $2.458 billion increased 4.4% as reported and 5.2% organic, with a low-double digit increase in Neuromodulation, mid-single digit increase in CST, and low-single digit increase in Specialty Therapies, all on an organic basis.
Medical Surgical Portfolio
The Medical Surgical Portfolio includes the Surgical & Endoscopy (SE) and the Acute Care & Monitoring (ACM) divisions. Revenue of $2.072 billion decreased 1.9% as reported and decreased 0.4% organic, with flat organic result in SE and low-single digit organic decline in ACM.
Diabetes
Revenue of $694 million increased 8.4% as reported and 10.4% organic.
Guidance
Medtronic today reiterated its revenue growth and EPS guidance for FY25.
The company continues to expect FY25 organic revenue growth in the range of 4.75% to 5%. The organic revenue growth guidance excludes the impact of foreign currency and revenue reported as Other. Including Other revenue and the impact of foreign currency exchange, if recent foreign currency exchange rates hold, FY25 revenue growth would be in the range of 3.4% to 3.8%.
The company continues to expect FY25 diluted non-GAAP EPS in the range of $5.44 to $5.50 . This includes an estimated -5% impact from foreign currency exchange based on recent rates. The company's guidance represents FY25 diluted non-GAAP EPS growth in the range of 4.6% to 5.8%.
"EPS came in above the high end of our guidance range. We were pleased with the operational performance of the business this quarter, turning mid-single digit organic growth into leveraged earnings, highlighted by healthy gross margin improvement," said Gary Corona , Medtronic interim chief financial officer. "Looking ahead, our restored earnings power continues. We will accelerate both top and bottom line growth in Q4, resulting in high-single digit adjusted EPS growth in the back half of our fiscal year."
Video Webcast Information
Medtronic will host a video webcast today, February 18 , at 8:00 a.m. EST ( 7:00 a.m. CST ) to provide information about its businesses for the public, investors, analysts, and news media. This webcast can be accessed by clicking on the Events icon at investorrelations.medtronic.com , and this earnings release will be archived at news.medtronic.com . Within 24 hours of the webcast, a replay of the webcast and transcript of the company's prepared remarks will be available by clicking on the Events icon at investorrelations.medtronic.com .
Medtronic plans to report its FY25 fourth quarter results on Wednesday, May 21, 2025 . For fiscal year 2026, Medtronic plans to report its first, second, third, and fourth quarter results on Tuesday, August 19, 2025 , November 18, 2025 , February 17, 2026 , and Wednesday, May 20, 2026 , respectively. Confirmation and additional details will be provided closer to the specific event.
Financial Schedules and Earnings Presentation
The third quarter financial schedules and non-GAAP reconciliations can be viewed by clicking on the Investor Events link at investorrelations.medtronic.com . To view a printable PDF of the financial schedules and non-GAAP reconciliations, click here . To view the third quarter earnings presentation, click here .
MEDTRONIC PLC WORLD WIDE REVENUE (1) (Unaudited) | ||||||||||||||||||||||||||||
THIRD QUARTER | YEAR-TO-DATE | |||||||||||||||||||||||||||
REPORTED | ORGANIC | REPORTED | ORGANIC | |||||||||||||||||||||||||
(in millions) | FY25 | FY24 | Growth | Currency | Adjusted | Adjusted | Growth | FY25 | FY24 | Growth | Currency | Adjusted | Adjusted | Growth | ||||||||||||||
Cardiovascular | $Â Â Â Â 3,037 | $Â Â Â Â 2,929 | 3.7Â % | $Â Â Â Â Â Â Â (38) | $Â Â Â Â 3,075 | $Â Â Â Â 2,929 | 5.0Â % | $Â Â Â Â 9,145 | $Â Â Â Â 8,702 | 5.1Â % | $Â Â Â Â Â Â Â (62) | $Â Â Â Â 9,207 | $Â Â Â Â 8,702 | 5.8Â % | ||||||||||||||
Cardiac Rhythm & Heart Failure | 1,545 | 1,470 | 5.1 | (18) | 1,563 | 1,470 | 6.3 | 4,659 | 4,408 | 5.7 | (26) | 4,684 | 4,408 | 6.3 | ||||||||||||||
Structural Heart & Aortic | 874 | 843 | 3.7 | (13) | 887 | 843 | 5.2 | 2,610 | 2,475 | 5.4 | (21) | 2,631 | 2,475 | 6.3 | ||||||||||||||
Coronary & Peripheral Vascular | 618 | 616 | 0.3 | (8) | 626 | 616 | 1.6 | 1,876 | 1,818 | 3.2 | (15) | 1,891 | 1,818 | 4.0 | ||||||||||||||
Neuroscience | 2,458 | 2,355 | 4.4 | (21) | 2,478 | 2,355 | 5.2 | 7,226 | 6,861 | 5.3 | (29) | 7,255 | 6,861 | 5.7 | ||||||||||||||
Cranial & Spinal Technologies | 1,250 | 1,204 | 3.8 | (9) | 1,259 | 1,204 | 4.6 | 3,632 | 3,465 | 4.8 | (15) | 3,646 | 3,465 | 5.2 | ||||||||||||||
Specialty Therapies | 732 | 726 | 0.8 | (8) | 740 | 726 | 1.9 | 2,181 | 2,126 | 2.6 | (10) | 2,191 | 2,126 | 3.1 | ||||||||||||||
Neuromodulation | 476 | 425 | 12.0 | (4) | 480 | 425 | 12.9 | 1,413 | 1,270 | 11.2 | (5) | 1,417 | 1,270 | 11.6 | ||||||||||||||
Medical Surgical | 2,072 | 2,112 | (1.9) | (32) | 2,104 | 2,112 | (0.4) | 6,196 | 6,219 | (0.4) | (50) | 6,246 | 6,219 | 0.4 | ||||||||||||||
Surgical & Endoscopy | 1,596 | 1,616 | (1.2) | (26) | 1,622 | 1,616 | 0.4 | 4,790 | 4,803 | (0.3) | (40) | 4,829 | 4,803 | 0.5 | ||||||||||||||
Acute Care & Monitoring | 476 | 495 | (3.9) | (5) | 481 | 495 | (2.8) | 1,406 | 1,416 | (0.7) | (10) | 1,417 | 1,416 | — | ||||||||||||||
Diabetes | 694 | 640 | 8.4 | (12) | 706 | 640 | 10.4 | 2,027 | 1,829 | 10.8 | (8) | 2,035 | 1,829 | 11.3 | ||||||||||||||
Total Reportable Segments | 8,260 | 8,035 | 2.8 | (103) | 8,363 | 8,035 | 4.1 | 24,593 | 23,610 | 4.2 | (149) | 24,742 | 23,610 | 4.8 | ||||||||||||||
Other (2) | 32 | 53 | (41.1) | (1) | — | — | — | 17 | 164 | (89.9) | (3) | — | — | — | ||||||||||||||
TOTAL | $Â Â Â Â 8,292 | $Â Â Â Â 8,089 | 2.5Â % | $Â Â Â Â Â (104) | $Â Â Â Â 8,363 | $Â Â Â Â 8,035 | 4.1Â % | $Â Â Â 24,610 | $Â Â Â 23,775 | 3.5Â % | $Â Â Â Â Â (152) | $Â Â Â 24,742 | $Â Â Â 23,610 | 4.8Â % | ||||||||||||||
(1) | The data in this schedule has been intentionally rounded to the nearest million and, therefore, may not sum. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. |
(2) | Includes historical operations and ongoing transition agreements from businesses the Company has exited or divested, and specifically for the three months ended July 26, 2024, impacting year-to-date figures, $90 million of incremental Italian payback accruals resulting from the two July 22, 2024 rulings by the Constitutional Court of Italy relating to certain prior years since 2015. |
(3) | The currency impact to revenue measures the change in revenue between current and prior year periods using constant exchange rates. |
(4) | The three months ended January 24, 2025 excludes $71 million of revenue adjustments related to $32 million of inorganic revenue for the transition activity noted in (2) and $103 million of unfavorable currency impact on the remaining segments. The three months ended January 26, 2024 excludes $53 million of inorganic revenue related to the transition activity noted in (2). |
(5) | The nine months ended January 24, 2025 excludes $132 million of revenue adjustments related to $90 million of incremental Italian payback accruals further described in note (2), $106 million of inorganic revenue related to the transition activity noted in (2), and $149 million of unfavorable currency impact on the remaining segments. The nine months ended January 26, 2024 excludes $164 million of inorganic revenue related to the transition activity noted in (2). |
MEDTRONIC PLC U.S. REVENUE (1)(2) (Unaudited) | ||||||||||||||||||||||||
THIRD QUARTER | YEAR-TO-DATE | |||||||||||||||||||||||
REPORTED | ORGANIC | REPORTED | ORGANIC | |||||||||||||||||||||
(in millions) | FY25 | FY24 | Growth | Adjusted | Adjusted | Growth | FY25 | FY24 | Growth | Adjusted | Adjusted | Growth | ||||||||||||
Cardiovascular | $Â Â Â Â 1,405 | $Â Â Â Â 1,373 | 2.4Â % | $Â Â Â Â 1,405 | $Â Â Â Â 1,373 | 2.4Â % | $Â Â Â Â 4,242 | $Â Â Â Â 4,149 | 2.2Â % | $Â Â Â Â 4,242 | $Â Â Â Â 4,149 | 2.2Â % | ||||||||||||
Cardiac Rhythm & Heart Failure | 775 | 745 | 4.1 | 775 | 745 | 4.1 | 2,309 | 2,247 | 2.8 | 2,309 | 2,247 | 2.8 | ||||||||||||
Structural Heart & Aortic | 372 | 363 | 2.6 | 372 | 363 | 2.6 | 1,129 | 1,087 | 3.9 | 1,129 | 1,087 | 3.9 | ||||||||||||
Coronary & Peripheral Vascular | 258 | 265 | (2.8) | 258 | 265 | (2.8) | 804 | 816 | (1.4) | 804 | 816 | (1.4) | ||||||||||||
Neuroscience | 1,689 | 1,556 | 8.5 | 1,689 | 1,556 | 8.5 | 4,931 | 4,614 | 6.9 | 4,931 | 4,614 | 6.9 | ||||||||||||
Cranial & Spinal Technologies | 943 | 875 | 7.8 | 943 | 875 | 7.8 | 2,724 | 2,560 | 6.4 | 2,724 | 2,560 | 6.4 | ||||||||||||
Specialty Therapies | 419 | 407 | 3.0 | 419 | 407 | 3.0 | 1,235 | 1,202 | 2.7 | 1,235 | 1,202 | 2.7 | ||||||||||||
Neuromodulation | 327 | 275 | 19.0 | 327 | 275 | 19.0 | 972 | 852 | 14.1 | 972 | 852 | 14.1 | ||||||||||||
Medical Surgical | 893 | 947 | (5.8) | 893 | 947 | (5.8) | 2,718 | 2,763 | (1.6) | 2,718 | 2,763 | (1.6) | ||||||||||||
Surgical & Endoscopy | 623 | 663 | (6.1) | 623 | 663 | (6.1) | 1,928 | 1,971 | (2.2) | 1,928 | 1,971 | (2.2) | ||||||||||||
Acute Care & Monitoring | 269 | 284 | (5.1) | 269 | 284 | (5.1) | 790 | 792 | (0.2) | 790 | 792 | (0.2) | ||||||||||||
Diabetes | 236 | 224 | 5.6 | 236 | 224 | 5.6 | 683 | 629 | 8.7 | 683 | 629 | 8.7 | ||||||||||||
Total Reportable Segments | 4,223 | 4,100 | 3.0 | 4,223 | 4,100 | 3.0 | 12,573 | 12,154 | 3.4 | 12,573 | 12,154 | 3.4 | ||||||||||||
Other (3) | 15 | 20 | (26.4) | — | — | — | 51 | 65 | (21.3) | — | — | — | ||||||||||||
TOTAL | $Â Â Â Â 4,237 | $Â Â Â Â 4,120 | 2.8Â % | $Â Â Â Â 4,223 | $Â Â Â Â 4,100 | 3.0Â % | $Â Â 12,624 | $Â Â 12,219 | 3.3Â % | $Â Â 12,573 | $Â Â 12,154 | 3.4Â % | ||||||||||||
(1) | U.S. includes the United States and U.S. territories. |
(2) | The data in this schedule has been intentionally rounded to the nearest million and, therefore, may not sum. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. |
(3) | Includes historical operations and ongoing transition agreements from businesses the Company has exited or divested. |
MEDTRONIC PLC INTERNATIONAL REVENUE (1) (Unaudited) | ||||||||||||||||||||||||||||
THIRD QUARTER | YEAR-TO-DATE | |||||||||||||||||||||||||||
REPORTED | ORGANIC | REPORTED | ORGANIC | |||||||||||||||||||||||||
(in millions) | FY25 | FY24 | Growth | Currency | Adjusted | Adjusted | Growth | FY25 | FY24 | Growth | Currency | Adjusted | Adjusted | Growth | ||||||||||||||
Cardiovascular | $Â Â Â Â 1,632 | $Â Â Â Â 1,556 | 4.9Â % | $Â Â Â Â Â Â Â (38) | $Â Â Â Â 1,670 | $Â Â Â Â 1,556 | 7.3Â % | $Â Â Â Â 4,904 | $Â Â Â Â 4,552 | 7.7Â % | $Â Â Â Â Â Â Â (62) | $Â Â Â Â 4,966 | $Â Â Â Â 4,552 | 9.1Â % | ||||||||||||||
Cardiac Rhythm & Heart Failure | 770 | 726 | 6.1 | (18) | 788 | 726 | 8.6 | 2,350 | 2,161 | 8.7 | (26) | 2,376 | 2,161 | 9.9 | ||||||||||||||
Structural Heart & Aortic | 502 | 480 | 4.6 | (13) | 515 | 480 | 7.2 | 1,482 | 1,389 | 6.7 | (21) | 1,503 | 1,389 | 8.2 | ||||||||||||||
Coronary & Peripheral Vascular | 360 | 350 | 2.6 | (8) | 368 | 350 | 4.9 | 1,072 | 1,002 | 7.0 | (15) | 1,087 | 1,002 | 8.5 | ||||||||||||||
Neuroscience | 769 | 799 | (3.7) | (21) | 790 | 799 | (1.1) | 2,295 | 2,248 | 2.1 | (29) | 2,324 | 2,248 | 3.4 | ||||||||||||||
Cranial & Spinal Technologies | 307 | 329 | (6.7) | (9) | 316 | 329 | (3.9) | 907 | 905 | 0.3 | (15) | 922 | 905 | 1.9 | ||||||||||||||
Specialty Therapies | 313 | 319 | (2.0) | (8) | 321 | 319 | 0.4 | 947 | 924 | 2.4 | (10) | 957 | 924 | 3.5 | ||||||||||||||
Neuromodulation | 149 | 150 | (0.7) | (4) | 153 | 150 | 1.8 | 441 | 419 | 5.4 | (5) | 446 | 419 | 6.5 | ||||||||||||||
Medical Surgical | 1,180 | 1,164 | 1.3 | (32) | 1,211 | 1,164 | 4.0 | 3,478 | 3,456 | 0.6 | (50) | 3,528 | 3,456 | 2.1 | ||||||||||||||
Surgical & Endoscopy | 973 | 953 | 2.1 | (26) | 999 | 953 | 4.9 | 2,862 | 2,832 | 1.1 | (40) | 2,902 | 2,832 | 2.5 | ||||||||||||||
Acute Care & Monitoring | 206 | 211 | (2.3) | (5) | 212 | 211 | 0.2 | 616 | 624 | (1.4) | (10) | 626 | 624 | 0.3 | ||||||||||||||
Diabetes | 457 | 416 | 9.9 | (12) | 470 | 416 | 12.9 | 1,344 | 1,200 | 12.0 | (8) | 1,351 | 1,200 | 12.6 | ||||||||||||||
Total Reportable Segments | 4,038 | 3,935 | 2.6 | (103) | 4,141 | 3,935 | 5.2 | 12,020 | 11,456 | 4.9 | (149) | 12,169 | 11,456 | 6.2 | ||||||||||||||
Other (2) | 17 | 34 | (49.8) | (1) | — | — | — | (35) | 99 | (134.8) | (3) | — | — | — | ||||||||||||||
TOTAL | $Â Â Â Â 4,055 | $Â Â Â Â 3,968 | 2.2Â % | $Â Â Â Â Â (104) | $Â Â Â Â 4,141 | $Â Â Â Â 3,935 | 5.2Â % | $Â Â 11,986 | $Â Â 11,555 | 3.7Â % | $Â Â Â Â Â (152) | $Â Â 12,169 | $Â Â 11,456 | 6.2Â % | ||||||||||||||
(1) | The data in this schedule has been intentionally rounded to the nearest million and, therefore, may not sum. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. |
(2) | Includes historical operations and ongoing transition agreements from businesses the Company has exited or divested, and specifically for the three months ended July 26, 2024, impacting year-to-date figures, $90 million of incremental Italian payback accruals resulting from the two July 22, 2024 rulings by the Constitutional Court of Italy relating to certain prior years since 2015. |
(3) | The currency impact to revenue measures the change in revenue between current and prior year periods using constant exchange rates. |
(4) | The three months ended January 24, 2025 excludes $86 million of revenue adjustments related to $17 million of inorganic revenue for the transition activity noted in (2), and $103 million of unfavorable currency impact on the remaining segments. The three months ended January 26, 2024 excludes $34 million of inorganic revenue related to the transition activity noted in (2). |
(5) | The nine months ended January 24, 2025 excludes $183 million of revenue adjustments related to $90 million of incremental Italian payback accruals further described in note (2), $55 million of inorganic revenue related to the transition activity noted in (2), and $149 million of unfavorable currency impact on the remaining segments. The nine months ended January 26, 2024 excludes $99 million of inorganic revenue related to the transition activity noted in (2). |
MEDTRONIC PLC CONSOLIDATED STATEMENTS OF INCOME (Unaudited) | |||||||
Three months ended | Nine months ended | ||||||
(in millions, except per share data) | January 24, | January 26, | January 24, | January 26, | |||
Net sales | $Â Â Â Â Â Â Â Â Â Â Â 8,292 | $Â Â Â Â Â Â Â Â Â Â Â 8,089 | $Â Â Â Â Â Â Â Â Â 24,610 | $Â Â Â Â Â Â Â Â Â 23,775 | |||
Costs and expenses: | |||||||
Cost of products sold, excluding amortization of intangible assets | 2,779 | 2,782 | 8,485 | 8,172 | |||
Research and development expense | 675 | 695 | 2,048 | 2,060 | |||
Selling, general, and administrative expense | 2,717 | 2,673 | 8,129 | 7,971 | |||
Amortization of intangible assets | 416 | 419 | 1,243 | 1,274 | |||
Restructuring charges, net | 43 | 20 | 120 | 114 | |||
Certain litigation charges, net | 22 | — | 104 | 105 | |||
Other operating (income) expense, net | (5) | 17 | (38) | (13) | |||
Operating profit | 1,646 | 1,483 | 4,519 | 4,091 | |||
Other non-operating income, net | (72) | (177) | (403) | (407) | |||
Interest expense, net | 179 | 188 | 555 | 517 | |||
Income before income taxes | 1,540 | 1,472 | 4,367 | 3,982 | |||
Income tax provision | 237 | 135 | 737 | 936 | |||
Net income | 1,303 | 1,337 | 3,630 | 3,045 | |||
Net income attributable to noncontrolling interests | (9) | (15) | (24) | (23) | |||
Net income attributable to Medtronic | $Â Â Â Â Â Â Â Â Â Â Â 1,294 | $Â Â Â Â Â Â Â Â Â Â Â 1,322 | $Â Â Â Â Â Â Â Â Â Â Â 3,606 | $Â Â Â Â Â Â Â Â Â Â Â 3,022 | |||
Basic earnings per share | $Â Â Â Â Â Â Â 1.01 | $Â Â Â Â Â Â Â 0.99 | $Â Â Â Â Â Â Â 2.80 | $Â Â Â Â Â Â Â 2.27 | |||
Diluted earnings per share | $Â Â Â Â Â Â Â 1.01 | $Â Â Â Â Â Â Â 0.99 | $Â Â Â Â Â Â Â 2.79 | $Â Â Â Â Â Â Â 2.27 | |||
Basic weighted average shares outstanding | 1,282.4 | 1,329.7 | 1,286.7 | 1,330.1 | |||
Diluted weighted average shares outstanding | 1,286.2 | 1,331.7 | 1,290.6 | 1,332.4 | |||
The data in the schedule above has been intentionally rounded to the nearest million. |
MEDTRONIC PLC GAAP TO NON-GAAP RECONCILIATIONS (1) (Unaudited) | |||||||||||||||||
Three months ended January 24, 2025 | |||||||||||||||||
(in millions, except per share data) | Net | Cost of | Gross | Operating | Operating | Income | Net Income | Diluted | Effective | ||||||||
GAAP | $Â 8,292 | $Â Â 2,779 | 66.5Â % | $Â Â Â Â 1,646 | 19.9Â % | $Â Â Â 1,540 | $Â Â Â Â Â Â 1,294 | $Â Â Â Â 1.01 | 15.4Â % | ||||||||
Non-GAAP Adjustments: | |||||||||||||||||
Amortization of intangible assets | — | — | — | 416 | 5.0 | 416 | 339 | 0.26 | 18.5 | ||||||||
Restructuring and associated costs (2) | — | (4) | — | 46 | 0.6 | 46 | 37 | 0.03 | 19.6 | ||||||||
Acquisition and divestiture-related items (3) | — | (1) | — | 28 | 0.3 | 28 | 23 | 0.02 | 17.9 | ||||||||
Certain litigation charges, net | — | — | — | 22 | 0.3 | 22 | 18 | 0.01 | 22.7 | ||||||||
(Gain)/loss on minority investments (4) | — | — | — | — | — | 68 | 52 | 0.04 | 22.1 | ||||||||
Medical device regulations (5) | — | (8) | 0.1 | 11 | 0.1 | 11 | 9 | 0.01 | 18.2 | ||||||||
Certain tax adjustments, net | — | — | — | — | — | — | 15 | 0.01 | — | ||||||||
Non-GAAP | $Â 8,292 | $Â Â 2,766 | 66.6Â % | $Â Â Â Â 2,169 | 26.2Â % | $Â Â Â 2,130 | $Â Â Â Â Â Â 1,787 | $Â Â Â Â 1.39 | 15.7Â % | ||||||||
Currency impact | 104 | 61 | (0.3) | (4) | (0.4) | (0.01) | |||||||||||
Currency Adjusted | $Â 8,396 | $Â Â 2,827 | 66.3Â % | $Â Â Â Â 2,165 | 25.8Â % | $Â Â Â Â 1.38 | |||||||||||
Three months ended January 26, 2024 | |||||||||||||||||
(in millions, except per share data) | Net | Cost of | Gross | Operating | Operating | Income | Net Income | Diluted | Effective | ||||||||
GAAP | $Â 8,089 | $Â Â 2,782 | 65.6Â % | $Â Â Â Â 1,483 | 18.3Â % | $Â Â Â 1,472 | $Â Â Â Â Â Â 1,322 | $Â Â Â Â 0.99 | 9.2Â % | ||||||||
Non-GAAP Adjustments: | |||||||||||||||||
Amortization of intangible assets | — | — | — | 419 | 5.2 | 419 | 354 | 0.27 | 15.5 | ||||||||
Restructuring and associated costs (2) | — | (12) | 0.1 | 55 | 0.7 | 55 | 46 | 0.03 | 16.4 | ||||||||
Acquisition and divestiture-related items (3) | — | (12) | 0.1 | 58 | 0.7 | 58 | 52 | 0.04 | 10.3 | ||||||||
(Gain)/loss on minority investments (4) | — | — | — | — | — | 24 | 24 | 0.02 | — | ||||||||
Medical device regulations (5) | — | (18) | 0.2 | 26 | 0.3 | 26 | 21 | 0.02 | 19.2 | ||||||||
Certain tax adjustments, net (6) | — | — | — | — | — | — | (92) | (0.07) | — | ||||||||
Non-GAAP | $Â 8,089 | $Â Â 2,740 | 66.1Â % | $Â Â Â Â 2,042 | 25.2Â % | $Â Â Â 2,055 | $Â Â Â Â Â Â 1,728 | $Â Â Â Â 1.30 | 15.2Â % | ||||||||
See description of non-GAAP financial measures contained in the press release dated February 18, 2025. | |
(1) | The data in this schedule has been intentionally rounded to the nearest million or $0.01 for EPS figures, and, therefore, may not sum. |
(2) | Associated costs primarily include salaries and wages for employees supporting the restructuring activities, consulting expenses, and asset write-offs. |
(3) | The charges primarily include business combination costs, changes in fair value of contingent consideration, and exit of business-related charges. |
(4) | We exclude unrealized and realized gains and losses on our minority investments as we do not believe that these components of income or expense have a direct correlation to our ongoing or future business operations. |
(5) | The charges represent incremental costs of complying with the new European Union (E.U.) medical device regulations for previously registered products and primarily include charges for contractors supporting the project and other direct third-party expenses. We consider these costs to be duplicative of previously incurred costs and/or one-time costs, which are limited to a specific time period. |
(6) | The net tax benefit primarily relates to a change in a Swiss Cantonal tax rate associated with previously established deferred tax assets from intercompany intellectual property transactions and the step up in tax basis for Swiss Cantonal purposes. |
MEDTRONIC PLC GAAP TO NON-GAAP RECONCILIATIONS (1) (Unaudited) | |||||||||||||||||
Nine months ended January 24, 2025 | |||||||||||||||||
(in millions, except per share data) | Net | Cost of | Gross | Operating | Operating | Income | Net Income | Diluted | Effective | ||||||||
GAAP | $ 24,610 | $Â Â 8,485 | 65.5Â % | $Â Â Â Â 4,519 | 18.4Â % | $Â Â Â 4,367 | $Â Â Â Â Â Â Â Â 3,606 | $Â Â Â Â 2.79 | 16.9Â % | ||||||||
Non-GAAP Adjustments: | |||||||||||||||||
Amortization of intangible assets | — | — | — | 1,243 | 4.9 | 1,243 | 1,017 | 0.79 | 18.3 | ||||||||
Restructuring and associated costs (2) | — | (24) | 0.1 | 154 | 0.6 | 154 | 124 | 0.10 | 19.5 | ||||||||
Acquisition and divestiture-related items (3) | — | (17) | — | 15 | 0.1 | 15 | 3 | — | 73.3 | ||||||||
Certain litigation charges, net | — | — | — | 104 | 0.4 | 104 | 86 | 0.07 | 17.3 | ||||||||
(Gain)/loss on minority investments (4) | — | — | — | — | — | 41 | 14 | 0.01 | 61.0 | ||||||||
Medical device regulations (5) | — | (27) | 0.1 | 38 | 0.2 | 38 | 30 | 0.02 | 21.1 | ||||||||
Other (6) | 90 | — | 0.2 | 90 | 0.4 | 90 | 70 | 0.05 | 22.2 | ||||||||
Certain tax adjustments, net (7) | — | — | — | — | — | — | 49 | 0.04 | — | ||||||||
Non-GAAP | $ 24,700 | $Â Â 8,417 | 65.9Â % | $Â Â Â Â 6,162 | 24.9Â % | $Â Â Â 6,051 | $Â Â Â Â Â Â Â Â 4,999 | $Â Â Â Â 3.87 | 17.0Â % | ||||||||
Currency impact | 150 | (72) | 0.5 | 241 | 0.9 | 0.15 | |||||||||||
Currency Adjusted | $ 24,850 | $Â Â 8,345 | 66.4Â % | $Â Â Â Â 6,403 | 25.8Â % | $Â Â Â Â 4.02 | |||||||||||
Nine months ended January 26, 2024 | |||||||||||||||||
(in millions, except per share data) | Net | Cost of | Gross | Operating | Operating | Income | Net Income | Diluted | Effective | ||||||||
GAAP | $ 23,775 | $Â Â 8,172 | 65.6Â % | $Â Â Â Â 4,091 | 17.2Â % | $Â Â Â 3,982 | $Â Â Â Â Â Â Â Â 3,022 | $Â Â Â Â 2.27 | 23.5Â % | ||||||||
Non-GAAP Adjustments: | |||||||||||||||||
Amortization of intangible assets | — | — | — | 1,274 | 5.4 | 1,274 | 1,078 | 0.81 | 15.4 | ||||||||
Restructuring and associated costs (2) | — | (43) | 0.2 | 237 | 1.0 | 237 | 198 | 0.15 | 16.5 | ||||||||
Acquisition and divestiture-related items (3) | — | (24) | 0.1 | 165 | 0.7 | 165 | 149 | 0.11 | 9.7 | ||||||||
Certain litigation charges, net | — | — | — | 105 | 0.4 | 105 | 81 | 0.06 | 22.9 | ||||||||
(Gain)/loss on minority investments (4) | — | — | — | — | — | 113 | 109 | 0.08 | 4.4 | ||||||||
Medical device regulations (5) | — | (60) | 0.3 | 88 | 0.4 | 88 | 70 | 0.05 | 20.5 | ||||||||
Certain tax adjustments, net (8) | — | — | — | — | — | — | 282 | 0.21 | — | ||||||||
Non-GAAP | $ 23,775 | $Â Â 8,046 | 66.2Â % | $Â Â Â Â 5,961 | 25.1Â % | $Â Â Â 5,965 | $Â Â Â Â Â Â Â Â 4,988 | $Â Â Â Â 3.74 | 16.0Â % | ||||||||
See description of non-GAAP financial measures contained in the press release dated February 18, 2025. | |
(1) | The data in this schedule has been intentionally rounded to the nearest million or $0.01 for EPS figures, and, therefore, may not sum. |
(2) | Associated costs primarily include salaries and wages for employees supporting the restructuring activities, consulting expenses, and asset write-offs. |
(3) | The charges primarily include business combination costs, changes in fair value of contingent consideration, and exit of business-related charges. The nine months ended January 24, 2025, also include gains related to certain business or asset sales. |
(4) | We exclude unrealized and realized gains and losses on our minority investments as we do not believe that these components of income or expense have a direct correlation to our ongoing or future business operations. |
(5) | The charges represent incremental costs of complying with the new European Union (E.U.) medical device regulations for previously registered products and primarily include charges for contractors supporting the project and other direct third-party expenses. We consider these costs to be duplicative of previously incurred costs and/or one-time costs, which are limited to a specific time period. |
(6) | Reflects the recognition of incremental Italian payback accruals resulting from the two July 22, 2024 rulings by the Constitutional Court of Italy relating to certain prior years since 2015. |
(7) | Primarily relates to amortization of previously established deferred tax assets from intercompany intellectual property transactions. |
(8) | The net charge primarily relates to an income tax reserve adjustment associated with the June 2023, Israeli Central-Lod District Court decision and the establishment of a valuation allowance against certain net operating losses which were partially offset by a benefit from the change in a Swiss Cantonal tax rate associated with previously established deferred tax assets from intercompany intellectual property transactions and the step up in tax basis for Swiss Cantonal purposes. |
MEDTRONIC PLC GAAP TO NON-GAAP RECONCILIATIONS (1) (Unaudited) | |||||||||||||||
Three months ended January 24, 2025 | |||||||||||||||
(in millions) | Net Sales | SG&A | SG&A | R&D | R&D | Other | Other | Other Non- | |||||||
GAAP | $Â Â Â Â Â 8,292 | $Â Â Â Â 2,717 | 32.8Â % | $Â Â Â Â Â Â 675 | 8.1Â % | $Â Â Â Â Â Â Â Â Â Â (5) | (0.1)Â % | $Â Â Â Â Â Â Â Â Â Â (72) | |||||||
Non-GAAP Adjustments: | |||||||||||||||
Acquisition and divestiture-related items (2) | — | (13) | (0.2) | — | — | (13) | (0.2) | — | |||||||
Medical device regulations (3) | — | — | — | (3) | — | — | — | — | |||||||
(Gain)/loss on minority investments (4) | — | — | — | — | — | — | — | (68) | |||||||
Non-GAAP | $Â Â Â Â Â 8,292 | $Â Â Â Â 2,704 | 32.6Â % | $Â Â Â Â Â Â 672 | 8.1Â % | $Â Â Â Â Â Â Â Â (18) | (0.2)Â % | $Â Â Â Â Â Â Â Â Â (140) | |||||||
Nine months ended January 24, 2025 | |||||||||||||||
(in millions) | Net Sales | SG&A | SG&A | R&D | R&D | Other | Other | Other Non- | |||||||
GAAP | $Â Â Â 24,610 | $Â Â Â Â 8,129 | 33.0Â % | $Â Â Â 2,048 | 8.3Â % | $Â Â Â Â Â Â Â Â (38) | (0.2)Â % | $Â Â Â Â Â Â Â Â Â (403) | |||||||
Non-GAAP Adjustments: | |||||||||||||||
Restructuring and associated costs (5) | — | (10) | (0.1) | — | — | — | — | — | |||||||
Acquisition and divestiture-related items (2) | — | (40) | (0.3) | — | — | 42 | 0.2 | — | |||||||
Medical device regulations (3) | — | — | — | (10) | — | — | — | — | |||||||
Other (6) | 90 | — | — | — | — | — | — | — | |||||||
(Gain)/loss on minority investments (4) | — | — | — | — | — | — | — | (41) | |||||||
Non-GAAP | $   24,700 | $    8,078 | 32.7 % | $   2,038 | 8.3 % | $            4 | — % | $         (443) | |||||||
See description of non-GAAP financial measures contained in the press release dated February 18, 2025. | |
(1) | The data in this schedule has been intentionally rounded to the nearest million, and, therefore, may not sum. |
(2) | The charges primarily include business combination costs, changes in fair value of contingent consideration, exit of business-related charges, and gains related to certain business or asset sales. The nine months ended January 24, 2025, also include gains related to certain business or asset sales. |
(3) | The charges represent incremental costs of complying with the new European Union medical device regulations for previously registered products and primarily include charges for contractors supporting the project and other direct third-party expenses. We consider these costs to be duplicative of previously incurred costs and/or one-time costs, which are limited to a specific time period. |
(4) | We exclude unrealized and realized gains and losses on our minority investments as we do not believe that these components of income or expense have a direct correlation to our ongoing or future business operations. |
(5) | Associated costs primarily include salaries and wages for employees supporting the restructuring activities, consulting expenses, and asset write-offs. |
(6) | Reflects the recognition of incremental Italian payback accruals resulting from the two July 22, 2024 rulings by the Constitutional Court of Italy relating to certain prior years since 2015. |
MEDTRONIC PLC GAAP TO NON-GAAP RECONCILIATIONS (1) (Unaudited) | |||
Nine months ended | |||
(in millions) | January 24, 2025 | January 26, 2024 | |
Net cash provided by operating activities | $Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 4,516 | $Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 4,010 | |
Additions to property, plant, and equipment | (1,400) | (1,161) | |
Free Cash Flow (2) | $Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 3,116 | $Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 2,849 | |
See description of non-GAAP financial measures contained in the press release dated February 18, 2025. | |
(1) | The data in this schedule has been intentionally rounded to the nearest million, and, therefore, may not sum. |
(2) | Free cash flow represents operating cash flows less property, plant, and equipment additions. |
MEDTRONIC PLC CONSOLIDATED BALANCE SHEETS (Unaudited) | ||||
(in millions) | January 24, 2025 | April 26, 2024 | ||
ASSETS | ||||
Current assets: | ||||
Cash and cash equivalents | $Â Â Â Â Â Â Â Â Â Â Â Â Â Â 1,240 | $Â Â Â Â Â Â Â Â Â Â Â Â Â Â 1,284 | ||
Investments | 6,682 | 6,721 | ||
Accounts receivable, less allowances and credit losses of $204 and $173, respectively | 6,115 | 6,128 | ||
Inventories | 5,610 | 5,217 | ||
Other current assets | 2,865 | 2,584 | ||
Total current assets | 22,513 | 21,935 | ||
Property, plant, and equipment, net | 6,593 | 6,131 | ||
Goodwill | 40,819 | 40,986 | ||
Other intangible assets, net | 12,184 | 13,225 | ||
Tax assets | 3,614 | 3,657 | ||
Other assets | 4,250 | 4,047 | ||
Total assets | $Â Â Â Â Â Â Â Â Â Â Â Â 89,973 | $Â Â Â Â Â Â Â Â Â Â Â Â 89,981 | ||
LIABILITIES AND EQUITY | ||||
Current liabilities: | ||||
Current debt obligations | $Â Â Â Â Â Â Â Â Â Â Â Â Â Â 2,622 | $Â Â Â Â Â Â Â Â Â Â Â Â Â Â 1,092 | ||
Accounts payable | 2,286 | 2,410 | ||
Accrued compensation | 2,281 | 2,375 | ||
Accrued income taxes | 1,125 | 1,330 | ||
Other accrued expenses | 3,526 | 3,582 | ||
Total current liabilities | 11,840 | 10,789 | ||
Long-term debt | 23,985 | 23,932 | ||
Accrued compensation and retirement benefits | 1,063 | 1,101 | ||
Accrued income taxes | 1,485 | 1,859 | ||
Deferred tax liabilities | 452 | 515 | ||
Other liabilities | 1,533 | 1,365 | ||
Total liabilities | 40,358 | 39,561 | ||
Commitments and contingencies | ||||
Shareholders' equity: | ||||
Ordinary shares— par value $0.0001, 2.6 billion shares authorized, 1,283,266,154 and 1,311,337,531 shares issued and outstanding, respectively | — | — | ||
Additional paid-in capital | 20,910 | 23,129 | ||
Retained earnings | 31,317 | 30,403 | ||
Accumulated other comprehensive loss | (2,839) | (3,318) | ||
Total shareholders' equity | 49,387 | 50,214 | ||
Noncontrolling interests | 228 | 206 | ||
Total equity | 49,615 | 50,420 | ||
Total liabilities and equity | $Â Â Â Â Â Â Â Â Â Â Â Â 89,973 | $Â Â Â Â Â Â Â Â Â Â Â Â 89,981 | ||
The data in this schedule has been intentionally rounded to the nearest million, and, therefore, may not sum. |
MEDTRONIC PLC CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) | |||
Nine months ended | |||
(in millions) | January 24, 2025 | January 26, 2024 | |
Operating Activities: | |||
Net income | $Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 3,630 | $Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 3,045 | |
Adjustments to reconcile net income to net cash provided by operating activities: | |||
Depreciation and amortization | 2,021 | 1,993 | |
Provision for credit losses | 96 | 62 | |
Deferred income taxes | (81) | (250) | |
Stock-based compensation | 340 | 303 | |
Other, net | 14 | 265 | |
Change in operating assets and liabilities, net of acquisitions and divestitures: | |||
Accounts receivable, net | (184) | (140) | |
Inventories | (478) | (530) | |
Accounts payable and accrued liabilities | (157) | (253) | |
Other operating assets and liabilities | (685) | (485) | |
Net cash provided by operating activities | 4,516 | 4,010 | |
Investing Activities: | |||
Acquisitions, net of cash acquired | (98) | (74) | |
Additions to property, plant, and equipment | (1,400) | (1,161) | |
Purchases of investments | (6,093) | (5,422) | |
Sales and maturities of investments | 6,255 | 5,142 | |
Other investing activities, net | (111) | (155) | |
Net cash used in investing activities | (1,447) | (1,670) | |
Financing Activities: | |||
Change in current debt obligations, net | (1,070) | 1,010 | |
Issuance of long-term debt | 3,209 | — | |
Dividends to shareholders | (2,692) | (2,753) | |
Issuance of ordinary shares | 400 | 206 | |
Repurchase of ordinary shares | (2,961) | (510) | |
Other financing activities, net | 96 | (44) | |
Net cash used in financing activities | (3,018) | (2,091) | |
Effect of exchange rate changes on cash and cash equivalents | (95) | (170) | |
Net change in cash and cash equivalents | (44) | 80 | |
Cash and cash equivalents at beginning of period | 1,284 | 1,543 | |
Cash and cash equivalents at end of period | $Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 1,240 | $Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 1,623 | |
Supplemental Cash Flow Information | |||
Cash paid for: | |||
Income taxes | $Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 1,515 | $Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 1,403 | |
Interest | 567 | 568 | |
The data in this schedule has been intentionally rounded to the nearest million, and, therefore, may not sum. |
About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland , is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE: MDT), visit www.Medtronic.com and follow on LinkedIn .
FORWARD LOOKING STATEMENTS
 This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties, including risks related to competitive factors, difficulties and delays inherent in the development, manufacturing, marketing and sale of medical products, government regulation, geopolitical conflicts, changing global trade policies, general economic conditions, and other risks and uncertainties described in the company's periodic reports on file with the U.S. Securities and Exchange Commission including the most recent Annual Report on Form 10-K of the company. In some cases, you can identify these statements by forward-looking words or expressions, such as "anticipate," "believe," "could," "estimate," "expect," "forecast," "intend," "looking ahead," "may," "plan," "possible," "potential," "project," "should," "going to," "will," and similar words or expressions, the negative or plural of such words or expressions and other comparable terminology. Actual results may differ materially from anticipated results. Medtronic does not undertake to update its forward-looking statements or any of the information contained in this press release, including to reflect future events or circumstances.
NON-GAAP FINANCIAL MEASURES
 This press release contains financial measures, including adjusted net income, adjusted diluted EPS, and organic revenue, which are considered "non-GAAP" financial measures under applicable SEC rules and regulations. References to quarterly or annual figures increasing, decreasing or remaining flat are in comparison to fiscal year 2024, and references to sequential changes are in comparison to the prior fiscal quarter.
Medtronic management believes that non-GAAP financial measures provide information useful to investors in understanding the company's underlying operational performance and trends and to facilitate comparisons with the performance of other companies in the med tech industry. Non-GAAP net income and diluted EPS exclude the effect of certain charges or gains that contribute to or reduce earnings but that result from transactions or events that management believes may or may not recur with similar materiality or impact to operations in future periods (Non-GAAP Adjustments). Medtronic generally uses non-GAAP financial measures to facilitate management's review of the operational performance of the company and as a basis for strategic planning. Non-GAAP financial measures should be considered supplemental to and not a substitute for financial information prepared in accordance with U.S. generally accepted accounting principles (GAAP), and investors are cautioned that Medtronic may calculate non-GAAP financial measures in a way that is different from other companies. Management strongly encourages investors to review the company's consolidated financial statements and publicly filed reports in their entirety. Reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures are included in the financial schedules accompanying this press release.
Medtronic calculates forward-looking non-GAAP financial measures based on internal forecasts that omit certain amounts that would be included in GAAP financial measures. For instance, forward-looking organic revenue growth guidance excludes the impact of foreign currency fluctuations, as well as significant acquisitions or divestitures. Forward-looking diluted non-GAAP EPS guidance also excludes other potential charges or gains that would be recorded as Non-GAAP Adjustments to earnings during the fiscal year. Medtronic does not attempt to provide reconciliations of forward-looking non-GAAP EPS guidance to projected GAAP EPS guidance because the combined impact and timing of recognition of these potential charges or gains is inherently uncertain and difficult to predict and is unavailable without unreasonable efforts. In addition, the company believes such reconciliations would imply a degree of precision and certainty that could be confusing to investors. Such items could have a substantial impact on GAAP measures of financial performance.
-end-
Contacts: | |
Erika Winkels | Ryan Weispfenning |
Public Relations | Investor Relations |
+1-763-526-8478 | +1-763-505-4626 |
View original content to download multimedia: https://www.prnewswire.com/news-releases/medtronic-reports-third-quarter-fiscal-2025-financial-results-302378617.html
SOURCE Medtronic plc
News Provided by PR Newswire via QuoteMedia
